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Pseudotyped viruses (PVs) provide a safe, flexible platform for fundamental virological 
studies and antibody screening assays. Generation of influenza PVs involves co-
transfection of producer cells with plasmids encoding the necessary viral components. 
The pseudotype virus neutralisation assay (PVNA) is a sensitive technique to measure 
protective antibody responses which cause neutralisation of virus particles. Many 
traditional methodologies, e.g. Haemagglutination Inhibition (HI) and Single Radial 
Haemolysis (SRH), detect only surface glycoprotein binding antibodies whereas the 
PVNA quantifies infectivity-neutralising responses. 
 Haemagglutinin (HA) and neuraminidase (NA) are the two major surface 
glycoproteins embedded within the membrane of an influenza virion. HA is responsible 
for virion attachment and entry into a host cell and NA is essential for viral egress and 
thus spread of infection. Two enzymes crucial for the infectivity of influenza viruses are; 
HA-cleaving cellular proteases and the NA itself. Optimisation of both enzymes in PV 
production is necessary to increase the titre of PVs. Producing high titre PVs is important 
as this permits minimal quantities to be used in PVNAs, and repeat experiments can be 
carried out using the same batch of virus, minimising intra-study variability. 
 Optimising PVs and employing them in a novel situation, such as an equine 
influenza vaccine efficacy trial, has been carried out with promising results. We have 
demonstrated that data obtained from the PVNA correlates well with the traditional SRH 
assay and consequently there is the potential for more widespread adoption in research 
and commercial settings. Furthermore, PVs have been manipulated to assess how single 
amino acid changes with equine influenza virus can affect the neutralisation efficacy of 
sera generated by vaccination. 
 Novel PVs, such as those derived from canine and phocine (seal) influenza strains 
have also been produced and provide a new platform for sero-surveillance of these 
viruses particularly in the case of wild or feral animals, due to issues with obtaining 
samples from wild animals during acute infection. 
 Overall, PVs have been demonstrated as useful and readily-manipulated tools 
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1.1 Influenza virus 
1.1.1 Classification 
Influenza, the disease caused by the influenza virus, is a global concern for humans and 
many other animal species. There are four genera of influenza viruses belonging to the 
Orthomyxoviridae family; A, B, C and D. Influenza A virus is responsible for most 
morbidity and mortality amongst humans due to seasonal and pandemic outbreaks. It is 
also capable of causing global pandemics in humans (Chang et al., 2009; Viboud et al., 
2005) and widespread outbreaks in birds (Alexander, 2000; Guan and Smith, 2013), pigs 
(Smith et al., 2009), horses (Newton et al., 2006), dogs (Yoon et al., 2005), and seals 
(Anthony et al., 2012). Influenza B virus currently circulates amongst humans but due to 
a slower rate of evolution they are a less likely pandemic threat. Humans and seals are 
the only known influenza B hosts (Osterhaus, 2000). Influenza C virus causes very mild 
disease in humans, pigs and dogs (Speranskaya et al., 2012). Influenza D virus is the most 
recent addition to the Orthomyxoviridae family, isolated from pigs and cattle in 2011. 
Cattle workers have been shown to be seropositive for anti-influenza D antibodies but 
were not symptomatic for influenza (White et al., 2016). Since the first isolation in pigs, 
the animal host range has extended to sheep and goats (Quast et al., 2015). 
 
1.1.2 Influenza A virion and genome structure 
The influenza virion encapsulates a single stranded negative sense RNA genome that 
must first be transcribed into positive sense RNA before the genes can be translated into 
viral proteins. The genome consists of eight individual segments of viral RNA (vRNA), 
some of which code for multiple proteins. The pleomorphic, enveloped virion is studded 
with two main surface glycoproteins; haemagglutinin (HA) and neuraminidase (NA), 
which are expressed in approximately a 4:1 ratio respectively (Webster et al., 1968; 
Figure 1). Cryoelectron tomography images suggest that there are between 300  ? 400 
HA spikes per virion (Harris et al., 2006). Embedded within the envelope are ion channels 
formed by the M2 protein (matrix protein 2) and underlying the lipid envelope is matrix 
protein 1 (M1). The two M proteins are coded by one vRNA segment. The segments are 
[2] 
 
tightly arranged by the attraction of positively charged nucleoprotein (NP) to the 
negatively charged phosphate backbone of the vRNA. The virus encodes a 
heterotrimeric RNA polymerase complex; polymerase basic proteins (PB1 & PB2) and 
polymerase acidic protein (PA), which associates with each of the eight vRNA segments, 
ĞŶĂďůŝŶŐƚƌĂŶƐĐƌŝƉƚŝŽŶĂŶĚƌĞƉůŝĐĂƚŝŽŶŽĨƚŚĞǀŝƌƵƐŐĞŶŽŵĞ ?W ?ďŝŶĚƐƚŚĞ ?഻ĐĂƉƉĞĚŚŽƐƚ
pre-mRNA that is then cleaved by PA, essentially creating a primer from which PB1 
synthesises mRNA (reviewed in te Velthuis and Fodor, 2016). The combination of vRNA 
segments, NP and trimeric-polymerase group form vRNP complexes that associate with 
M1 beneath the lipid envelope (Eisfeld et al., 2014). Non-structural protein 1 (NS1) and 
nuclear export protein (NEP or sometimes referred to as NS2) are encoded on the same 
vRNA segment. The influenza genome was originally thought to encode ten proteins 
(highlighted in bold text above ) but in 2001, the proteome was extended to 11 proteins 
and since then a further six proteins have been discovered (reviewed in Vasin et al., 

























Table 1. Summary of influenza viral RNA (vRNA) segments, the proteins coded by each vRNA 




Viral Protein Function 
1 Polymerase basic protein 2 (PB2) Polymerase subunit required for initiation of 
transcription via binding of 5഻ capped host 
pre-mRNA (Guilligay et al., 2008) 
2 Polymerase basic protein 1 (PB1) Polymerase subunit responsible for 
elongation of RNA 
PB1-F2 Virulence factor associated with death of 
host immune cells (Chen et al., 2001)  
PB1-N40 Regulates expression of PB1  
(Wise et al., 2009) 
3 Polymerase acidic protein (PA) Polymerase subunit with RNA endonuclease 
activity (cap-snatching mechanism)  
(Dias et al., 2009) 
PA-X Alters host cell function via degradation of 
host cell mRNA (Jagger et al., 2012)  
PA-N155 Role in virus replication but not yet fully 
understood (Muramoto et al., 2013) PA-N182 
4 Haemagglutinin (HA) Surface glycoprotein responsible for virus 
attachment to host cell sialic acid receptors, 
the major viral antigen and target of 
neutralising antibodies 
5 Nucleoprotein (NP) Import of vRNA into host cell nucleus and 
compact arrangement of vRNPs  
6 Neuraminidase (NA) Surface glycoprotein responsible for 
cleavage of sialic acid receptors enabling 
virus release 
7 Matrix protein 1 (M1)  Interaction with vRNPs and export of vRNA 
from host cell nucleus 
Matrix protein 2 (M2) Ion channel responsible for release of vRNA 
from endosome 
M42 Alternative M2 protein (Wise et al., 2012) 
8 Non-structural protein 1 (NS1) Interferon antagonist 
Nuclear export protein (NEP) Export of vRNA from host cell nucleus 
NS3 Possible link to adaptation in novel hosts 








The two major surface glycoproteins (HA and NA) are used as the basis for influenza 
virus nomenclature e.g. H5N1. At present there are 18 HA and 11 NA known subtypes 
(Centers for Disease Control and Prevention, 2016). Influenza strains are recorded as 
shown in Figure 2. Human influenza strains follow the same nomenclature pattern as 







Figure 2. Example of influenza virus nomenclature. 
 
1.1.4 Influenza virus life cycle 
Attachment of an influenza virion to a host cell depends on the HA surface glycoprotein 
binding to sialic (N-acetylneuraminic) acid receptors. The receptors are abundant on 
many different cell types found across a variety of animal species. Two different linkages 
can be formed between the carbon backbone of the terminal sialic acid and galactose, 
in a 2,3 or 2,6 arrangement, forming ɲ- ? ? ?Žƌɲ-2,6 linkages (Bouvier & Palese, 2008). 
The HA protein recognises the different linkages and preferentially binds to one type. 
A prerequisite to successful infection is cleavage of the HA precursor, HA0, into 
HA1 and HA2 subunits by specific cellular proteases (Figure 3). Cleavage occurs 
subcellularly within the trans-Golgi network but can also take place at the cell surface 
(Garten et al., 2015). Once the HA is bound to the surface of the cell, the virion is 
endocytosed into an endosome. The acidic pH within the endosome triggers a 
conformational change in the HA trimeric-structured protein. The change in protein 
structure is crucial for exposure of a fusion peptide, facilitating the fusion of the HA with 
the endosomal membrane, which creates a pore for the vRNPs to escape into the cell 
cytoplasm (Stegmann, 2000). The M2 ion channel reduces the pH within the virion, as 
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hydrogen ions are pumped in from the endosome, encouraging the dissociation of M1 
and aiding the release of genetic material (Martin & Helenius, 1991). 
 
 
Figure 3. Cleavage of the influenza HA protein. Specific cellular proteases are responsible for 
cleaving the HA between HA1 and HA2 subunits and exposing the fusion peptide (modified from 
Hamilton et al., 2012). 
 
 
Viral RNPs are trafficked into the host cell nucleus by nucleoprotein, where 
transcription and replication of the negative sense viral genome takes place. 
Transcription involves the production of capped, polyadenylated messenger RNA 
(mRNA) and positive strand complementary RNA (cRNA). Further transcription, using 
the cRNA as a template, produces complementary negative sense vRNA that is packaged 
into progeny virions. Post transcription capped and polyadenylated viral mRNAs are 
processed alongside host-cell mRNAs and, without the help of viral proteins, pass out of 
the nucleus to be translated. However, full-length vRNA is dependent on M1 and NEP 
proteins to exit the nucleus via nuclear pores (Cros & Palese, 2003). 
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Translation of viral proteins occurs on membrane-bound ribosomes on the rough 
endoplasmic reticulum. Post translation modification then takes place within the Golgi 
and signals for the surface glycoproteins HA, NA and M2 to assemble at the host cell 
surface. Original theories described a random vRNA packaging process whereby only 
virions containing complete genomes became infectious (Bancroft & Parslow, 2002). 
Subsequently however, a selective packaging process of all eight vRNA segments within 
the progeny virions prior to budding has been proposed (Fujii et al., 2003). Once the 
progeny virions bud from the host cell the final stage of virus release depends on NA to 
cleave the sialic acid receptor bound to the HA on the surface. 
 
1.2 Mechanisms of influenza virus evolution 
The RNA polymerase enzyme, incorporated within the influenza viral genome, is 
relatively low fidelity and lacks the ability to proof read RNA transcripts (Szewczyk et al., 
2014). Consequently, an accumulation of random mutations within the genome occurs 
over time. Of the mutants that are produced, selection pressure allows those with a 
growth advantage over the parental strain to proliferate (Zambon, 1999). Changes to 
the HA surface glycoprotein, the major antigen on an influenza virion, are of importance 
as these changes can alter antigenic epitopes. Small changes to the surface 
glycoproteins may allow for immune escape in some individuals, which can result in an 
outbreak. The steady incremental change that leads to antibodies no longer recognising 
the HA is described as antigenic drift. Every year the World Health Organisation (WHO) 
meets to discuss necessary changes to human influenza vaccines in an attempt to 
protect against circulating strains. Therefore, identifying the mutations responsible for 
immune escape and vaccine failure is important. The rate of amino acid changes in 
human HA over a period of 14 years was reported as 0.87% (Skehel et al., 1983), 
compared to 0.36% changes over 16 years for equine HA (Daniels et al., 1985), these 
findings were confirmed in 1991 (Bean et al., 1992). 
The segmented nature of the RNA virus genome facilitates the possible exchange 
of genes with another influenza strain during co-infection and replication within a cell. 
If this reassortment event occurs between different virus subtypes and causes a change 
in one or both of the major surface glycoproteins, HA and/or NA, the change is referred 
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to as antigenic shift as these are major immune targets. Antigenic shift is often 
responsible for causing human pandemics. A potent reminder of such an event was 
demonstrated by the swine flu pandemic that spread to humans in 2009 (Isaacs, 2010). 
dŚĞŶŽƚŝŽŶŽĨĂƉŝŐĂĐƚŝŶŐĂƐĂ ‘ŵŝǆŝŶŐǀĞƐƐĞů ?ĨŽƌinfluenza viruses had been suggested 
prior to the outbreak (Ito et al., 1998; Yasuda et al., 1991); two avian viruses and a 
human virus reassorted within the pig, acquiring the necessary genes to infect humans 
(Smith et al., 2009). Such a dramatic change in the virus genome renders most, if not all, 
of a population susceptible to infection as no antibodies are present to combat infection. 
It is the continued transmission of influenza viruses to new host species that can 
potentially act as intermediate hosts, leading to human susceptibility, which causes 
particular concern. 
 
1.3 Transmission of influenza virus 
The dynamics of influenza virus transmission are complicated and it is difficult to predict 
how and when a pandemic may arise. There are two main factors to consider; the 
ecology of species and host range. Migration of birds (Dugan, 2012), changes to habitats 
(Sehgal, 2010), domestication of animal species (Munoz et al., 2016) and conditions in 
food markets (Yu et al., 2014), are all environmental factors that can affect transmission 
of influenza viruses. Wild aquatic birds are known to be the reservoir of influenza A 
viruses that have been transmitted to sea-mammals and land-mammals over time 
(Figure 4). The factors that determine host range are vast and not yet fully understood 
(Barclay et al., 2014). Upon inhalation or consumption of the virus, the binding 
specificity of HA to sialic acid receptors can determine infection success. Different 
species contain different types and quantities of sialic acid receptors: the long-standing 
theory is that aǀŝĂŶ ƐƉĞĐŝĞƐ ĐŽŶƚĂŝŶ ŵŽƌĞ ɲ-2,3 linked sialic acid receptors whereas 
ŚƵŵĂŶƐ ĐŽŶƚĂŝŶ ŵŽƌĞ ɲ-2,6 (Matrosovich et al., 1997). Intermediate species such as 
ƐǁŝŶĞŚĂǀĞďĞĞŶŚŝŐŚůŝŐŚƚĞĚĂƐŵŝǆŝŶŐǀĞƐƐĞůƐďĞĐĂƵƐĞƚŚĞǇĐŽŶƚĂŝŶďŽƚŚɲ-2,3 and ɲ-
2,6 sialic acid receptors, which makes them susceptible to multiple infections (Imai & 
Kawaoka, 2012). EquŝĚƐŚĂǀĞŵŽƌĞɲ-2,3 linked sialic acid receptors (Suzuki et al., 2000) 
whereas the composition of receptors found in dogs and seals is often debated (Anthony 
et al., 2012; Muranaka et al., 2011). Furthermore, sialic acid receptors can be modified, 
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and due to their role in maintaining multiple cell functions, this may impact the host 
tropism of influenza viruses. For example, acetylation of the most common form of sialic 
acid receptor N-acetylneuraminic acid (Neu5Ac) at carbon atoms 4, 7, 8 or 9 can occur 
and such chemical changes may interfere with host-pathogen interactions. Recently 
developed probes have been used to identify modified sialic acid receptors in influenza 
host species/animal models, specifically those that are acetylated in positions 4, 9 and 
7,9. Results indicated that 9 and 7,9-O-acetyl modified receptors were much more 
abundant in a variety of hosts including humans, pigs, guinea pigs horses, dogs and ducks 
whereas 4-O-acetyl receptors were only found in guinea pigs and horses (Wasik et al., 
2017). As well as chemical additions to the sialic acid receptors, a single amino acid 
mutation within the receptor binding site of the HA protein can alter the preferential 
binding to a different form of sialic acid receptor (Connor et al., 1994). It is also 
noteworthy that although the HA protein is known to play an important role in the 
transmission of the influenza virus, other proteins have also been shown to impact the 
process (reviewed in Barclay et al., 2014). Surveillance of circulating influenza viruses is 
a necessity in order to try and identify the on-going changes within virus genomes and 














Figure 4. Transmission of influenza virus between different host species (modified from Manz et 
al., 2013).  
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1.4 Neglected influenza hosts 
Aside from the human, avian and swine viruses that form the main focus of influenza 
research, other species remain relatively neglected. Horses, dogs and seals are examples 
ŽĨƐƵĐŚ  ‘ŶĞŐůĞĐƚĞĚ ?ƐƉĞĐŝĞƐ ƚŚĂƚŚĂǀĞĂůůďĞĞŶĚĞƚƌŝŵĞŶƚĂůůǇĂĨĨĞĐƚĞĚďǇŽƵƚďƌĞĂŬƐŽĨ
influenza. 
 
1.4.1 Equine influenza 
Equine influenza (EI) causes disease amongst equids worldwide. Naïve horses infected 
with EI typically present with the following clinical signs; coughing, nasal discharge, 
pyrexia and lethargy. Mortality rates as high as 20% from primary influenza A type virus 
infections have been reported (Guo et al., 1991; Yondon et al., 2013). However, fatalities 
are more likely in young horses that suffer from secondary bacterial infections 
(Patterson-Kane et al., 2008; Peek et al., 2004). The close proximity of stable-kept horses 
facilitates rapid transmission of EI. Furthermore, EI is highly infectious, with large 
quantities of virus expelled during coughing episodes. The global movement of horses 
heavily influences transmission of EI. The equine sporting industry, including horse 
racing and polo, involves transporting horses around the world to participate in 
competitions. Outbreaks of the disease have affected race meetings since the late 1970s 
and can lead to the cancellation of events: Clinical signs of the disease appear more 
severe when a horse continues to exercise (Gross et al., 1998). As well as participation 
in sport, equids remain a very valuable working animal in developing countries and as 
such, outbreaks of EI in countries such as India are a concern (Virmani et al., 2010). Prior 
to introducing horses to a new population it is essential to place the horses in quarantine 
in order to prevent an outbreak from occurring (Morley et al., 2000). A potential 
complication during the quarantine procedure is that vaccinated horses may have a 
subclinical infection and therefore be released with the potential to transmit the virus. 
There are very few nations that have not experienced EI (Cullinane & Newton, 2013). 
Australia was considered EI-free until 2007 when a quarantine procedure failed, leading 
to an outbreak that affected thousands of horses (Webster, 2011). The Australian 
government spent in excess of $1 billion to control the disease (Callinan, 2008). These 
circumstances highlight the importance of controlling EI. 
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1.4.1.1 Immune response 
The non-specific, innate immune response to influenza virus infection aims to contain 
and prevent propagation of the virus. The innate response is thought to be initially 
triggered by cellular pattern recognition receptors, which induce an antiviral state within 
infected and surrounding cells, usually via the interferon pathway (Rehwinkel et al., 
2010). Other non-specific immune mechanisms that aim to limit viral spread include 
lymphocytes, complement and the activation of macrophages. This first line of defence 
is followed by a specific immune response. 
In order to combat an influenza infection, cell-mediated and humoral immunity 
are both essential (Hannant et al., 1989; Hannant & Mumford, 1989). Cell-mediated 
responses can be considered as heterologous due to the broad range of peptides that 
T-cells can recognise, some of which are conserved among different strains and subtypes 
of influenza. The importance of cell-mediated responses to EI infections was made 
apparent by a study that demonstrated how ponies with very low levels of antibodies 
against HA, as measured by SRH, retained clinical and virological protection one year 
post infection with EI virus (Hannant et al., 1988). Consequently, it is desirable for 
vaccines to induce cytotoxic T lymphocyte responses (CTL) as well as specific antibody 
responses (Slater & Hannant, 2000). Assays for equine cell mediated responses against 
influenza have been developed and implemented (Adams et al., 2011; Paillot et al., 
2007). However, it is important to note that cell mediated responses do not provide 
protection against infection. T-cells function to eliminate a viral infection and thus 
cannot be used to determine if an individual will be protected. Antibody levels, derived 
from natural infection or vaccination, can be measured to ascertain protective 
thresholds. 
When challenged with an influenza virus, neutralising antibodies provide 
subtype specific protection by preventing viral entry into host cells. The antibody 
response is primarily driven against the surface glycoprotein HA. Horses have 11 
immunoglobulin isotypes IgG (7 subclasses), IgA, IgM, IgE and IgD; each involved in 
aspects of the immune response against different pathogens. Antibody isotypes IgA 
(mucosal) IgGa and IgGb (serum) are associated with natural protection against 
influenza infection (Nelson et al., 1998). Monoclonal antibodies are manufactured and 
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used to investigate the equine immune response, such as quantifying isotype 
concentrations in the horse (Keggan et al., 2013). Our knowledge and further 
understanding of the equine immune response is important if we are to produce 
effective vaccines. Different approaches to producing effective vaccines are 
continuously being reviewed (Paillot et al., 2007). Interestingly, similarities between 
human and equine immune responses to influenza have recently been highlighted, 
which supports the potential use of horses as an animal model for influenza infection 




Diagnosis of an EI infection is typically achieved by direct detection of viral antigens or 
genetic material contained in nasal swab samples. There are many different diagnostic 
tests available however the sensitivity and specificity varies greatly between them 
(Yamanaka et al., 2016). The current gold-standard is RT-PCR (Quinlivan et al., 2005). 
Alternatively, indirect detection of the virus can be attained through serological assays 
(Zimmerman & Crisman, 2008). These assays identify the presence of antibodies against 
EI within test blood sera. If the individual is seronegative in the acute phase (blood 
sample taken upon the onset of clinical signs) and seropositive in the convalescent 
period (sample taken around two weeks later) the individual is said to have 
seroconverted, which is indicative of infection. 
 
1.4.1.3 Surveillance 
Surveillance is an essential part of the process to produce a vaccine that will provide 
ƉƌŽƚĞĐƚŝŽŶĂŐĂŝŶƐƚĐŝƌĐƵůĂƚŝŶŐ/ǀŝƌƵƐĞƐ ?ZĞƉŽƌƚƐŽĨ ‘ŝŶĨůƵĞŶǌĂ-ůŝŬĞ ?ŝůůŶĞƐƐĚĂƚĞďĂĐŬƚŽ
the 1200s and were particularly prevalent in the United States during the 1800s (Morens 
& Taubenberger, 2010). Two subtypes have been established within the equine 
population; H7N7 and H3N8. The first confirmed report of an EI infection was H7N7 in 
1956, Prague, Czechoslovakia (Sovinova et al., 1958). This virus subtype has not been 
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isolated for more than 20 years and is therefore considered extinct (Webster, 1993). The 
H3N8 subtype was first identified in Miami, Florida, 1963 (Waddell et al., 1963) and 
continues to circulate globally. In the late 1980s, initially based on the geographical 
distribution of viruses, H3N8 diverged into Eurasian and American-like lineages. Notably, 
American-like viruses were also isolated in Europe and vice versa (Daly et al., 1996). 
Furthermore, in 2001, it was reported that the American lineage had further diverged 
into three sub-lineages; South American, Kentucky and Florida (Lai et al., 2001). At 
present, the Florida sub-lineage is divided into two clades; 1 & 2. Both Florida clade 1 
and 2 viruses continue to circulate in Europe while clade 1 predominates in America 
(Bryant et al., 2011). 
 
1.4.1.4 Vaccination 
Vaccines against EI were made available in the late 1960s and became mandatory for 
thoroughbred racehorses under the Jockey Club Rules of Racing in March 1981. Other 
regulatory equine bodies including the British Show Jumping Association (BSJA) and FEI 
(Federation Equestrian International) also impose a mandatory vaccination programme 
for horses participating in national and international competitions, respectively. 
Mandatory vaccination programmes aid the control of the disease, however, not all 
ŚŽƌƐĞƐĨĂůůǁŝƚŚŝŶƚŚĞĐĂƚĞŐŽƌŝĞƐĨŽƌŵĂŶĚĂƚŽƌǇǀĂĐĐŝŶĂƚŝŽŶ ?&ŽƌƚŚĞ ‘ĞǀĞƌǇĚĂǇ ?ǁŽƌŬŝŶŐ 
or non-competition horse, vaccination is recommended to their owners but they are not 
obliged to comply. Herein, there are two major hurdles to consider; the control of EI 
transmission via unvaccinated populations and in the instances where vaccination is 
employed, to ensure that the component EI vaccine strains are up to date and provide 
optimal protection. 
Although EI vaccines were in use by the late 1960s, major UK outbreaks in 1979 
and 1989 highlighted the need for vaccine strains to be updated. Moreover, due to the 
phylogenetic diversity of EI viruses, vaccine strains representative of the different 
lineages were suggested for inclusion (Daly et al., 2004; Woodward et al., 2015; 
Yamanaka et al., 2015). Pony challenge studies are conducted to test the efficacy of 
vaccine strain components, however, it would be preferable to avoid these studies and 
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employ a sequence-based approach (Daly & Elton, 2013). The difficulty is that vaccine 
updates cannot simply be determined by the number of amino acid changes that appear 
in the HA, as a result of antigenic drift. An understanding of the key amino acid changes 
that infer antigenic differences are crucial to optimising protection (Woodward et al., 
2015). In the last decade, outbreaks amongst vaccinated populations have continued to 
occur due to the use of out-dated vaccines (Newton et al., 2006; Yamanaka et al., 2008). 
At present in the UK, there is only one EI vaccine that meets the recommendations of 
the OIE (World Organisation for Animal Health). The development of new effective 
vaccines is continuously underway but implementing production and marketing is a slow 
process (Paillot et al., 2006, 2016). 
 
 
1.4.2 Canine influenza 
Canine influenza (CI) disease causes similar clinical signs to that of equine influenza; 
coughing, nasal discharge, fever and lethargy. Furthermore, cases of mortality due to 
haemorrhagic pneumonia have been recorded (Yoon et al., 2005). 
 
1.4.2.1 Transmission and surveillance 
Influenza A subtypes H3N8 and H3N2 emerged in the canine host via separate 
transmission events from equine and avian origins, respectively. The history of CI is 
relatively short-lived as the first outbreak was recorded only 13 years ago. In 2004, the 
H3N8 subtype was identified in the canine host at a Greyhound racing track in Florida, 
USA (Crawford, 2005). The dogs at the facility had shown signs of respiratory disease, 
prior to the official isolation of influenza virus, but at the time the cause of disease was 
unknown. Serological assays on archived blood samples did however indicate that the 
virus was circulating in the USA as early as 1999 (Anderson et al., 2012a). In 2005, 
different breeds of dog were also noted to be affected by the disease (Payungporn et 
al., 2008). Genetic analysis confirmed that there was a direct transmission of the H3N8 
virus from horse to dog, in the US, with more than 96% nucleotide similarity to the 
original equine strain (Crawford, 2005). Investigations into how the virus was directly 
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transmitted found two possible explanations; inhalation via close contact (Yamanaka et 
al., 2009) and the consumption of infected horse meat (Daly et al., 2008). The 
independent transmission event of the H3N8 virus in the United Kingdom was reported 
after the outbreaks in the US (Daly et al., 2008) through re-examination of formalin-fixed 
paraffin-embedded tissue from a Foxhound that suffered with similar clinical signs. A 
partial HA sequence was recovered from the tissue and found to be related to recent EI 
virus strains (Janet Daly pers. comm.). 
In 2006, the first case of a canine H3N2 virus was reported, in a pet dog in 
Guangdong, China (Li et al., 2010). Within five years it was isolated from roaming dogs 
in China (Su et al., 2013) and furthermore, the virus was isolated in South Korea in 2007 
(Song et al., 2008). Similarly to the US H3N8 transmission event, direct transmission 
and/or the consumption of infected meat were thought to be the cause (Song et al., 
2008). Although H3N8 predominates in the US and H3N2 in Asia, recent studies have 
shown that the H3N2 virus is circulating in the US (Centers for Disease Control and 
Prevention, 2015) and there is serological evidence to suggest that H3N8 is present in 
China (Zhou et al., 2016). 
One of the initial, intriguing characteristics of CI was the ability of the virus to 
transmit between dogs in a relatively short amount of time. Most novel transmission 
events involve a single round of infection and do not establish within a new population. 
Occasionally viruses are transferred, spread efficiently and become established in a new 
population, as was demonstrated by CI. The genetic diversity of the virus within the 
canine host was studied and eluded to the transient nature of mutations that may 
enable antigenic escape or an increase in host range (Hoelzer et al., 2010). The 
transmission of canine influenza viruses, not only to other animals but to humans, is a 
particular concern as dogs are domestic companion animals. American Pet Products 
Association estimates that there are 89.7 million pet dogs in the US, based on the 2016 
National Pet Owners Survey and The National Bureau of Statistics of China reports that 
there are 27.4 million pet dogs. A novel canine H3N1 virus has evolved via an antigenic 
shift event in which the pandemic H1N1 2009 and canine H3N2 strains reassorted (Song 
et al., 2012). This novel virus, identified in Korea, highlights the permissibility of the 




In 2009, the first canine influenza inactivated vaccine against the H3N8 subtype was 
shown to significantly reduce the severity of clinical signs seen in puppies, as well as the 
quantity and duration of viral shedding (Deshpande et al., 2009). Nobivac® Canine Flu 
H3N8 was produced by Merck Animal Health and is licensed for use in the US. The 
inactivated H3N8 vaccine also provides some protection against the H3N2 subtype; 
Antibodies are elicited against the more conserved stalk region of the HA and internal 
viral proteins but do not eliminate infection (Willis et al., 2016). Furthermore, two live-
attenuated vaccines against H3N8 have been developed using different strategies; 
modification of the NS1 protein (Nogales et al., 2017a) and a temperature sensitive 
mutant virus (Nogales et al., 2017b). Both live-attenuated vaccines induced protection 
against the homologous H3N8 canine influenza virus in mice and discussions as to which 
vaccine is the best candidate for canine trials are underway. 
In 2013, a virus-like particle (VLP) vaccine was designed specifically to target the 
H3N2 subtype. The vaccine includes the H3 and M1 proteins and prevents any clinical 
signs of disease, reduces pulmonary pathology and viral shedding (Lee et al., 2013). In 
China, inactivated H3N2 vaccines have also been developed that prevent disease and 
reduce viral shedding (Cureton et al., 2016; Lee et al., 2010). Although the vaccines do 
not eliminate viral shedding, the reduction should help to reduce transmission of the 
virus at present. In addition, a live-attenuated H3N2 vaccine has recently been 
developed and induced a higher protection efficacy, during a challenge study in mice, 
than the inactivated H3N2 vaccine (Rodriguez et al., 2017a). 
It is noteworthy that the live-attenuated monovalent vaccines do not provide 
cross-protection against the heterologous virus strain. Therefore, the most promising 
candidate to date is a live-attenuated bivalent vaccine that does provide protection 




1.4.3 Phocine influenza  
Phocine (seal) influenza A virus outbreaks have been reported since the 1970s in 
different species (Fereidouni et al., 2014). In 1979 along the New England Coast, US, an 
epizootic involving an H7N7 subtype (A/seal/ Massachusetts/1/80) killed more than 400 
harbour seals (Phoca vitulina) (Geraci et al., 1982). Periodic outbreaks with other 
subtypes have also occurred in the US; H4N5 in 1982 (Hinshaw et al., 1984), H4N6 in 
1991, H3N3 in 1992 (Callan et al., 1995) and H3N8 in 2011 (Anthony et al., 2012). 
Furthermore, the H10N7 subtype was isolated from seals in Sweden, Denmark, Germany 
and the Netherlands (Bodewes et al., 2015; Zohari et al., 2014). Interestingly not all seal 
species appear to be clinically affected by the disease: Grey seals (Halichoerus grypus) 
do not present with clinical signs and it has recently been proposed that the seal may 
act as a form of reservoir for the disease (Puryear et al., 2016). Hooded seals (Cystophora 
cristata) and harp seals (Pagophilus groenlandicus) have also been identified as 
seropositive for influenza A infection but clinical signs were not recorded during 
sampling and so whether or not these animals were affected by the disease is unknown 
(Stuen et al., 1994). 
For the purpose of this thesis the H3N8 subtype is of particular interest because 
it also infects equine and canine species. It is interesting that H3N8 is found in a variety 
of species and is frequently isolated from aquatic birds (Hill et al., 2012). The emergence 
of the H3N8 subtype killed 162 harbour seals in New England, US (Anthony et al., 2012). 
Phylogenetic sequence analysis indicated that the subtype was of avian origin. The 
receptor binding specificity of the seal H3N8 virus was found to have an increased 
ĂĨĨŝŶŝƚǇĨŽƌɲ ? ? ?ůŝŶŬĞĚƐŝĂůŝĐĂĐŝĚƌĞĐĞƉƚŽƌƐ, which are associated with human influenza 
virus infections, ĐŽŵƉĂƌĞĚƚŽɲ ? ? ?. The virus infected human lung cell cultures and could 
undergo respiratory transmission in a ferret model (Karlsson et al., 2014). Although seals 
are less likely to come into contact with humans than dogs and horses, the virus still 
poses a potential threat to human health. Haemagglutinin Inhibition (HI) assays were 
performed using the A/harbour seal/Massachusetts/1/2011 (H3N8) virus against pre 
and post vaccination human H3 seasonal vaccine serum samples, resulting in no 
evidence of cross-reactivity. Therefore, this suggests that the seal H3 virus is significantly 
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different to the human vaccine strains and thus the human population could be 
susceptible to the virus if interspecies transmission occurred (Karlsson et al., 2014). 
 The transmission of human influenza viruses to seals has been documented: The 
human pandemic H1N1 2009 virus was isolated from Northern Elephant Seals 
(Mirounga angustirostris) on the central California coast. There was speculation that the 
virus may have been transmitted via aquatic birds at sea, however phylogenetic analysis 
confirmed high levels of similarity and an ancestral link that suggested a direct 
transmission from humans was more likely. As mentioned previously, it is unlikely that 
humans and seals have direct contact at sea, however water infected with human 
excrement could be a source of infection (Goldstein et al., 2013). In Russia, antibodies 
specific to a human H3N2 virus were detected in Baikal Seals (Phoca sibirica) and Ringed 
Seals (Phoca hispida) (Ohishi et al., 2004). These incidences further highlight the 





1.5 Serological Assays 
Further to using serological assays in diagnosing influenza infections, they are of great 
importance for global surveillance of the disease, subtyping isolates and in vaccine 
efficacy testing procedures (OIE World Organisation for Animal Health, 2016). Current 
assays in clinical use include the haemagglutination inhibition assay (HI), single radial 
haemolysis (SRH), enzyme-linked immunosorbent assay (ELISA), and virus neutralisation 
assay (VN). All serological assays detect the presence of antibodies within test blood 
sera. However, the application and interpretation of each assay is different. 
 
1.5.1 Haemagglutination inhibition assay (HI) 
The HI assay, developed in the 1940s, detects decreases in HA-binding to erythrocytes 
when antibodies are present within serum (Hirst, 1942). Serum must be pre-treated, 
with potassium periodate, kaolin or receptor-destroying enzyme, and heat inactivated 
to remove any non-specific agglutinins. Pre-treatment of serum is crucial to avoid false 
positive results. The consequences of ineffective pre-treatment were demonstrated 
when using kaolin to test for antibodies against equine H7N7 (Boliar et al., 2006). A 
Tween 80/ether solution can be added to the antigen, to prevent viral infectivity and 
cross-contamination, whilst increasing HA activity for H3N8 subtypes. However, a 
consequence of increasing sensitivity is a reduction in specificity (Mumford, 1992). The 
assay read-out is an HI titre; the reciprocal of the serum dilution at which agglutination 
is completely inhibited. The requirement for classification of seroconversion, between 
acute (onset of clinical signs) and convalescent (two weeks later) serum samples, is a 
minimum four-fold increase in titre (Morley et al., 1995). The OIE provide a detailed 
protocol for the HI assay (OIE, 2016). Figure 5 illustrates A) expected observations and 
B) an example assay. In practice, results are not always straightforward to interpret and 

























Figure 5. A) Principles of the haemagglutination inhibition assay. 1  ? Red blood cells (RBCs) alone 
do not agglutinate and thus a red pellet of cells forms at the bottom of a V-shaped well. 2  ? Virus 
added to RBCs, the virus binds to sialic acid receptors on the RBCs causing cells to agglutinate. A 
uniform shade of red is observed due to the formation of a cell ?virus lattice. 3  ? Upon addition 
of an antibody directed against the HA, the influenza virus is prevented from binding to the RBC 
thus agglutination is inhibited and a red pellet of cells is observed. B) Example HI assay plate. 
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1.5.1.1 HI applications: Advantages and disadvantages 
HI assays have multiple applications including HA subtyping, surveillance and vaccine 
testing. Recently HI was used to evaluate the seroprevalence of equine influenza in Israel 
(Aharonson-Raz et al., 2014) and Nigeria (Olusa & Adeyefa, 2009) as well as seal 
influenza in the Netherlands (Bodewes et al., 2015) and canine influenza in China (Zhou 
et al., 2016). Furthermore, HI is the global standard for antigenic characterisation of new 
isolates. Characterisation is achieved by a comparison of HI titre to a panel of reference 
sera. Isolates from Europe, Dubai and the USA were recently characterised in an attempt 
to improve surveillance of equine influenza (Woodward et al., 2014). In order to 
effectively discriminate between isolates, strain-specific antibodies are beneficial. Ferret 
anti-serum is typically more strain-specific than equine serum and is therefore the 
preferred source (Burrows & Denyer, 1982). Furthermore, data from HI assays using 
ferret anti-serum, are used to aid decision making on component equine influenza 
vaccine strains (Bryant et al., 2011). 
HI is officially recommended by the OIE for vaccine testing. It is also accredited 
by the Committee for Proprietary Medicinal Products (CPMP) as a determining factor 
for human vaccine licensing. In humans, a post vaccination HI titre of >1:40 is considered 
to be the protective threshold value, reducing the chance of natural infection by 50%. 
Recently, the US Food and Drug Administration (FDA) applied this threshold for licensing 
pandemic human influenza vaccines. Recent reviews on serological techniques used for 
ŚƵŵĂŶǀĂĐĐŝŶĞĞǀĂůƵĂƚŝŽŶŚŝŐŚůŝŐŚƚƚŚĞ ŝŵƉŽƌƚĂŶƚ ŝƐƐƵĞŽĨĚĞĨŝŶŝŶŐ  ‘ƉƌŽƚĞĐƚŝŽŶ ? (Cox, 
2013; Trombetta et al., 2014). For equine influenza, a mean HI titre of A? ? P ? ? is required 
to induce clinical protection. However, a higher titre may be necessary to confer 
protection against viral shedding (European Medicines Agency, 2014). 
A drawback to using the HI assay is the type of antibody that it quantifies. The HI 
assay focusses on HA binding to sialic acid residues on red blood cells, therefore 
measuring antibodies that bind to the trimeric head of HA and prevent 
haemagglutination. Neutralising antibodies correlate with protection and do not only 
bind to the head of HA, therefore HI titres are not an exact measure for protection. That 
considered, one report has shown good correlation between the HI and a virus 
neutralisation assay for equine (Morley et al., 1995). 
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Reproducibility of an assay is important for the integrity of studies, particularly 
those used in vaccine efficacy testing. The HI assay is simple to perform but the red blood 
cell component is difficult to standardise. The inter-laboratory variability of the assay is 
a well-documented issue. A four-fold difference in HI titres was documented between 
different laboratories for equine influenza (Daly et al., 2007a). Furthermore, in human 
influenza studies, greater than 80% variation has been recorded (Wood et al., 1994, 
2012). Despite the issues, HI remains a conventional assay for equine, canine and 
phocine influenza due to its simplicity and minimal associated costs. It is particularly 
favourable for diagnosis and surveillance in resource-poor countries. 
 
 
1.5.2 Single radial haemolysis (SRH) 
SRH has been used since the late 1970s to detect antibodies against influenza (Schild et 
al., 1975). The assay identifies antibodies in blood serum by utilising the cell lysis 
properties of complement. Serum is added to an agar plate containing virus-coated RBCs 
and, if anti-HA antibodies are present, the complement factors bind to antibody/antigen 
(HA) complexes on the influenza virus covered RBCs creating a zone of haemolysis 
(Figure 6). The level of strain-specific antibodies correlates with the size of the zone of 
lysis. Furthermore, seroconversion between acute and convalescent serum samples is 










Figure 6. Example of an SRH assay plate. Serum is added to the wells within the agar and if anti-
HA antibodies are present a zone of lysis forms (highlighted in the image).  
 








1.5.2.1 SRH applications: Advantages and disadvantages 
The OIE considers SRH to be of equal merit to the HI assay for equine influenza vaccine 
testing (OIE, 2008). There is a strong correlation between post-vaccination protective 
immunity and antibody detection in the SRH assay, hence why it is a favourable choice 
for testing vaccine immunogenicity. Another benefit of using SRH is the defined 
correlates of protection; antibody levels >150mm2 infer virological protection against 
homologous vaccine-challenge strains, clinical protection is seen between 85 and 
150mm2 and between 50 and 85mm2 only partial protection is seen (Mumford & Wood, 
1991). These measurements are used to determine when vaccine strain updates are 
necessary (Gildea et al., 2013). 
 The serum is not diluted in an SRH assay, which provides a linear readout 
compared to the titres used in HI. This makes SRH more sensitive than HI, hence a 50% 
increase in the zone of lysis will confirm seroconversion compared to a four-fold increase 
for HI. The assay is more reproducible than HI (Mumford & Wood, 1991, 1993). 
However, it is not without variation; up to 3.9-fold differences were calculated across 
nine laboratories for equine influenza assays (Daly et al., 2007a). SRH is not favourable 
for diagnostic purposes because the assay does not detect IgM antibodies seen in the 




An ELISA can be used to detect antibodies that bind viral proteins; typically the structural 
nucleoprotein (NP) is targeted (Ji et al., 2011). The ELISA is a flexible assay platform with 
variations such as; blocking, indirect, competition and cell-based. 
 
1.5.3.1 ELISA applications: Advantages and disadvantages 
An ELISA is quick to perform and high-throughput, which is beneficial for diagnostic 
purposes. Similar to HI, the ELISA is not necessarily representative of a neutralising 
antibody response due to the semi-quantitative measure of antibody binding. 
Furthermore, anti-NP antibodies are not subtype-specific and therefore other tests are 
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necessary to identify particular strains. For example, serosurveillance of seal influenza 
was conducted using both ELISA and HI assays (Bodewes et al., 2015). During the equine 
influenza outbreak in Australia 2007, the ELISA was the chosen assay for screening 
purposes, however some results were inconclusive and a follow-up HI test was actioned 
(Sergeant et al., 2011). A very useful aspect of the ELISA is the ability to Differentiate 
Infected from Vaccinated Animals (DIVA) in some cases. For example, animals 
vaccinated with subunit vaccines will not raise antibodies to all viral proteins whereas 
individuals who have been infected with a virus will. Therefore, depending on the 
protein measured, the ELISA can give differential results (Galvin et al., 2013; Kirkland & 
Delbridge, 2011). A cell-based ELISA measuring the non-structural NS1 protein has been 
suggested for DIVA as theoretically, only infected equines should mount an immune 
response to the non-structural NS1 protein, not those vaccinated with inactivated virus 
(Wojciech et al., 2011). 
 
1.5.4 Virus neutralisation (VN) 
Virus neutralisation assays identify antibodies that are capable of inhibiting virus entry 
and or preventing replication within cells (Han & Marasco, 2011). Different techniques 
have been developed, but all VN assays measure biological function, specifically, a 
ƌĞĚƵĐƚŝŽŶ ŝŶ ǀŝƌƵƐ ƉĂƌƚŝĐůĞ ŝŶĨĞĐƚŝŽŶ ? dŚĞ  ‘ŐŽůĚ ƐƚĂŶĚĂƌĚ ? ŝƐ ƚŚĞ ƉůĂƋƵĞ ƌĞĚƵĐƚŝŽŶ
neutralisation test (PRNT); serum is incubated with a standard amount of antigen and 
added to a monolayer of permissive cells, then an overlay of agarose or 
carboxymethylcellulose is necessary to prevent the virus spreading within the 
supernatant. Plaques formed are then analysed by microscopy or eye often following 
cell staining. Micro-neutralisation (MN) is a cell-based assay that incorporates a 
standard amount of antigen and a serial dilution of serum in a 96-well plate. The 
neutralising ability of antibodies can be measured by the presence/absence of 
cytopathic effect (CPE) or the quantity of virus within the supernatant, which is usually 
measured by an ELISA. Alternatively, serum-virus mixtures can be added to the allantoic 
ĐĂǀŝƚǇŽĨĞŵďƌǇŽŶĂƚĞĚŚĞŶƐ ?ĞŐŐƐ ?ŚĂƌǀĞƐƚĞĚĂŶĚƵƐĞĚŝŶ ĂŚĂĞŵĂŐŐůƵƚŝŶĂƚŝŽŶĂƐƐĂǇƚŽ




1.5.4.1 VN applications: Advantages and disadvantages 
As well as measuring biological function, VN assays are sensitive, and are therefore well-
suited for measuring vaccine-induced responses. Furthermore, the results can be used 
to advise on necessary vaccine strain updates (Ozaki et al., 2001; Yamanaka et al., 2015). 
VN assays would also be favourable for diagnosing infection but the associated costs are 
high compared to HI. The assays are not typically high-throughput, however fixing cells 
on a MN plate and using an NP ELISA to quantify virus can be achieved in 24 hours 
(Khurelbaatar et al., 2014). It is also important to note that infectious virus is necessary 
for VN assays and thus appropriate bio-containment protocols must be followed. 
Another limiting factor of VN is the limited CPE of some influenza viruses (equine) on 
commonly used cell lines, for example MDCK cells (Madin-Darby canine kidney). The 
assay has, however, been successfully implemented for canine influenza serology 
(Crawford, 2005) despite the difficulty in implementation for routine testing (Dubovi, 
2010). 
 
1.5.5 HA Microarray 
The HA protein microarray has been developed as a high throughput assay that detects 
antibody responses against a range of different HA subtypes (Koopmans et al., 2012). 
Antigen protein is spotted, usually in triplicate, on to a nitrocellulose-coated glass slide 
and the slides are left in a dark, drying chamber until use. A serial dilution of serum is 
added to the slide for one hour at 37oC in a moist chamber, then washed with a protein 
array wash-buffer before adding a secondary antibody conjugated with a fluorescent 
dye. After washing again with the wash-buffer and water, the signal can be quantified 
using appropriate fluorescence detection equipment. 
1.5.5.1 HA Microarray applications: Advantages and disadvantages 
The microarray was designed as an alternative to cell-based assays, such as HI, to 
exclude the issue of red blood cell variability. The quantity of serum required is minimal 
at 10µl and the durability of the assay has proven promising in dry storage conditions at 
21oC for up to 21 months (Freidl et al., 2017).  
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1.6 Pseudotyped viruses (PVs) 
PVs are chimeric virions that display a surface glycoprotein from a virus of interest, and 
typically contain a retroviral core (Temperton et al., 2015). Gene deletions within the 
core prevent viral replication (particles can enter target cells but no progeny are 
produced) thus the virion is safer to work with. Elements of retroviral functionality are 
retained with structural and enzymatic genes (reverse transcriptase and integrase), 
which facilitate the self-assembly of virions and integration of a reporter gene carried 
by the remaining viral genome into a target cell genome of choice (Temperton et al., 
2007). The morphology and size of an influenza pseudotyped virus is very similar to that 
of an influenza A virion, approximately 100nm (Nefkens et al., 2007), the length of the 
haemagglutinin spikes are also similar to an influenza A virion between 9-11nm (Sawoo 
et al., 2014). The density of haemagglutinin on a lentiviral PV surface has not been 
characterised, however, reports suggest that it can vary;  “At the protein level, all 
pseudotyped viruses have a composition similar to that of the wild-type virus, with the 
exception of the levels of HA, which appear to be slightly reduced ? (Martinez-Sobrido et 
al., 2010) ĂŶĚ “HA incorporation levels in each type of particle varied ?(Hsu et al., 2015). 
Following a systematic analysis, a consensus protocol for influenza PV production has 
been published (Carnell et al., 2015). Different reporter genes can be used during PV 












Figure 7. Examples of reporter genes used in pseudotype virus production with associated assay 
time and cost (modified from original that was kindly provided by Dr Edward Wright). The lower 
half of the figure illustrates the readout seen when PVs infect cells and the upper half of the 
figure illustrates the change in readout due to the presence of antibodies that prevent the PV 




X-gal, CPRG (chlorophenol red-ɴ-D-galactopyranoside) and ONPG (o-nitrophenyl-ɴ-D-
ŐĂůĂĐƚŽƉǇƌĂŶŽƐŝĚĞ ?ĂůůŝŶǀŽůǀĞĐŽůŽƌŝŵĞƚƌŝĐĐŚĂŶŐĞƐŝŶĚƵĐĞĚďǇɴ-galactosidase activity 
encoded by the lacZ gene. GFP (green fluorescent protein) indicates PV infectivity 
through fluorescence and upon cell lysis luciferase (Luc) catalyses the conversion of 
Luciferin into Oxyluciferin and light, the light is detected and recorded as relative 
luminescence units. 
1.6.1 Pseudotype virus neutralisation assay (PVNA) 
PVs are used in PVNAs to determine the presence of neutralising antibodies within 
serum samples. A knock-down in luminescence, reduction in fluorescence or a colour 
change, depending on the reporter system used (Figures 7 and 8), indicates the presence 
of neutralising antibodies against the envelope protein that inhibit PV entry into a target 
cell line of choice. An IC50 (the reciprocal of the serum dilution that causes 50% 




Figure 8. Principles of the pseudotype virus neutralisation assay using the luciferase reporter 
gene. 1  W Target cells alone do not luminesce. 2  W Virus added to target cells, the virus infects 
target cells and the reporter gene is integrated into the cell genome causing cells to luminesce. 
3  W Upon addition of antisera containing  antibodies directed against the HA, the influenza 
pseudotyped virus is prevented from transducing target cells thus infection is reduced and the 
luminescence measured, decreases (Kinsley et al., 2016).  
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1.6.2 PVNA applications: Advantages and disadvantages 
The PVNA is a novel assay employing the safer, chimeric PV (as an alternative to 
infectious wild-type virus) to measure a neutralising antibody response. The PVNA 
provides a platform to research highly pathogenic viruses in a safer environment. A 
multiple plasmid transfection technique is used to produce the PVs, which facilitates an 
opportunity for individual gene manipulations that are potentially useful to study 
specific mutations. The costs associated with the PVNA can be higher than HI and thus 
it is less favourable in a diagnostic setting, however measuring the neutralising antibody 
response is beneficial for vaccine efficacy testing. The assay requires a minimal amount 
of serum, 2 ?10µl per replicate. Moreover, the neutralising antibody response to 
multiple viruses can be measured within a single assay by using two different reporter 
ŐĞŶĞƐ ‘ŵƵůƚŝƉůĞǆŝŶŐ ? ?ĨƵƌƚŚĞƌƌĞĚƵĐŝŶŐƚŚĞƋƵĂŶƚŝƚǇŽĨƐĞƌƵŵƵƐĞĚ(Molesti et al., 2014). 
 The PVNA was compared to traditional assays such as HI and MN for human 
influenza studies to assess whether PVs can act as substitutes for wild-type virus. The 
results demonstrated that the PVNA detects similar antibody responses with increased 
sensitivity (Garcia et al., 2010; Kong et al., 2006; Yang et al., 2014). Emerging diseases 
pose a serious health aŶĚƐĂĨĞƚǇƚŚƌĞĂƚĂŶĚƚŚƵƐƚŚĞWsEŝƐďĞŝŶŐĐŽŶƐŝĚĞƌĞĚĂ ‘ŶĞǆƚ
ŐĞŶĞƌĂƚŝŽŶĂƐƐĂǇ ?ĨŽƌĂƉŽƚĞŶƚŝĂůƐŽůƵƚŝŽŶƚŽƚŚŝƐƉƌŽďůĞŵ(Mather et al., 2013). Equine 
influenza PVs have been produced and trialled in PVNAs; the results showed 65% 
correlation with SRH results. There was an evident increase in sensitivity as some 




1.7 Comparisons of assays 
HI and SRH assays were established in the early 1930s and 1970s, respectively, and are 
still relied upon today. HI is inexpensive and quick to perform, lending itself for use in a 
diagnostic setting. Alternatively, SRH is more sensitive than HI and measures 
complement-mediated lysis, which is beneficial for vaccine immunogenicity testing. A 
disadvantage of employing either HI or SRH is the associated high level of inter-
laboratory variability due to a lack of standardisation (Wood et al., 2011). Vaccine 
immunogenicity testing requires a high level of consistency and accuracy and therefore 
the European Medicines Agency (EMA) suggest that a centralised laboratory should 
perform all assays for a vaccine study (European Medicines Agency, 2014). In such 
instances the VN assay is particularly beneficial, as the measurement of virus 
neutralising antibodies is most appropriate for evaluating vaccine immunogenicity. 
However, VN can be more variable than HI, is more expensive and difficult to reproduce 
(Stephenson et al., 2007; Trombetta & Montomoli, 2016). Furthermore, particularly for 
equine influenza the VN assay can be complicated to perform due to the lack of CPE 
caused. The PVNA provides a potential solution to these problems but the 
reproducibility of the assay needs to be assessed, PV production optimised and the 





2 MATERIALS AND METHODS 
2.1 Molecular biology 
2.1.1 Plasmids 
The production of all lentiviral pseudotype viruses in this study was dependent on plasmid 
p8.91, which encodes the HIV gag-pol genes and facilitates viral particle formation. Due to 
the low copy nature of p8.91, the plasmid DNA was purified in bulk by GenScript®. Upon 
receipt of plasmid from GenScript®, the lyophilised pellets were resuspended in 20µl of 
double distilled (dd) H2O (manufacturer guidelines). Firefly luciferase was the chosen 
reporter gene, encoded by pCSFLW, provided by Dr Temperton (Viral Pseudotype Unit, 
Kent). 
HA and NA genes were sub-cloned into mammalian expression plasmid pI.18 using 
restriction enzyme (RE) sites present in the multiple cloning site (MCS) (Figure 9). Details 
of the restriction enzymes used for cloning individual genes are reported in the methods 














Figure 9. pI.18 mammalian expression plasmid with multiple cloning site. The plasmid was 
developed by I. Tarpey and N. Greenwood (US patent number US6187759 B1). The Human 
Cytomegalovirus (CMV) promotor facilitates expression of a gene cloned into the multiple cloning 
site and Intron A enhances expression. The plasmid harbours an ampicillin resistance gene (AMP) 
for clone selection.  
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2.1.2 Restriction enzyme digests (for cloning and screening purposes) 
Fastdigest® restriction enzymes (RE) used were obtained from ThermoFisher Scientific. 
Table 2 indicates the quantity of DNA used per reaction along with other necessary 
reagents. Water and DNA volumes were adjusted depending on original DNA 
concentrations. Fastdigest® Green buffer was used as an alternative to adding loading dye 
when running digest reactions on an agarose gel (Methods section 2.1.7). Reactions were 
incubated at 37oC for 20 minutes and then heat inactivated at 80oC for 5 minutes. 
 
Table 2. Restriction enzyme DNA digest reaction volumes. 
Reagent Genomic/Plasmid DNA PCR product 
DNA 2µl (~1ug) 10µl (~500ng) 
Fastdigest® Green buffer 2µl 2µl 
Fastdigest® Enzyme 1µl 1µl 
H2O 15µl 17µl 
Total reaction volume 20µl 30µl 
 
2.1.3 Ligations 
Following successful digestion of plasmid and genomic DNA for cloning, the vector and 
gene insert were ligated at a 1:3 molar ratio using 1 unit of T4 DNA Ligase (ThermoFisher 
Scientific, catalogue number EL0011) with the designated buffer (ThermoFisher Scientific, 
catalogue number B69) and H2O, in a total volume of 10µl. A vector only control reaction 
was also set up to determine the presence of any undigested or re-ligated vector DNA. The 
reaction was incubated at room temperature overnight before being transformed 
(Methods section 2.1.3). 
 
2.1.4 Transformation 
Transformation of plasmid DNA was carried out using ^ƵďĐůŽŶŝŶŐ ĨĨŝĐŝĞŶĐǇ ? , ?ɲ ?
Chemically Competent Cells (ThermoFisher Scientific, catalogue number 18265017). A 
25µl aliquot of these E. coli cells was thawed on ice for 20 minutes before adding ~10ng of 
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DNA. After ligation, 2.5µl of the ligation reaction was added to the cells and mixed gently 
with end of pipette tip. After incubating on ice for 20 minutes, the cells were heat shocked 
in a water bath at 42oC for 20 seconds, then immediately placed on ice for 2 minutes. 
Nutrient-rich SOC media (200µl) (InvitrogenTM, catalogue number 15544034) was added 
to the cells for maximum transformation efficiency before placing in a shaking incubator 
for one hour at 37oC with 225 revolutions per minute (rpm). LB broth with agar (Sigma, 
catalogue number L3147) plates were made following manufacturer guidelines by adding 
16g into 400ml of ddH2O. Ampicillin was also added to the agar plates at 100µg/ml. All 
200µl of the SOC, containing transformed cells, was plated and incubated at 37oC 
overnight. 
 The following afternoon, colonies were picked and inoculated in 6ml of LB broth 
growth media (ThermoFisher Scientific, catalogue number BP1426) containing ampicillin 
at 100ug/ml, to grow overnight (~16-18 hours) at 37oC and 225 revolutions per minute 
(rpm). Plasmid DNA was then extracted from the bacterial cells the following day (Methods 
section 2.1.6). 
 
2.1.5 Colony Polymerase Chain Reaction (PCR)  
If there were more than 50 colonies present post-ligation, and particularly in cases where 
the vector-only control indicated the presence of undigested/re-ligated vector, a colony 
PCR was carried out to identify positive clones with the correct size insert. Primers 
designed by Nigel Temperton (VPU, Kent) were utilised and synthesised by Eurofins 
Genomics (sequences below). The primers facilitated amplification of the DNA region 
bounded by the arms of the pI.18 vector, for example the gene cloned within the MCS. 
 
pI.18 Forward primer  ? ?''d''''''d'd'dd ? ?
pI.18 Reverse primer  ? ?''''d'dd'd'' ? ?
 
Individual colonies were picked with a sterile pipette tip and left in ddH2O for 10 minutes 
before heating at 94oC for 3 minutes in a thermal cycler to burst-open the bacterial cells. 
Once cooled to room temperature 5µl of the lysed cell mix was added to a PCR reaction 
mix, which consisted of; 12.5µl of DreamTaq Green PCR Master Mix (2X) (ThermoFisher 
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Scientific, catalogue number K1081), 0.1µl FWD primer (0.2µM), 0.1µl REV primer (0.2µM) 
and 7.3µl ddH2O. The DNA mixtures were placed in a thermal cycler and the following 
program run; 94oC for 2 minutes before commencing 30 cycles of 94oC for 30 seconds, 
51oC for 1 minute, 72oC for 1 minute (allowing 30 seconds per Kb for extension) and then 
finally holding at 72oC for 5 minutes. The resulting PCR products were analysed on an 
agarose gel (Methods section 2.1.7) to identify clones with the correct size insert (loading 
dye was not required due to presence of optimised Green dye within the DreamTaq Green 
PCR Master Mix). From these results, the respective colonies were re-picked and grown 
overnight in 6ml of LB broth growth media (ThermoFisher Scientific, catalogue number 
BP1426) for 16-18 hours at 37oC and 225 revolutions per minute (rpm). 
 
2.1.6 Plasmid DNA purification 
The extraction and purification of plasmid DNA from transformed bacterial cells 
 ?^ƵďĐůŽŶŝŶŐĨĨŝĐŝĞŶĐǇ ?, ?ɲ ?ŽŵƉĞƚĞŶƚĞůůƐĨƌŽŵdŚĞƌŵŽ&ŝƐŚĞƌ^ĐŝĞŶƚŝĨŝĐ ?ĐĂƚĂůŽŐƵĞ 
number 18265017) was carried out using a commercially available kit, the QIAprep Spin 
Miniprep Kit (QIAGEN, catalogue number 27104) ? DĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ ŐƵŝĚĞůŝŶĞƐ ǁĞƌĞ
followed with a final elution of the DNA in 30µl of H2O at 70oc to maximise the DNA yield. 
For DNA extraction from an agarose gel a commercially available QIAGEN kit was also used 
(QIAGEN, catalogue number 28704). 
 
2.1.7 Measuring the concentration of DNA 
The concentration and purity of DNA was determined by ultraviolet spectrophotometry at 
an absorbance ratio of 260/280nm using the EĂŶŽƌŽƉ ?  ? ? ? ? ^ƉĞĐƚƌŽƉŚŽƚŽŵĞter 
 ?EĂŶŽƌŽƉ ?WƌŽĚƵĐƚƐ ?dŚĞƌŵŽFisher Scientific). Manufacturer instructions were adhered 
to, blanking with water. 
 
2.1.8 Gel electrophoresis 
To visualise DNA under ultraviolet light, DNA reactions were loaded on to a 1% (w/v) 
agarose gel (Fisher Scientific, catalogue number BP1356) consisting of 0.5X Tris-Acetate-
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Ethylenediaminetetraacetic acid (EDTA) buffer (TAE 50X stock solution from Fisher 
Scientific, catalogue number BP1332) with the addition of Nancy-520 fluorescent stain 
(Sigma, catalogue number 01494). When the addition of a loading dye was required 6X 
DNA Loading Dye was used (Thermo Fisher Scientific, catalogue number R0611).  
 The agarose gel was placed in an appropriately sized gel tank in 0.5X TAE buffer 
with a power supply of 90V (Consort, catalogue number EV231) for 30 minutes. Once the 
run was complete, a G:Box gel imager (Syngene, G:Box Chemi XT Imaging System) and 
GeneSnap software were used to acquire images of the DNA migration patterns within the 
gel. 
1 
2.1.9 Site directed mutagenesis (SDM) 
Primers were designed using Agilent Technologies QuikChangeTM Site-Directed Mutagenesis 
Kit primer design program (http://www.genomics.agilent.com/primerDesignProgram.jsp) and 
are detailed in the methods section of relevant chapters. The PCR was set up using 
AccuzymeTM mix (25µl), 140ng of template DNA, 125ng1 of FWD and REV primers, adding 
H2O to a final volume of 50µl. The DNA mixtures were placed in a thermal cycler and 
initially denatured at 98oC for 3 minutes, before commencing 25 cycles of denaturation at 
98oC for 20 seconds, annealing at 60oC2 for 15 seconds, extending the DNA at 72oC for 12 
minutes3 and then further extension at 72oC for 20 minutes to maximise full length 
products. A small volume of PCR product, 5µl, was run on a 1% (w/v) agarose gel to check 
for amplification by visualising bands of DNA (Methods section 2.1.7). If positive for 
amplification, the PCR product was purified using a Qiagen PCR purification kit (Methods 
section 2.1.5) and the concentration of the resulting DNA was measured (Methods section 
2.1.6). At this point it was necessary to digest the DNA with Dpn1 enzyme to remove any 
remaining parental (methylated) DNA; 700ng of DNA was digested with 1µl of fast digest 
Dpn1 enzyme, 1µl of fast digest buffer (ThermoFisher, catalogue number FD1703) and H2O 
                                                          
1 Quantity of primers required should be calculated using Agilent QuikChangeTM formula: 
X pmoles of primer = (125ng of primer / 330 x number of bases in primer) x 1000 
2Annealing temperature to be defined according to primer design. 




for a total reaction volume of 10µl. The digestion reaction was incubated for 20 minutes 
at 37oC, followed by 80oC for 5 minutes to deactivate the enzyme. 
 dŚĞƌĞƐƵůƚŝŶŐƉůĂƐŵŝĚEǁĂƐƚƌĂŶƐĨŽƌŵĞĚŝŶƚŽ, ?ɲƐƵďĐůŽŶŝŶŐĞĨĨŝĐŝĞŶĐǇE. coli 
competent cells and plated onto agar plates containing ampicillin (100µg/ml) overnight 
(Methods section 2.1.3). After successful transformation, two colonies were picked and 
overnight LB cultures were prepared. Plasmid DNA was purified from the bacterial cells 
using a Qiagen miniprep kit (Methods section 2.1.5), eluting in 50µl of H2O at 70oC and was 
sent for sequencing at GATC Biotech (Methods section 2.1.9). 
 
2.1.10 Sequencing 
To verify that the correct DNA sequence was inserted into pI.18 during cloning or to ensure 
the correct change had been incorporated during SDM, the recombinant DNA was sent for 
sequencing. Sanger sequencing via GATC Biotech was carried out by the LightRUN system, 




2.2 Cell culture 
2.2.1 Cell lines and maintenance 
Human embryonic kidney (HEK) 293T/17 cells were purchased from ATCC® (catalogue 
number CRL- ? ? ? ? ? ? ? for use as a producer and target cell line. The A72 cell line originated 
from a tumour of canine thigh tissue and was a kind gift from Dr Pablo Murcia (Centre for 
Virus Research, Glasgow). Both cell lines were cultured in ƵůďĞĐĐŽ ?Ɛ DŽĚŝĨŝĞĚ ĂŐůĞ
Medium (DMEM PAN Biotech, catalogue number P04-04510) supplemented with 10% 
(v/v) heat inactivated fetal bovine serum (FBS PAN Biotech, catalogue number P40-
37500HI) and 1% (v/v) 1mg/ml penicillin-streptomycin (Sigma, catalogue number P4333), 
together referred to as D-10. Cells were grown on Nunclon® surface petri dishes (Sigma, 
catalogue number Z763632) at 37oC in 5% CO2. To sub-culture the cells, D-10 was removed 
from the plate and trypsin EDTA solution (Sigma, catalogue number T3924) was added to 
detach cells from the surface of the plate. Cells were then resuspended in fresh D-10 and 
seeded at an appropriate density to maintain the cells. 
 
2.2.2 Freezing and thawing cell lines 
At 80% confluence, cells were trypsinised and resuspended in D-10 (three times the 
volume of trypsin) before centrifuging for 5 minutes at 500rpm. The pellet of cells from 
one 10cm Nunclon® dish was gently resuspended in a mixture of D-10 with 10% (v/v) 
dimethyl sulfoxide (DMSO from VWR International Ltd, catalogue number 282164K) in a 
total volume of 2ml. To freeze, 1ml aliquots in cryovials were stored in a Mr FrostyTM for 
24 hours at -80oC before transferring to a storage box at -80oC. 
 To thaw an aliquot of cells, the cryovial was placed in a 37oC water bath for 
approximately 5 minutes (caution was taken not to allow the cells to reach 37oC to prevent 
DMSO toxicity affecting the health of the cells). The cells were resuspended in D-10 and 
centrifuged at 1000g for 5 minutes to remove the freezing media and finally resuspended 




2.3 Influenza lentiviral pseudotype virus (PV) protocol 
2.3.1 PV production 
2.3.1.1 Haemagglutinin (HA) only PVs 
HA-only PVs were generated via a four plasmid co-transfection of HEK293T/17 cells using 
polyethylenimine (PEI) transfection reagent (Sigma, catalogue number 408727) at 1mg/ml 
(Figure 10). The HA surface glycoprotein expressed by pI.18, p8.91-HIV gag-pol retroviral 
core, pCSFLW-firefly luciferase reporter gene and endoprotease expressing plasmid (to 
cleave the HA) were combined with OptiMEMTM (ThermoFisher, catalogue number 
11058021), whilst a separate OptiMEMTM-PEI mixture was left to incubate at room 
temperature for 5 minutes. The OptiMEMTM-DNA mix was then added to the OptiMEMTM-
PEI and incubated at room temperature for 20 minutes. The quantity of DNA plasmids and 
volumes of OptiMEMTM and PEI used were dependent on the size of the cell culture vessel 
(Table 3). Following 20 minutes of incubation at room temperature, the transfection mix 
was added to the monolayer of cells (at 70-80% confluence) and incubated at 37oC for 24 
hours. Recombinant neuraminidase from Clostridium perfringens (Sigma, catalogue 
number N2876) was added 24 hours post-transfection, to ensure exit of viral progeny from 
producer cells. The pseudotyped virus was harvested at 48 hours through 0.45µm filters 
and virus supernatant was stored at -80oC in appropriate sized aliquots. 
 
2.3.1.2 Haemagglutinin and neuraminidase PVs 
To generate PVs that display both HA and NA glycoproteins on their surface, an NA-
expressing plasmid was added to the OptiMEMTM-DNA mix instead of the exogenous NA 




Table 3. Transfection reagents and the quantity required for transfection within different sized cell 
culture vessels.  
 
Transfection reagent 
Quantity of reagent 
EƵŶĐ ?EƵŶĐůŽŶ ?sŝƚĂ6-
Well Multidish 
Nunclon® 10cm dish 
PEI (1mg/ml) 17.5 µl 35 µl 
OptiMEMTM 100 µl 200 µl 
pI.18-HA 500 ng 1 µg 
p8.91-gag-pol 500 ng 1 µg 
pCSFLW 1 µg 1.5 µg 
Exogenous NA 50 µl 100 µl 




Figure 10. Schematic of four/five plasmid co-transfection system using HEK293T/17 cells (modified 
from Scott et al.2012) to generate pseudotype viruses.  
[38] 
 
2.3.2 PV titration 
PVs were titrated using HEK293T/17 cells (1x104 cells/well) with an initial 100µl of neat 
virus-containing supernatant that was subsequently serially diluted 1:2 across a white 96-
well plate (ThermoScientificTM NuncTM, catalogue number 136101) and incubated for 48 
hours at 37oC. After 48 hours the cell cultures were assessed and luminescence read using 
the Bright-Glo assay system with a GloMax luminometer (Promega, UK). The PV titres are 
reported as relative luminescence units (RLU)/ml. 
 
2.3.3 Pseudotyped virus neutralisation assay (PVNA) 
Each serum sample was diluted 1/40 (unless otherwise stated in results chapters) with 
subsequent two-fold dilutions in a 96-well plate, using D-10 media. A PV input of 1x106 
RLU was added per well and then incubated for one hour at 37oC to allow neutralisation 
to proceed. HEK293T/17 cells (1x104 cells/well) were added to the serum plus PV 
combination and incubated for a further 48 hours at 37oC. Luminescence was measured 
following the same procedure as the PV titration (Methods section 2.3.2). PV only (no 
neutralisation) and cell only (equivalent to complete neutralisation) controls were 
included on each 96-well plate. 
[39] 
 
2.3.4 Statistical analysis 
For analysis of PVNAs, the raw RLU data points were converted to a percentage 
neutralisation value, whereby 100% neutralisation equals the mean cell-only RLU value 
and 0% neutralisation equals the mean PV-only RLU value. The normalised data was then 
plotted on a neutralisation percentage scale and an IC50 value calculated, using the non-
linear regression analysis on GraphPad Prism (Figure 11). The IC50 is the reciprocal of the 
serum dilution that induces 50% neutralisation. 
 
 















Figure 11. Example of GraphPad equation: log(inhibitor) vs. normalized response -- Variable slope 
 ? model used to fit curve for neutralisation data. 
 
 
Each combination of serum and PV was tested at least in duplicate to calculate a mean 
IC50. All IC50 values within the serum dilution range of the assay, were used to calculate a 
mean IC50. Following this, fold-differences were calculated between different PVs assayed 




2.4 Influenza MUNANA neuraminidase activity assay 
The influenza 20-(4-methylumbelliferyl)-a-D-N-acetylneuraminic acid (MUNANA) 
neuraminidase activity assay protocol was edited from SOP V-6815/01-10 Angie Lackenby, 
Respiratory Virus Unit, Health Protection Agency (Wetherall et al., 2003). 
 
Table 4. Influenza MUNANA neuraminidase activity assay reagents. 
Master stock solutions  
1) 325mM MES: 31.72g MES in 500ml ddH2O (pH to 6.5 with 
concentrated NaOH) 
2) 100mM CaCl2: 5.55g CaCl2 in 500ml ddH2O 
3) 1M Glycine: 37.5g in 500ml ddH2O (pH to 10.7 with 
concentrated NaOH) 
4) 1mM MUNANA: 25mg in 51ml MES assay buffer (store -20OC) 
Working solutions and buffers  
5) MES assay buffer: 32.5mM MES (50ml solution 1) 
4mM CaCl2 (20ml solution 2) 
ddH2O 430ml 
pH to 6.5 with concentrated NaOH 
6) 100µM MUNANA (per plate): 300µl of solution 4 
2.7ml of solution 5 
7) Stop solution (500ml): 25% ethanol (125ml absolute ethanol) 
ddH2O 325ml 
pH to 10.7 with concentrated NaOH 
 
 
MES assay buffer was added to each well of black 96-well flat bottomed plate (20µl). PVs 
were then added and mixed well by pipetting, in duplicate, at a starting dilution of 1/2. A 
two-fold serial dilution was carried-out, leaving the final row as a negative control, 
containing the buffer only. The MUNANA substrate (working solution 5; Table 4) was 
prepared with 3ml for each plate and 30µl added to each well, including the blank row. 
The plates were sealed, wrapped in foil and placed in a shaking incubator, at 37oC, for one 
hour. To terminate the reaction, 150µl of solution7 (Table 10) was added to all wells. The 
plate was read within 30 minutes of adding the stop solution with the following settings; 




3 EQUINE INFLUENZA PSEUDOTYPE VIRUS PRODUCTION AND 
OPTIMISATION 
3.1 Introduction 
Optimisation of pseudotype virus (PV) production protocols is necessary to ensure efficient 
generation of high-titre PVs. High-titre PV preparations are desirable as this reduces the 
need to use multiple batches during large-ƐĐĂůĞƐƚƵĚŝĞƐ ?Ws ‘ďĂƚĐŚ ?ĐŽŶƐŝƐƚƐŽĨƚŚĞƚŽƚĂů
volume of PV-containing cell culture supernatant that is collected and pooled (if necessary) 
on the same day. There are several aspects to the production of PVs that can be optimised 
but the haemagglutinin (HA) and neuraminidase (NA) surface glycoproteins form the main 
focus of this chapter. Specifically, the cleavage of HA and the source of NA. 
The HA protein is fundamental for influenza virion binding to sialic acid-containing 
receptors on a target cell. A prerequisite for successful infection is cleavage of the HA 
precursor (HA0) into its respective HA1 and HA2 subunits, which can occur intra- or extra-
cellularly (Bertram et al., 2010). Once a virion is endocytosed, the cleaved form of HA 
undergoes a conformational change triggered by a low pH within the endosome. The 
change in protein structure exposes a fusion peptide that facilitates fusion of the virion 
with the endosomal membrane (reviewed in Skehel and Wiley, 2000). The fusion event is 
essential for release of viral RNA into the cytosol, which can then be used for replication 
of the viral genome. 
Cleavage recognition sites differ between strains of influenza; polybasic cleavage 
sites within highly pathogenic influenza strains (H5 and H7) can be cleaved by non tissue-
specific proteases such as furin whereas low pathogenic variants (for example the H3 
strains used in this study) require cell specific protease activity. Therefore, for the 
production of an influenza pseudotyped virus with a monobasic cleavage site, the correct 
choice of protease is essential. Type II transmembrane serine proteases TMPRSS2 
(transmembrane protease serine 2), TMPRSS4 and HAT (human airway trypsin-like 
protease) are known to cleave HA of human influenza viruses (Böttcher et al., 2006). 
TMPRSS2 has been shown to effectively cleave group two human HAs (subtypes H3, H4, 
H7, H10, H14 and H15) (Ferrara et al., 2012) as well as an equine H3 HA (Scott et al., 2012). 
However, the optimisation and efficacy of potential alternatives such as TMPRSS4 and 
HAT, have only been tested for human H3 PVs (Bertram et al., 2010). 
[42] 
 
In nature, influenza NA cleaves sialic acid receptors permitting viral egress. The NA 
enzyme is therefore essential for efficient influenza PV production (Cheresiz et al., 2014). 
Both the source and quantity of NA can be altered during the production of PVs. An 
exogenous source of NA (often from Clostridium perfringens) is typically added for 
cleavage (Scott et al., 2012). However, an endogenous source of NA (i.e. NA-encoding 
plasmid) has also been trialled alongside different HA subtypes (e.g. H5 with N1 (Cheresiz 
et al., 2014) and H7 with N1, N3 and N7 (Molesti et al., 2012). This results in NA being 
expressed on the pseudotype virus envelope. The titres of PVs incorporating both HA and 
NA have been shown to vary. One study showed that the utilisation of an N2 plasmid, 
compared to an exogenous source of NA, increased the titre of a human H3 PV (Ferrara, 
2016). Similarly, co-transfection of matched H1 and N1 avian glycoproteins yielded a 
higher PV titre than an exogenous source of NA (Molesti et al., 2012). Therefore, the 
addition of an NA plasmid may be useful to increase PV titre in some instances.  
The aim of this chapter was to optimise the production of equine influenza PVs, first 
through trialling different types and quantities of protease plasmid and secondly, by 
adding an endogenous NA plasmid in contrast to exogenous NA during PV production. 
 
 
3.2 Materials and methods 
3.2.1 Plasmids 
A/equine/Newmarket/1979 (H3) (Nm79) and A/equine/Richmond/1/2007 (H3) (Rich07) 
PCR products, amplified to include restriction enzyme (RE) recognition sites for 
EcoRV/BamHI and BamHI/XhoI Ăƚ  ? ? ? ? ? ƚĞƌŵŝŶŝŝ (enzymes from Thermo Scientific) 
respectively, were kindly provided by Dr Adam Rash and Dr Debra Elton at the Animal 
Health Trust. These H3 genes were cloned into the mammalian expression plasmid pI.18 
(see Chapter 2 Methods section 2.1.2) for PV production at the University of Kent. 
 The N8 (A/equine/Richmond/1/2007 (H3N8), GenBank: KF559336.1) gene 
sequence was synthesised with terminal BamHI/XhoI sites incorporated for cloning into 
pUC57 by GenScript®. The lyophilised pellet of this pUC57 N8 equine recombinant plasmid 
was resuspended in 20µl of ddH2O (manufacturer guidelines) and re-transformed into 
[43] 
 
chemically competent Subcloning EfficiencyTM , ?ɲTM Competent Cells (Chapter 2 
Methods section 2.1.4). The gene was then subcloned into plasmid vector pI.18 (Chapter 
2 Methods section 2.1.2). 
The plasmids expressing the pCAGGS-TMPRSS2 and pCAGGS-HAT endoproteases 
were kindly provided by Dr Eva Böttcher and Professor Hans Dieter Klenk, and pCMV-Tag3-
TMPRSS4 was gifted by Professor Stefan Pöhlmann. 
 
3.2.2 PV production 
PVs displaying only HA were produced as described in (Chapter 2 Methods section 2.3.1.1). 
Briefly, HEK293T/17 cells were co-transfected (using transfection reagent PEI) with 
plasmids expressing an equine influenza H3 surface glycoprotein, HIV gag-pol, firefly 
luciferase reporter gene and endoprotease. All three proteases were tested using 125, 
250, 500, 750 and 1000ng of expression plasmid DNA. 
After protease optimisation, optimal protease conditions were used in a five p 
lasmid co-transfection protocol, with the addition of 125ng of NA plasmid (4:1 ratio 
of HA:NA). All PV titrations were performed as described previously and titres calculated 
in RLU/ml (Chapter 2 Methods section 2.3.2). 
 
3.2.3 Statistical analysis 
Comparison of two data sets was carried out using an unpaired T-test, except in cases 
where a normal distribution could not be assumed. In such cases, the Mann-Whitney test 
was applied. Values outside of the 95% confidence limits were deemed to be statistically 






3.3.1  Cloning of Nm79 and Rich07 HAs 
The Nm79 HA PCR product was amplified with primers incorporating BamHI and XhoI sites 
and ligated into pI.18, which was digested with the same enzymes. Post transformation, 
three colonies were picked, cultured overnight and the plasmids purified (Chapter 2 
Methods section 2.1.4). The plasmids were screened by restriction enzyme digest, to 
determine if the ligation had been successful. One positive colony was identified, however 
the gene was truncated at ~1100bp not the expected 1700bp for HA (Figure 12). The full 
Nm79 sequence was checked for restriction sites and a BamHI site was identified between 




















Figure 12. Digest screen of A/equine/Newmarket/1979 HA in pI.18 (1-3) using KpnI and XhoI REs. 
All three clones were negative for the correct size insert. Positive control (+ve) was 






         430        440        450        460        470        480 
 acatggacag gtgtcactca aaacggaaga agtggcgcct gcagaagggg atcagccgat 
 
         490        500        510        520        530        540 
 agtttcttta gccgactgaa ttggctaaca aaatctggag attcttaccc cacattgaat 
 
         550        560        570        580        590        600 
Agtgacaatgc ctaacaataa caatttcgat aaactataca tctgggggat ccatcacccg 
 
 
Figure 13. Section of A/equine/Newmarket/1979 HA nucleotide sequence with BamHI restriction 
site (GGATCC) highlighted at positions 587 ?592. 
 
 
In order to address this truncation issue, a blunt end cloning technique was adopted. The 
Nm79 HA PCR product was digested with Xho/ ? ?഻ĞŶĚ ?ĂŶĚƉ/ ? ? ?ǁĂƐĚŝŐĞƐƚĞĚƐĞƋƵĞŶƚŝĂůůǇ
with EcoRV and Xho/ ? ĨĂĐŝůŝƚĂƚŝŶŐ ƚŚĞ  ?഻ ĚŝƌĞĐƚŝŽŶĂů ? ?഻ ďůƵŶƚ ĞŶĚ ĐůŽŶŝŶŐ ƐƚƌĂtegy. After 
ligating the inserts into pI.18 and transforming them, a colony PCR was carried out, to 
identify colonies containing the correct size insert at ~1700bp. Eight colonies were picked 
and five out of the eight were positive for 1700bp inserts (Figure 14). Sequence analysis 













Figure 14. Colony PCR of A/equine/Newmarket/1979 HA insert in pI.18. Lanes 1, 3, 4, 5 and 8 were 
positive for the correct size insert at 1.7Kb. Lanes 2, 7 and 9 were negative for HA. Positive control 
(+ve) was A/equine/Sussex/1989 HA in pI.18 and negative control (-ve) was pI.18 cut with BamHI 
and XhoI.  
[46] 
 
Primers designed to amplify Rich07 cDNA also incorporated BamHI and XhoI sites, neither 
of which appear within the HA sequence of this strain. Cloning was carried out without any 
unforeseen digestion issues and a colony PCR of ten colonies identified one positive clone 
(Figure 15). The positive colony was cultured, purified, confirmed positive by RE digest and 












Figure 15. Colony PCR of A/equine/Richmond/1/2007 HA insert in pI.18. Lane 6 contains a positive 
clone, whereas 1 ?5 and 7 ?10 appeared negative. Positive control (+ve) was 





3.3.2 Protease dependent generation of Nm79 and Rich07 PVs 
The newly cloned Nm79 and Rich07 HA-pI.18 plasmids were transfected alongside HIV gag-
pol, firefly luciferase and various protease plasmids at different concentrations into 
HEK293T/17 cells. Two controls were incorporated; delta protease (HA but no protease) 
and delta env (no HA envelope protein or protease). The former indicates luminescence 
attributed to HA-mediated entry without specific protease activity. The latter indicates 
background luminescence not attributed to glycoprotein-specific mediated entry. It is 
evident that PV titre does differ, depending on the quantity and type of protease plasmid 
used (Figure 16). The titres of Rich07 with TMPRSS2 and HAT differed significantly when 
125 and 1000ng were compared (unpaired T-test; p = 0.016 and p = 0.023, respectively). 
This was also the case for Nm79 (p = 0.010 and p = 0.008, respectively). Interestingly, the 
smallest quantity of TMPRSS2 and HAT protease expression plasmids (125ng) generated 
the highest titres. However, for TMPRSS4 the titres were not significantly different (Nm79 
p = 0.198 and Rich07 p = 0.325) from the delta protease, implying that it does not 
effectively cleave either of the equine H3 HAs. Cleavage of the HA using 125ng of TMPRSS2 
for both Nm79 and Rich07 significantly increased PV titre compared to delta envelope (p 
= 0.004 and p = 0.009 respectively), likewise with HAT (p = 0.004 and p = 0.020). For Nm79 
there was no significant improvement in titre between TMPRSS2 and HAT (p = 0.217) but 





















Figure 16. PV titres obtained with A) A/equine/Richmond/1/2007 H3 and  
B) A/equine/Newmarket/1979 H3 in combination with selected protease-expressing plasmids. 
TMPRSS2 (TMP2), TMPRSS4 (TMP4) and HAT proteases were trialled, each number denotes the 
quantity of protease plasmid used (ng). PV titres reported in relative luminescent units (RLU/ml) 






3.3.3 Sub-cloning of Rich07 N8 gene 
Transformation of E. coli host cells with pUC57-N8 was successful. The plasmid-containing 
E. coli cells were then cultured and the plasmids purified. The N8 gene was then excised 
from pUC57 using BamHI/XhoI REs: Gel electrophoresis confirmed that the digestion was 
successful (gel photo not shown) and subsequently the DNA was extracted from the gel 
and purified (Chapter 2 Methods section 2.1.6). Plasmid vector pI.18 was digested with the 
same REs (BamHI/XhoI) and ligated with the N8 gene. Ligations were set up at a 1:3 molar 
ratio of vector: insert (plus a vector only control). Post transformation, more than 1000 
colonies were obtained for pI.18-N8. A smaller volume of bacterial culture was plated and 
re-plated until individual colonies were discreet. A colony PCR identified that all colonies 
were negative for the insert. Therefore, a new plasmid stock of pI.18, digested with BamHI 
and XhoI was prepared and resulted in a much higher concentration of DNA with a 260/280 
ratio of 1.85. Using the new plasmid stock, ligations with N8 were set up at 1:1 and 1:3 
ratio of vector: insert. Transformations were successful and ten colonies were carried 
forward into a colony PCR. One positive clone was identified at the 1:3 ratio (Figure 17). 
 
 
Figure 17. Colony PCR of pI.18-N8 equine (from A/equine/Richmond/1/2007 H3N8). Lanes 2-13 (A) 
are 1:1 molar ratio ligations, all negative for N8 gene. Lanes 2-13 (B) are 1:3 molar ratio ligations, 
with a positive clone in lane 2. Positive control (+ve) is A/chicken/Italy/1067/1999 N1 in pI.18 and 





3.3.4 Equine H3 and N8 PV 
In order for a PV preparation to be considered functional, the difference in RLU/ml 
between ȴenv negative control (no HA or NA present) and the PV, should be significant, as 
particles have been demonstrated to enter target cells via the surface envelope 
glycoprotein. The addition of exogenous NA to generate an H3 only 
A/equine/Richmond/1/2007 PV yielded a titre much greater than ȴenv (p < 0.001). The co-
transfection of H3 and N8 plasmids to produce Rich07 H3N8 PV, was also successful  
(p < 0.001), however the titre was not as high as using exogenous NA (Figure 18).  As 
expected, there was no difference in RLU/ml when the H3ȴNA control and ȴenv were 























Figure 18. A/equine/Richmond/1/2007 H3 PV titres of preparations generated by co-transfection 
with an N8 encoding plasmid or using the standard technique of adding exogenous (Ex) NA 
(positive control). H3ȴNA (H3 without NA) and ȴenv (no HA or NA) were generated as negative 
controls. Average PV titres reported in relative luminescent units (RLU/ml), with error bars 
indicating +SEM, based on 8 replicates. The statistically significant difference between H3+ExNA 







A/equine/Richmond/2007 and A/equine/Newmarket/79 H3 glycoproteins were 
effectively cleaved by TMPRSS2 and HAT proteases, facilitating PV production. In both 
cases, the smallest quantity of transfected protease plasmid (125ng) yielded the highest 
PV titre, implying that a greater quantity of protease does not enable more effective 
cleavage of the HA. TMPRSS2 is known to play an HA cleavage role in the activation of 
human H3 HA. A recent study also showed that TMPRSS2 knock-out mice experienced 
reduced weight-loss when infected with an H3N2 virus. However, survival was not 
improved, indicating the role of another protease (Hatesuer et al., 2013). Interestingly, 
survival against a H3N2 virus was greatly improved for knock-out TMPRSS2 and TMPRSS4 
mice, highlighting the role of TMPRSS4 in H3 cleavage and subsequent virus infectivity 
(Kühn et al., 2016). By contrast, in the current study, TMPRSS4 did not activate the HA to 
facilitate the production of either equine H3 PVs. Similarly, to TMPRSS2 and HAT, 125ng of 
TMPRSS4 plasmid yielded the highest PV titre, however this was not significantly different 
from the delta protease controls (Nm79 p = 0.198 and Rich07 p = 0.325). TMPRSS4 has 
been shown to effectively cleave H3s during PV production (Ferrara, 2016), however, the 
H3s were of human not equine origin. The cleavage sites of the human H3s 
(A/Udorn/307/1972 and A/California/7/2004) used in that study and the equine H3s differ, 
which may explain the lack of cleavage. The human H3 cleavage sites contain a threonine, 
 ‘W<YTZ ?' ? ŝŶ ƚŚĞ ƉůĂĐĞ ŽĨ ĂŶ ŝƐŽůĞƵĐŝŶĞ ?  ‘W<YIR/' ? ĨŽƌ ĞƋƵŝŶĞ , ?  ?dĂďůĞ5). The 
consensus sequence for the H3 HA cleavage site is PEKQTR, with cleavage occurring after 
the single arginine (Sun et al., 2010). From the limited data available (Chaipan et al., 2009; 
Ferrara, 2016), TMPRSS4 most effectively cleaves influenza HA sequences with a polar 
amino acid threonine/serine preceding the cleavage site (Table 5). Interestingly the 1918 
 ‘^ƉĂŶŝƐŚ &ůƵ ? ǀŝƌƵƐ  ?, ?E ? ? ? ǁŚŝĐŚ ĐůĂŝŵĞĚ ŵŽƌĞ ƚŚĂŶ  ? ? ŵŝůůŝŽŶ ůŝǀĞƐ, contained a 
monobasic cleavage site.  Chaipan et al. (2009) illustrated how TMPRSS4 successfully 





Table 5. Comparison of cleavage sites from pseudotype viruses that have been successfully cleaved 
with TMPRSS4 (9) and those that were not (X). 
 
Influenza strain Subtype Cleavage site Cleaved 
H3 consensus H3 P E K Q ± T R  
A/South Carolina/1/1918    H1 . S I . - S . 9 
A/Korea/426/1968           H2 . Q I E - . . 9 
A/Udorn/307/1972           H3 . . . . - . . 9 
A/California/7/2004        H3 . . . . - . . 9 
A/Wisconsin/67/2005        H3 . . . . - . . 9 
A/equine/Richmond/1/07     H3 . . . . - I . X 
A/equine/Newmarket/1979    H3 . . . . - I . X 
A/duck/Czechoslovakia/1956 H4 . . . A - S . 9 
A/turkey/Ontario/6118/1968 H8 . S V E ± P . 9 
A/chicken/Germany/N/1949 H10 . . V V Q G . X 
A/shearwater/West Australia/2576/79 H15 . . . I R T . 9 
 
It would be advantageous to be able to identify an optimal protease for HA cleavage during 
pseudotype virus production by sequence analysis, however, more data would be 
necessary to determine if this is a plausible approach. It has been shown that the 
matriptase protein (another member of the type II transmembrane serine family) cleaves 
some strains, though not all, within the H1 subtype (Hamilton et al., 2012). This suggests 
using consensus sequences may not be accurate for determining the optimal protease to 
use. It might be appropriate to use a site directed mutagenesis approach to confirm 
specific amino acids that affect cleavage by particular proteases (Passero et al., 2012). Site 
directed mutagenesis has already been trialled with respect to introducing a polybasic in 
place of a monobasic cleavage site, in an attempt to improve pseudotype production, but 
unfortunately it did not yield higher titre PVs as typically seen with polybasic H5 strains 
(Sawoo et al., 2014).  
An interesting finding is the effect of multiple proteases on the HA cleavage 
process. Different combinations of proteases have been shown to increase the 
[53] 
 
effectiveness of cleavage; TMPRSS2 with HAT (Sawoo et al., 2014) and TMPRSS2 with 
TMPRSS4 (Kühn et al., 2016). TMPRSS2 is known to cleave HA during transport to the host 
cell membrane of an infected cell, whereas HAT cleaves upon insertion to the cell 
membrane (Bertram et al., 2010b). Therefore, any uncleaved HA that bypassed TMPRSS2 
essentially has another opportunity to be cleaved by HAT. It is possible that proteases 
could be selected by sequence analysis and two proteases that act at different time points 
in the influenza life cycle utilised to provide increased opportunities for cleavage. 
Studies have already shown it is possible to produce human and avian influenza 
PVs that express both HA and NA (Cheresiz et al., 2014; Molesti et al., 2012) but not thus 
far for equine PVs. Here, it is evident that an exogenous source of NA generates a higher 
titre PV than an endogenous source of NA but nevertheless the N8-encoding plasmid does 
facilitate the production of a functional PV. Neuraminidase antibodies are known to aid 
virus neutralisation (Marcelin et al., 2012). Therefore, production of PVs incorporating 
both HA and NA could be beneficial for quantifying the additive effect of anti-NA 
antibodies, as well as anti-HA, in neutralisation assays. The functional H3N8 PV could be a 
useful tool for vaccine immunogenicity trials in the future. For studies that focus on anti-
HA antibody responses, the HA-only PVs produced with exogenous NA are a more 
appropriate tool to dissect a specific response. Similarly, NA-only PVs would be useful for 
studying anti-NA antibodies, however a new approach to quantify these PVs would be 
necessary as the currently employed titration assay quantifies PVs based on virus particle 
entry rather than exit and without the HA, quantification would not be possible.  
Optimising the titre of HA-only equine PVs will be useful for future investigations 
to reduce the likelihood of having to use different PV batches, which may potentially 
introduce an additional study variable. Furthermore, the production of HA+NA PVs will 
broaden the application of PVs as tools to study different aspects of equine influenza 
biology, specifically seroepidemiology and vaccine evaluation. It is also important to 
consider that working within strict budgets can be a challenge and thus investigating ways 
to reduce cost, without impeding the quality of data, may help such financial situations. 
Further to employing different HA and NA approaches in pseudotype production, it is 
possible to use different reporter gene/substrate systems that will further reduce the cost 
of pseudotyping and hopefully make reagents more accessible to laboratories in low-and-
middle-income countries.  
[54] 
 
4 APPLICATION OF THE PSEUDOTYPED VIRUS NEUTRALISATION ASSAY 
TO EQUINE INFLUENZA VACCINE EFFICACY TESTING 
4.1 Introduction 
Equine influenza vaccines were made available in the UK in the late 1960s, shortly after 
the first human influenza vaccines. There are currently four different equine influenza A 
vaccines available in the UK (Animal Health Trust, 2017). For human influenza vaccines, a 
panel of experts meet annually to recommend the strains to be included in equine 
influenza vaccines. At present, Florida-sublineage clade 1 and 2 viruses continue to 
circulate in Europe while clade 1 predominates in America (Bryant et al., 2011). The current 
recommendation is for strains representative of both clades to be included in vaccines 
(OIE, 2017). 
 Vaccine manufacturers have to conduct efficacy studies to assess the level of 
antibodies induced by vaccination and whether or not the vaccine provides protection 
against clinical signs after challenge with a representative virus. The serological assays 
currently employed to measure antibody responses against equine influenza vaccination 
are SRH and HI. Notably, these assays do not measure neutralising antibody responses and 
at present, there is not a serological assay readily available to measure neutralising 
antibody responses to equine influenza. The advantages and disadvantages of different 
serological assays for equine influenza are reviewed in Kinsley et al., 2016. As the PVNA 
has already been shown to distinguish between positive and negative equine influenza 
serum samples, neutralisation data would help to identify promising vaccine candidates 
and evaluate the neutralising antibody response from experimentally infected equines. 
 Assessments of intra-lab and inter-lab variability have been carried out for Single 
Radial Haemolysis (SRH) and Haemagglutination Inhibition (HI) assays but not thus far for 
the PVNA. The high variability in results across laboratories that is seen with HI and SRH 
has been well-documented for many years and still needs to be addressed (Daly et al., 
2007a; Wood et al., 1994, 2011, 2012). Assays that can be used in laboratories within 
different institutions, with limited variability, will ultimately infuse more confidence in 
results, which could increase their adoption, for example in vaccine efficacy testing. 
Therefore, comparisons between traditional assays and investigations into the variation of 
newer assays such as the PVNA are important if they are to be considered for use in large 
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scale studies internationally. Comparative studies between the HI assay and the PVNA for 
human influenza have so far been carried out with promising results (Alberini et al., 2009; 
Garcia & Lai, 2011; Yang et al., 2014). Additionally, there is some evidence that the assay 
demonstrates greater sensitivity as some serum samples (from vaccinated animals) have 
been defined as negative by SRH but positive by PVNA (Scott et al., 2012). 
 It is not always possible to produce large-enough quantities of pseudotyped virus 
(PV) at one time to complete a project. This may be because the particular pseudotype has 
a low titre and production in larger culture vessels is not as efficient, but also unplanned 
repeats may necessitate using different PV batches. Therefore, it would be beneficial to 
investigate variation between PV batches. Furthermore, the assessment of the 
reproducibility of the pseudotype virus neutralisation assay (PVNA) would give an insight 
into the robustness of the assay. This is essential if the assay were to be adopted by 
numerous laboratories and considered for use in a commercial setting. There are several 
variables that could affect the repeatability of the PVNA. The two primary variables are 
serum and PV; neat or pre-diluted sera can be used and batches of PV can vary in titre. 
 The aim of this study was to assess performance of PVNA in the context of a vaccine 
efficacy trial. Objectives were to (i) assess the reproducibility of the PVNA (ii) the capability 
of the assay to distinguish between homologous and heterologous PV and serum pairings 
(iii) employ PVNA in a vaccine efficacy trial to evaluate the neutralising antibody response 
to two different monovalent vaccines and to compare the results to those acquired 
through traditional methods such as SRH and HI. 
 
4.2 Materials and methods 
4.2.1 Serum samples 
A positive H3 polyclonal equine serum sample was gifted by Dr Janet Daly for use in the 
repeatability studies. Post infection ferret sera against Nm79, Sx89, Nm/1/93, Nm/5/03 
and SA/4/03 as well as post vaccination equine sera against Nm79, Sx89 and Rich07, 
containing subtype-specific antibodies, all kindly provided by Dr Adam Rash and Dr Debra 
Elton of the Animal Health Trust (AHT), were used in PVNAs where 
homologous/heterologous serum vs. PVs combinations were tested. During a vaccine 
efficacy trial, which was conducted by Dr Romain Paillot (Study Investigator) at the Animal 
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Health Trust for reasons unrelated to this thesis, serum samples were collected from 
Welsh mountain ponies housed at the AHT for use in PVNAs. Serum samples were 
collected at five time points (D0, D28, D56, pre-C and C+14) as described in Figure 19 from 





Figure 19. Timeline of study. V1, V2 = vaccination 1 and vaccination 2, C = challenge. Blood samples 
were collected at five time points; day 0 (D0), day 28 (D28), day 56 (D56), pre-challenge (Pre-C) 
and 14 days post challenge (C+14). 
 
 
Table 6. Serum samples collected during the vaccine efficacy trial at the Animal Health Trust. The 
five ponies in groups 1 ?4 were administered a high or low dose of vaccine containing a Florida 
clade 2 (FC2) or a Florida clade 1 (FC1) strain. The FC1 and FC2 strains and the vaccine dose 
administered to groups 1 ?4 remain undisclosed for vaccine manufacturer confidentiality reasons. 
The 4 ponies in group 5 served as unvaccinated controls to confirm infectivity of the FC2 challenge 
virus. The 3 ponies in group 6 were administered a commercial EI vaccine (canarypox-based EI 








Group n (horses) n (samples) Vaccination Challenge 
1 5 25 FC2 (high dose) FC2 
2 5 25 FC2 (low dose) FC2 
3 5 25 FC1 (high dose) FC2 
4 5 25 FC1 (low dose) FC2 
5 4 20 None FC2 
6 3 14 FC1+FC2 FC2 
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4.2.2 Pseudotype virus production and titration 
A/equine/Newmarket/1979 (H3) (Nm79) and A/equine/Richmond/1/2007 (H3) (Rich07) 
HA gene PCR products, amplified with primers containing EcoRV/BamHI and BamHI/XhoI 
ƌĞƐƚƌŝĐƚŝŽŶƐŝƚĞƐĂƚƚŚĞŝƌ ? ?ĂŶĚ ? ?ƚĞƌŵŝŶŝ ?ƌĞƐƉĞĐƚŝǀ ůǇ ?were kindly provided by Dr Adam 
Rash and Dr Debra Elton at the Animal Health Trust. The H3 genes were cloned into the 
mammalian expression plasmid pI.18 and PV produced, by co-transfection (using 
transfection reagent PEI) of the equine influenza H3 surface glycoprotein alongside HIV 
gag-pol, firefly luciferase reporter gene and endoprotease pCAGGS-HAT (kindly donated 
by Dr Eva Böttcher, Philipps University Marburg) at the University of Kent. Two batches of 
the Nm79 PV were produced 11 months apart and stored at -80oC to test the variation of 
PVNAs associated with different batches of PV. All PV titrations were performed as 
described previously and titres calculated in RLU/ml (Chapter 2 Methods section 2.3.2). 
 
4.2.3 Serological assays 
PVNAs were performed as described in (Chapter 2 Methods section 2.3.3). Briefly, serum 
samples were serially diluted and mixed with PVs for 1hr at 37°C. HEK293T/17 cells were 
then added and the reagents incubated for 48hrs. Luciferase expression was quantified 
using BrightGlo reagent (Promega). HI and SRH assays were performed at the Animal 
Health Trust. 
 
4.2.4 Statistical analysis 
IC50 values were calculated using GraphPad Prism software and repeat values were 
averaged using a mean. Statistical tests such as the paired T-test, one-way ANOVA and 





4.3.1 Reproducibility of PVNA 
To analyse the reproducibility of the PVNA, the equine H3 positive serum (Methods section 
4.2.1) was tested in quadruplicate, without pre-dilution, using a single batch of PV. The 
assays were conducted within a 24-hour period, using the same passage of cells, to 
establish the consistency of IC50 readings (Figure 20). The IC50 values from each of the four 
groups were compared and were found not to exhibit significant differences (comparison 













Figure 20. IC50 values calculated for an equine H3 positive control serum tested in quadruplicate 
(or quintuplicate) against A/equine/Richmond/1/2007 H3 PV in four independent assay plates (the 
four coloured symbols indicate data from each test repeat). Diluted serum was added to the assay 





Depending on the size of a study, it may not be possible to carry out all assays at the same 
time. To investigate the impact of increasing time between testing on data reproducibility, 
five independent PVNA assays were conducted at a minimum interval of one week. Again, 
there were no significant differences in the IC50 values between assays  












Figure 21. IC50 values calculated for an equine H3 positive control serum tested in triplicate against 
A/equine/Newmarket/1979 PV H3 PV at weekly intervals. Neat serum was added to the assay for 




The next stage was to compare different batches of PVs. PV batch 1 gave consistent IC50 
results compared to PV batch 2 (Figure 22). However, comparing the combined data points 











Figure 22. Comparison of IC50 values for two different batches of PV A/equine/Newmarket/1979 
PV H3. Line with error bars represents mean with SEM. 
 
Adding neat serum into the assay, instead of pre-diluting to spare serum stocks, reduced 
the IC50 but not significantly (Figure 23; p = 0.163). These data imply that it is acceptable 
to use different batches of PV within a study and to start with either neat or 1/10 pre-










Figure 23. Comparison of IC50 values using different starting dilutions of serum; neat and diluted 
(pre-diluted 1/10).  
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In addition to looking at the difference in IC50 values, which is the most commonly reported 
output of a PVNA, the gradient of the neutralisation curves was analysed.  The gradient of 
the neutralisation curve illustrates the trend in neutralisation of the PV, as the 
concentration of serum decreases. Both neat and pre-diluted equine sera were diluted 
two-fold across a 96-well plate and therefore theoretically the gradient of the curves 
should be the same. There is an expected shift along the independent x-variable axis due 
to a different starting dilution of serum (illustrated by Figure 24). Statistical analysis (using 
an unpaired T-test) confirmed that there was no significant difference between the 
gradients of the curves when comparing PV batch or serum dilution (Table 7), further 















Figure 24. Comparison of neutralisation curves starting with either neat or pre-diluted serum. 
Mean and SEM of triplicate values are shown. 
 
 
Table 7. Comparisons of IC50 values (orange) and gradients of neutralisation curves (grey), between 
different batches of PVs and starting dilution of serum (n = 3) using an unpaired T-test. Pre-diluted 
serum = starting dilution 1/400 and neat serum = 1/40. 
 
  
PV Batch 1  
(pre-diluted) 
PV Batch 2  
(neat)  
PV Batch 1 
(neat) 
p = 0.42 p = 0.53 p = 0.11 p = 0.79 
PV Batch 2 
(pre-diluted) 
p = 0.22 p = 0.23 p = 0.26 p = 0.24 
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4.3.2 Specificity of PVNA 
To determine whether the PVNA can distinguish between homologous and heterologous 
antibodies, different combinations of PV and serum were assayed and mean IC50 values 
calculated (Table 9). Homologous pairings exhibited higher IC50 values than heterologous 
pairings except for the Nm/1/93 PV with sera raised in a ferret against Sx89 and SA/4/03. 
In both cases, the IC50 value was extrapolated from the inhibition curve because a serum 
dilution range at which there was 50% neutralisation was not reached. To test the accuracy 
of the extrapolated IC50 values, the two serum samples were diluted to the reciprocal of 
the IC50 previously obtained and tested in triplicate without titration (Table 8). 
Interestingly, these diluted sera did not bring about the expected 50% neutralisation and 
therefore it appears important to ensure that IC50 values are obtained empirically by 
diluting sera sufficiently to measure 50% neutralisation. In all cases where the IC50 value 
was extrapolated, the assays were repeated with further dilution of the serum and IC50 
values recalculated. After diluting the Sx89 and SA/4/03 serum and assaying against the 




Table 8. PVs (A/equine/Newmarket/1979; Nm79 and A/equine/Sussex/1989; Sx89) were assayed 
against a single serum dilution, calculated as the reciprocal of the extrapolated IC50 value (to the 
nearest 10,000). Mean percentage neutralisation calculated (n=3). 
 
WT PV Serum (ferret) Extrapolated IC50  Serum dilution % neutralisation  
Nm79 Nm79 115175 » 120000 9.2 







Table 9. Mean IC50 values of PVs against homologous and heterologous sera based on three replicates. A) post-infection ferret sera titrated to 1/51,200 with 
shaded boxes indicating where the IC50 value was obtained by extrapolation of the inhibition curve; B) post-infection sera titrated to 1/819,200; C) post-




A) Antisera raised in ferrets   B) Antisera raised in ferrets 
Wildtype PV Nm/79 Sx/89 Nm/1/93 Nm/5/03 SA/4/03  Wildtype PV Nm/79 Sx/89 Nm/1/93 Nm/5/03 SA/4/03 
Nm/79 115175 1219 2951 18579 16809  Nm/79 104294 1238 3199 19077 17995 
Sx/89 1161 99239 4006 5187 2171  Sx/89 1610 127532 4934 5274 2501 
Nm/1/93 52786 819397 86748 54788 562464  Nm/1/93 58796 16134 104950 60597 40777 
Nm/5/03 83152 41544 74867 126096 33828  Nm/5/03 65349 43764 116223 106163 34448 
SA/4/03 41034 35922 20534 67902 107542  SA/4/03 50869 40231 21364 41118 152887 
 
 
C) Antisera raised in equines        
Wildtype PV Nm/79 Sx/89 Rich/1/07        
Nm/79 24982 10270 12979 
       
Sx/89 366 3437 1269        





4.3.3 Application of the PVNA for a vaccine efficacy trial 
4.3.3.1 Virus neutralising antibody response 
After completion of the vaccine efficacy trial, in which a recent FC2 EIV strain was used 
as the challenge virus for equines inoculated with two different clade specific vaccines 
(FC1 and FC2), all sera were tested by PVNA with a FC2 PV. Initially, all day 0 sera (n=27) 
were tested and compared to two known negative controls. All sera were negative using 
a cut-off of IC50 = 80 (LogIC50 1.9) as previously reported (Scott et al., 2012). 
Furthermore, four negative control ponies were included in the vaccine efficacy trial and 
were bled at each of the five time points. All 16 samples pre-challenge had very low IC50 
values although three were above the negative cut-off, with a mean IC50 of 158 (LogIC50 
2.20). The positive threshold for this study was therefore set at an IC50 of 158 (or LogIC50 
2.20). 
PVNA measured seroconversion in the control ponies occurred as expected after 
experimental infection with the FC2 strain at 14 days post challenge (Figure 25E). The 
commercial vaccine group 6 seroconverted by day 28, with a peak on day 56 (Figure 
25F), and the same was observed with groups 1 and 3 (Figures 25A&C); FC2 and FC1 high 
dose, respectively. The FC2 and FC1 low dose groups (2 and 4, respectively) showed 
partial seroconversion by day 28 but did not fully convert until day 56 (Figure 25B&D). 
Considering groups 1 to 4, irrespective of the vaccine strain or dose, overall the post 
challenge titres were significantly higher than pre-challenge (paired T-test; p=<0.001) 
and there was no significant difference between the post challenge responses (ANOVA; 





Figure 25. A-F. Neutralising antibody responses as measured by PVNA at five different time 
points during the vaccine efficacy trial; Day 0, Day 28, Day 56, pre-Challenge (preC) and 14 days 
post challenge (C+14). . Pony groups; A) FC2 (high dose), B) FC2 (low dose), C) FC1 (high dose), 
D) FC1 (low dose), E) controls and F) HA vaccine group. Antibody responses were recorded as 
IC50 values (reciprocal value of the serum dilution at which 50% neutralisation of the PV was 
reached). The positive response threshold is indicated by the dotted line at a LogIC50 of 2.20. 
Coloured data points represent different ponies.  
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4.3.3.2 Comparison of SRH to PVNA responses 
The correlation between antibody response to the FC2 antigen as measured by SRH and 
neutralising antibody response against the equivalent PV using PVNA was calculated 













Figure 26. Correlation of antibody responses measured by pseudotype virus neutralisation assay 
ĂŶĚƐŝŶŐůĞƌĂĚŝĂůŚĂĞŵŽůǇƐŝƐ ?ŶA? ? ? ? ? ?WĞĂƌƐŽŶ ?ƐĐŽƌƌĞůĂƚŝŽŶĐŽĞĨĨŝĐŝĞŶƚƌA? ? ? ? ? ?p < 0.01. 
 
 
Notably the PVNA appears more sensitive than SRH at the pre-challenge time point; 
positive levels of neutralising antibodies were detected in the high-dose experimental 
vaccine and commercial vaccine groups (Figure 27A, C & F) whereas no haemolysis was 
visible to determine an SRH value from these serum samples (Figure 27B, D & E). 
Therefore, the PVNA appears to facilitate the measurement of remaining low antibody 
levels at a later time point after vaccination. At earlier stages of the immune response 
(Day 28) SRH values for individual ponies were more diverse, compared with the more 
homogenous results obtained with the PVNA.  









































Figure 27. Neutralising antibody responses as measured by PVNA (A, C, E) compared to SRH (B, 
D, F). Responses were recorded at five different time points during the vaccine efficacy  
trial; Day 0, Day 28, Day 56, pre-Challenge (preC) and 14 days post challenge (C+14). Red circles 




4.3.3.3 Comparison of HI to PVNA responses 
The correlation between HI antibody response to the FC2 antigen and PVNA response 
against the equivalent PV was calculated between all samples (n=134) and 













Figure 28. Correlation of antibody responses measured by pseudotype virus neutralisation assay 
ĂŶĚŚĂĞŵĂŐŐůƵƚŝŶŝŶŝŶŚŝďŝƚŝŽŶ ?ŶA? ? ? ? ? ?WĞĂƌƐŽŶ ?ƐĐŽƌƌĞůĂƚŝŽŶĐŽĞĨĨŝĐŝĞŶƚƌA? ? ? ? ? ?p < 0.01. 
 
 
Furthermore, and in agreement with the SRH results, the PVNA appeared to identify 
neutralising antibody responses in the cases where the HI antibody response was low 
(Day 28 and pre-challenge; Figure 29).  
 
  















































Figure 29. A-F. Neutralising antibody responses as measured by PVNA (IC50 values) (A, C, E) 
compared to HI titres (dilution) (B, D, F). Responses were recorded at five different time points 
during the vaccine efficacy trial; Day 0, Day 28, Day 56, pre-Challenge (preC) and 14 days post 




























































































































Group 3: FC1 (high dose) 
A) 



































Group 3: FC1 (high dose) 
C) 
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In order to assess the reproducibility of the equine influenza PVNA, a single batch of PV 
and a known positive, neat serum sample were assayed during a 24-hour period and 
then at minimum weekly intervals. At weekly intervals, the main variable was the 
passage number of the HEK293T/17 target cells. Based on statistical analysis, the results 
indicate that the assay can be conducted at different times without a significant change 
in IC50 readings. However, it should be taken into consideration that there was a log 
difference between the IC50 values in some assays and the reasons as to why this 
happened should be investigated further. Next, different batches of PVs and different 
initial dilutions of serum (neat or pre-diluted) were compared. Both variations did not 
have a detrimental effect on the consistency of results. This would be advantageous if 
limited volumes of sera are available. 
In a prior study the PVNA was tested with equine influenza virus PVs and a 
threshold for negative samples (non-vaccinated Irish ponies) was set at <80, after direct 
comparison with serum samples negative by SRH (Scott et al., 2012). This provided a 
starting point for determining positive and negative serum samples in the study but was 
adjusted to the mean value of the negative control ponies used in this study. 
One difficulty that had to be overcome was choosing an appropriate dilution 
series. Monovalent serum samples against homologous viruses are likely to be highly 
neutralising, but knowing which serum dilution range to use in order to capture the 
point of 50% neutralisation is difficult. In cases where the dilution range was not broad 
enough, GraphPad Prism software extrapolated an IC50 value based on the dynamics of 
the curve, however this was not always accurate. It is not possible to accurately predict 
the IC50 if all serum dilutions cause more than 50% neutralisation of the PV. However, 
after pre-diluting the initial serum samples, 50% neutralisation was reached and an IC50 
calculated. The exact method for calculating an average IC50 is often not reported. 
Results may or may not be transformed (Log10) before calculating the mean. Using the 
data set collected for this study, analysis was carried out using two methods; 
transforming the IC50 values, calculating the geometric mean and converting back to an 
IC50 value or simply calculating a geometric mean of all repeats without transformation. 
The difference in IC50 values was minimal, and always within the same two-fold serum 
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dilution range, indicating that either calculation method generates a very similar 
outcome. 
In order to determine the specificity of the PVNA, a selection of sera and PVs 
were assayed in different combinations, both heterologous and homologous (Table 9). 
All homologous pairings led to higher levels of neutralisation for a given serum dilution 
and thus higher IC50 values than the heterologous pairings. For traditional assays such as 
HI, ferret serum is thought to be preferential for dissecting immune responses to equine 
influenza (Burrows & Denyer, 1982). Here, the PVNA was trialled with equine and ferret 
serum and both enabled heterologous and homologous pairings to be distinguished: 
Homologous pairings generated higher IC50 values. 
Employing the PVNA in an equine influenza vaccine efficacy trial is the first 
known study of its kind. An assay that can measure neutralisation would be beneficial 
to deliver data on the neutralising antibody responses elicited post vaccination in 
comparison to the more traditional assays such as HI and SRH. HI measures the inhibition 
of agglutination between red blood cells and virus particles due to the presence of 
antibodies and SRH measures complement-mediated lysis of red blood cells, whereas 
the PVNA measures the neutralising antibody response. Comparative studies between 
the HI assay and the PVNA for human influenza have so far been carried out with 
promising positive results (Garcia & Lai, 2011; Yang et al., 2014). Preliminary results 
using the PVNA for equine influenza were also promising with variable levels of 
neutralising antibody responses recorded, at different time points, post vaccination with 
two different monovalent vaccine strains. Post challenge there was a significant increase 
in neutralising antibody response for all immunised groups, indicative of 
seroconversion. Furthermore, despite some differences, there was strong correlation 
between the PVNA and SRH assay.   
Differences in antibody responses measured by the different assays were 
observed, particularly at the pre-challenge stage, which may be explained by the 
previously reported increased sensitivity of the PVNA (Scott et al., 2012). Antibody 
kinetics measured by the SRH assays are typically low around Day 28, post initial 
vaccination, and pre-challenge (Paillot et al., 2010, 2015) but the PVNA indicated the 
presence of neutralising antibodies, particularly at the pre-challenge time point. As well 
as indicating an increased assay sensitivity it is possible that the neutralising antibody 
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response detected by the PVNA lasts longer than the SRH antibody response. The 
correlation between PVNA and HI was good but it is possible that the increased 
sensitivity in response of the PVNA at time points where HI responses were low, or 
negative, caused a decrease in the correlation coefficient. 
Further analyses are warranted to define correlates of protection and strain 
specificity but confidentiality agreements with the Study Sponsor must be adhered to. 
It is important to consider that statistical significance does not necessarily infer a result 
to be biological meaningful i.e. a significant increase in post challenge titre does mean 
that the horse had clinical (signs of disease) and/or virological (detecting presence of 




5 IMPACT OF ANTIGENIC DRIFT ON NEUTRALISING ANTIBODY 
RESPONSES AGAINST EQUINE INFLUENZA HAEMAGGLUTININ 
 
5.1 Introduction 
In 1979, a major equine influenza (EI) epidemic occurred across Europe (Burrows et al., 
1981; van Oirschot et al., 1981). A vaccine was available at the time, which included the 
original equine influenza H3N8 subtype prototype strain A/equine/Miami/1963 
(Miami/63), but it did not provide full protection, and vaccinated as well as unvaccinated 
horses were affected. Experimental infection with A/equine/Newmarket/1979 (Nm79) 
demonstrated that only 5% of ponies vaccinated against Miami/63 were protected 
against the new variant (Mumford et al., 1983). Extensive outbreaks were also reported 
in Kentucky and California during 1980 ?81 and consequently, by 1982, vaccines against 
EI were recommended to include a new prototype strain; A/equine/Fontainebleau/1/79 
or A/equine/Kentucky/1/81 (Hinshaw et al., 1983). Reports of outbreaks in the UK 
declined until 1989 when notably, vaccinated horses were again affected. Multiple 
amino acid changes occurred within the HA1 sequence of the HA gene between 1979 
(represented by Nm79) and 1989 (represented by A/equine/Sussex/89 - Sx89). Thus 
antigenic drift is thought to have reduced the efficacy of vaccines (Binns et al., 1993), 
but the specific changes attributable to vaccine failure were not confirmed. 
Three mutations were associated with changes in reactivity between virus and 
antibody in haemagglutination inhibition (HI) assays using mutant viruses generated 
with reverse genetics (Woodward et al., 2015). The mutations in Sx89 compared to 
Nm79 occurred at amino acid residues 159 (aspartic acid, D was substituted for 
asparagine, N), 189 (asparagine, N was substituted for lysine, K) and 227 (proline, P was 
substituted for serine, S). Furthermore the mutations were compared to the putative EI 
HA antigenic epitopes, based upon the human influenza H3 (Daniels et al., 1985) (Figures 
30 & 31), and all three changes occurred within these putative epitope sites (B, B and A, 
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    LVAPRGYFKM RTGKSSIMRS DAPIDTCVSE CITPNGSIPN DKPFQNVNKV  
  
              310         320        
    TYGKCPKYIK QNTLKLATGM RNVPEKQIR  
 
Figure 30. A/equine/Newmarket/1979 HA1 (GenBank Accession number: KJ643908) annotated 




Figure 31. Illustration of a haemagglutinin monomer 
(PDB: 2VIU) with putative antigenic sites circled in 
red (A-E). Protein figure edited using RasWin 
















                     10         20         30                46    
Nm79        SQNPTSGNNT ATLCLGHHAV ANGTLVKTIT DDQIEVTNAT ELVQSTSIGK 
Sx89        SQNPTSGNNT ATLCLGHHAV ANGTLVKTIT DDQIEVTNAT ELVQSISIGK 
 
                55   60         70         80         90         
Nm79        ICNNPYRVLD GRNCTLIDAM LGDPHCDVFQ YENWDLFIER SSAFSNCYPY 
Sx89        ICNNSYRVLD GRNCTLIDAM LGDPHCDVFQ YENWDLFIER SSAFSNCYPY 
 
                    110        120        130    135  140         
Nm79        DIPDYASLRS IVASSGTLEF TAEGFTWTGV TQNGRSGACR RGSADSFFSR 
Sx89        DIPDYASLRS IVASSGTLEF TAEGFTWTGV TQNGTSGACK RGSADSFFSR 
 
                    159  163       171           187 189     196   
Nm79        LNWLTKSGDS YPTLNVTMPN NNNFDKLYIW GIHHPSTNNE QTKLYVQESG 
Sx89        LNWLTKSGNS YPILNVTMPN NKNFDKLYIW GIHHPSSNKE QTKLYIQESG 
 
                  207    213            227         
Nm79        RVTVSTKRSQ QTIIPNIGSR PWVRGQPGRI SIYWTIVKPG DILMINSNGN 
Sx89        RVTVSTERSQ QTVIPNIGSR PWVRGQSGRI SIYWTIVKPG DILMINSNGN 
 
                     260     267         
Nm79        LVAPRGYFKM RTGKSSIMRS DAPIDTCVSE CITPNGSIPN DKPFQNVNKV 
Sx89        LVAPRGYFKL RTGKSSVMRS DAPIDTCVSE CITPNGSIPN DKPFQNVNKV 
 
                     310                
Nm79        TYGKCPKYIK QNTLKLATGM RNVPEKQIR  




Figure 32. Alignment of A/equine/Newmarket/1979 (Nm79) (GenBank Accession number: 
KJ643908) and A/equine/Sussex/1989 (Sx89) (GenBank accession number: KJ643906) HA1 
sequences. Sequence shown begins at amino acid after the 15-amino acid signal sequence. All 
amino acid changes between the two strains are highlighted. Red represents the three changes 
that form the focus of this study (positions 159, 189 & 227) and yellow indicates all other amino 
















Figure 33. Trimeric HA structure of A/Newmarket/2/93 (PDB: 4UNW) highlighting amino acid 
residues at positions of 159 (pink), 189 (white) and 227 (orange), on one chain, from A) the side-







Newmarket is the home of horseracing in the UK and serious outbreaks of EI can 
lead to the cancellation of race meetings. Following the 1989 epidemic, Newmarket was 
again affected by EI in 1993 and 2003. Based on the geographical distribution of viruses, 
it was deduced that equine influenza viruses had diverged in the late 1980s into two 
lineages; American and Eurasian (Daly et al., 1996). In 1993, Newmarket experienced 
outbreaks of EI from both American and Eurasian lineages, represented by 
A/equine/Newmarket/1/1993 (Nm/1/93) and A/equine/Newmarket/2/1993 (Nm/2/93) 
respectively. As a result, in 1995, it was recommended that EI vaccines be updated to 
include a representative of both lineages e.g. Nm/1/93 and Nm/2/93 (Anon, 1996). 
Moreover, in 2001, it was reported that the American lineage had further diverged into 
three sublineages; South American, Kentucky and Florida (Lai et al., 2001). In 2003 an 
epidemic arose, represented by A/equine/Newmarket/5/2003 (Nm/5/03), and 
sequencing revealed that the virus was phylogenetically related to the Florida 
sublineage. This was the first isolation of its kind in the UK. Horses vaccinated against 
Nm/1/93 were not protected against the Nm/5/03 strain and showed clinical signs such 
as coughing and nasal discharge (Newton et al., 2006). Furthermore, two unvaccinated 
horses were neurologically affected and had to be euthanased (Daly et al., 2006). There 
were a total of eight amino acid substitutions between Nm/1/93 and Nm/5/03 within 
HA1 (Figure 34), three of which were situated within the antigenic epitopes identified 
for human influenza H3 HA at amino acid residues; 48 (isoleucine, I was substituted for 
methionine, M in antigenic site C), 190 (glutamine, Q was substituted for glutamic acid, 
E in antigenic site B) and 193 (glutamic acid, E was substituted for lysine, K in antigenic 




                 5    10         20         30                  48   
Nm/1/93      SQNPTSGNNT ATLCLGHHAV ANGTLVKTIT DDQIEVTNAT ELVQSISIGK  
Nm/5/03      SQNPISGNNT ATLCLGHHAV ANGTLVKTIS DDQIEVTNAT ELVQSISMGK  
 
                    58             
Nm/1/93      ICNNSYRVLD GRNCTLIDAM LGDPHCDVFQ YENWDLFIER SSAFSNCYPY  
Nm/5/03      ICNNSYRILD GRNCTLIDAM LGDPHCDVFQ YENWDLFIER SSAFSNCYPY  
 
Nm/1/93      DIPDYASLRS IVASSGTLEF TAEGFTWTGV TQNGRSGACK RGSADSFFSR  
Nm/5/03      DIPDYASLRS IVASSGTLEF TAEGFTWTGV TQNGRSGACK RGSADSFFSR  
 
                     160        170        180         190 193         
Nm/1/93      LNWLTKSGNS YPTLNVTMPN NKNFDKLYIW GIHHPSSNQQ QTELYIQESG  
Nm/5/03      LNWLTKSGNS YPTLNVTMPN NKNFDKLYIW GIHHPSSNQE QTKLYIQESG  
 
Nm/1/93      RVTVSTKRSQ QTIIPNIGSR PWVRGQSGRI SIYWTIVKPG DILMINSNGN  
Nm/5/03      RVTVSTKRSQ QTIIPNIGSR PWVRGQSGRI SIYWTIVKPG DILMINSNGN  
 
                     260        270 272       280     289                 
Nm/1/93      LVAPRGYFKL KTGKSSVMRS DAPIDICVSE CITPNGSIPN DKPFQNVNKV  
Nm/5/03      LVAPRGYFKL KTGKSSVMRS DVPIDICVSE CITPNGSISN DKPFQNVNKV  
 
Nm/1/93      TYGKCPKYIR QNTLKLATGM RNVPEKQIR  




Figure 34. Alignment of A/equine/Newmarket/1/1993 (Nm/1/93) (Partial sequence GenBank 
Accession number: CAA59415.3) and A/equine/Newmarket/5/2003 (Nm/5/03) (GenBank 
Accession number: ACI48804.1). All amino acid changes between the two strains are 
highlighted. Red represents the three changes that form the focus of this study (positions 48, 
190 & 193) and yellow indicates all other changes. Affected antigenic sites B and C are 











Figure 35. Trimeric HA structure of A/Newmarket/2/93 (PDB: 4UNW) highlighting amino acid 
residues at positions of 63 (pink), 190 (brown) and 193 (white), on one chain, from A) the side-





South Africa experienced its second ever outbreak of EIV in 2003, after the first 
severe outbreak in 1986 (Kawaoka & Webster, 1989). In both cases, it was believed to 
be a lack of biosafety measures that led to the outbreak in a naïve population of horses, 
not a case of vaccine breakdown (Guthrie, 2006; Guthrie et al., 1999). However, when 
compared to the constituent vaccine strains at the time (Nm/1/93 and Nm/2/93), there 
were sufficient antigenic changes in the SA/4/03 virus to necessitate a vaccine update 
(OIE, 2006). Interestingly, sequence analysis of Nm/5/03 and A/equine/South 
Africa/4/2003 (SA/4/03) revealed that the viruses were related to two separate clades 
(clade 1 and 2 respectively) within the Florida lineage. The phylogenetic separation was 
distinguished by two amino acid differences at residues 78 (valine, V was substituted for 
alanine, A) and 159 (asparagine, N was substituted for serine, S) within HA1 (Figures 36 
and 37). Both of these mutations were within putative antigenic sites (E and B, 
respectively). 
 
                      10         20         30             
Nm/5/03      SQNPISGNNT ATLCLGHHAV ANGTLVKTIS DDQIEVTNAT ELVQSISMGK  
SA/4/03      SQNPISGNNT ATLCLGHHAV ANGTLVKTIS DDQIEVTNAT ELVQSISMGK  
 
                      60         70       78          
Nm/5/03      ICNNSYRILD GRNCTLIDAM LGDPHCDVFQ YENWDLFIER SSAFSNCYPY  
SA/4/03      ICNNSYRILD GRNCTLIDAM LGDPHCDAFQ YENWDLFIER SSAFSNCYPY  
 
 
Nm/5/03      DIPDYASLRS IVASSGTLEF TAEGFTWTGV TQNGRSGACK RGSADSFFSR  
SA/4/03      DIPDYASLRS IVASSGTLEF TAEGFTWTGV TQNGRSGACK RGSADSFFSR  
 
                     159        170        180        190       200 
Nm/5/03      LNWLTKSGNS YPTLNVTMPN NKNFDKLYIW GIHHPSSNQE QTKLYIQESG  
SA/4/03      LNWLTKSGSS YPTLNVTMPN NKNFDKLYIW GIHHPSSNQE QTKLYIQESG  
 
250         
Nm/5/03      RVTVSTKRSQ QTIIPNIGSR PWVRGQSGRI SIYWTIVKPG DILMINSNGN  
SA/4/03      RVTVSTKRSQ QTIIPNIGSR PWVRGQSGRI SIYWTIVKPG DILMINSNGN  
 
300         
Nm/5/03      LVAPRGYFKL KTGKSSVMRS DVPIDICVSE CITPNGSISN DKPFQNVNKV  
SA/4/03      LVAPRGYFKL KTGKSSVMRS DVPIDICVSE CITPNGSISN DKPFQNVNKV  
 
                     310        320           
Nm/5/03      TYGKCPKYIR QNTLKLATGM RNVPEKQIR 
SA/4/03      TYGKCPKYIR QNTLKLATGM RNVPEKQIR 
 
 
Figure 36. Alignment of A/equine/Newmarket/5/2003 (Nm/5/03) (GenBank Accession number: 
ACI48804.1) and A/equine/South Africa/4/2003 (SA/4/03) (GenBank Accession number: 
ADB45165.1) highlighting the two amino acid changes between the two strains. Affected 












Figure 37. Trimeric HA structure of A/Newmarket/2/93 (PDB: 4UNW) highlighting amino acid 
residues at positions of 78 (pink) and 159 (brown), on one chain, from A) the side-view and B) 
top view of the protein. Protein figures edited using RasWin software (Version 2.7.5.2). 
 
 
As mentioned earlier, studies have looked into the effect of amino acid changes using 
reverse genetics to generate equine (Woodward et al., 2015) and human (Lin et al., 
2012) influenza mutant viruses, which can be used in HI assays. A method to map the 
results of HI assays with integrated HA sequence data was developed in 2004 and coined 
 ‘ĂŶƚŝŐĞŶŝĐ ĐĂƌƚŽŐƌĂƉŚǇ ?(Smith et al., 2004). The method was initially employed for 
human influenza studies but has since been adopted for other species. Using this 
method, antigenic maps are generated as visual indicators of the antigenic viral clusters 
that evolve over time. An equine study highlighted how as few as two amino acid 
changes, within antigenically dominant regions, could result in virus escape from pre-
existing immunity (Park et al., 2009). Additionally, EI viruses from 1968 to 2007 were 
antigenically mapped and one amino acid change was found to be sufficient to 
determine a change between antigenic clusters. Notably, the changes were at amino 
acid residues 159 and 189 (Lewis et al., 2011). Here, we employed a novel approach, 
using pseudotyped viruses to identify potentially important amino acid changes and 
determine how they affect neutralising antibody responses. Single amino acid mutations 
within the HA protein can be relatively easily introduced into a PV for use in a PVNA. 
This is achieved using site-directed mutagenesis to introduce the nucleotide changes 




gene-plasmid construct before transfecting into producer cell lines. The PVs are a safer 
alternative to wild-type (WT) viruses mutated using reverse genetics and they also 
potentially allow dissection of antibody responses associated specifically with the HA 
glycoprotein. 
 The aim of this chapter was to look at the impact of single amino acid changes 
on H3 subtype specific neutralising antibody responses, using monospecific sera in 
pseudotype virus neutralisation assays (PVNA). Three outbreak scenarios were 
investigated: 
(i) Nm79 (D159N, N189K & P227S) and Sx89 (N159D, K189N & S227P) 
(ii) Nm/1/93 (I48M, Q190E & E193K) and Nm/5/03 (M48I, E190Q & K193E) 





5.2 Materials and methods 
5.2.1 HA and NA plasmids 
PCR products of WT Nm79 and Sx89 HA genes, as well as mutated HAs (Nm79; D159N, 
N189K & P227S.  Sx89; N159D, K189N & S227P) were generously provided by Dr Adam 
Rash and Dr Debra Elton from the Animal Health Trust. Restriction enzymes EcoRV/XhoI 
and BamHI/XhoI were used to clone Nm79 and Sx89 PCR products respectively, via 
recognition sites incorporated into the PCR primers, into the mammalian expression 
vector pI.18. The WT Nm/1/93 HA sequence was kindly provided by Dr Janet Daly (as 
only partial sequence is available in NCBI database; GenBank Accession number: 
CAA59415.3). The gene was synthesised, cloned into pI.18 and subsequently mutated 
to generate the HA mutants (Nm/1/93; I48M, Q190E & E193K) by GenScript®. A PCR 
product of WT Nm/5/03 HA was also kindly provided by Dr Janet Daly. Site-directed 
mutagenesis (SDM) to produce the HA mutants (Nm/5/03; M48I, E190Q & K193E) and 
cloning into pI.18 using BamHI/XhoI restriction enzymes was carried out at the 
University of Kent. SA/4/03 and HA mutants were generated through SDM of Nm/5/03-
pI.18 (Nm/5/03 - V78A & N159S; SA/4/03 - A78V & S159N). For detailed methods of 
cloning and PCR conditions for SDM see (Chapter 2 Methods section 2.1.9). Primer 
sequences for SDM are provided in Table 10. 
 
Table 10. Primer sequences designed using Agilent Technologies QuikChangeTM Site-Directed 







Nm/5/03 WT M 48 I 
& ? ?ŐƚƚŐĐĂƚĂƚƚƚƚĐĐĐƚĂƚƚŐĂĂĂƚŐĐƚĐƚŐĂĂĐƚĂĂƚƚĐƚŐƚĂŐĐ ? ?
Z ? ?ŐĐƚĂĐĂŐĂĂƚƚĂŐƚƚĐĂŐĂŐĐĂƚƚƚĐĂĂƚĂŐŐŐĂĂĂĂƚĂƚŐĐĂĂĐ ? ?
Nm/5/03 WT E 190 Q 
& ? ?ĂĂƚƚƚƚŐƚĐƚŐĐƚŐƚƚŐĂƚƚƚŐĂŐĐƚĐŐŐŐƚŐĂƚŐĂĂƚĐ ? ?
Z ? ?ŐĂƚƚĐĂƚĐĂĐĐĐŐĂŐĐƚĐĂĂĂƚĐĂĂĐĂŐĐĂŐĂĐĂĂĂĂƚƚ ? ?
Nm/5/03 WT K 193 E 
& ? ?ŐƚĐĐƚŐĂƚƚĐƚƚŐŐĂƚŐƚĂĐĂĂĐƚĐƚŐƚĐƚŐĐƚĐƚƚŐĂƚƚƚŐĂŐĐƚĐ ? ?
Z ? ?ŐĂŐĐƚĐĂĂĂƚĐĂĂŐĂŐĐĂŐĂĐĂŐĂŐƚƚŐƚĂĐĂƚĐĐĂĂŐĂĂƚĐĂŐŐĂĐ ? ?
Nm/5/03 WT V 78 A 
& ? ?ĂĂƚƚĐƚĐĂƚĂĐƚŐĂĂĂŐŐĐŐƚĐĂĐĂŐƚŐŐŐŐŐƚĐ ? ?
Z ? ?gctacagaattagttcagagcatttcaatagggaaaatatgcaac  ? ?
Nm/5/03 WT N 159 S & ? ?ĐĂĐĂƚƚĐĂĂƚŐƚŐŐŐĂƚĂĂŐĂŐĐƚƚĐĐĂŐĂƚƚƚƚŐƚƚĂŐĐĐĂĂƚƚĐ ? ?
Nm/5/03 78A N 159 S Z ? ?ŐĂĂƚƚŐŐĐƚĂĂĐĂĂĂĂƚĐƚŐŐĂĂŐĐƚĐƚƚĂƚĐĐĐĂĐĂƚƚŐĂĂƚŐƚŐ ? ?
Nm/5/03 190Q K 193 E 
& ? ?ŐƚĐĐƚŐĂƚƚĐƚƚŐŐĂƚŐƚĂĐĂĂĐƚĐƚŐƚĐƚŐĐƚŐƚƚŐĂƚƚƚŐĂŐĐƚĐ ? ?
Z ? ?ŐĂŐĐƚĐĂĂĂƚĐĂĂĐĂŐĐĂŐĂĐĂŐĂŐƚƚŐƚĂĐĂƚĐĐĂĂŐĂĂƚĐĂŐŐĂĐ ? ?
Nm/1/93 193K Q 190 E 
& ? ?ĂƚƚƚƚŐƚĐƚŐĐƚĐƚƚŐŐƚƚƚŐĂŐĐƚĐŐŐŐƚŐĂƚŐĂĂ ? ?
Z ? ?ƚƚĐĂƚĐĂĐĐĐŐĂŐĐƚĐĂĂĂĐĐĂĂŐĂŐĐĂŐĂĐĂĂĂĂƚ ? ?
Nm/5/03 WT 
E 190 Q &  
K 193 E 
& ? ?ŐĂƚƚĐƚƚŐŐĂƚŐƚĂĐĂĂĐƚĐƚŐƚĐƚŐĐƚŐƚƚŐĂƚƚƚŐĂŐĐƚĐŐŐŐƚŐĂƚŐ ? ?




5.2.2 PV production and titration 
PVs displaying only HA on their surface were produced as described in (Chapter 2 
Methods section 2.3.1.1). Briefly, a four plasmid co-transfection of HEK293T/17 cells 
(using transfection reagent PEI) with plasmids expressing an equine influenza H3 surface 
glycoprotein, HIV gag-pol, firefly luciferase reporter gene and pCAGGS-TMPRSS2 
endoprotease (kindly provided by Dr Eva Böttcher-Friebertshäuser) was employed. All 
PV titrations were performed as described previously and titres calculated in RLU/ml 
(Chapter 2 Methods section 2.3.2). 
 
5.2.3 Serum samples and PVNA 
Post infection ferret sera against Nm79, Sx89, Nm/1/93, Nm/5/03 and SA/4/03 as well 
as post vaccination equine sera against Nm79 and Sx89, containing subtype-specific 
antibodies, were all kindly provided by Dr Adam Rash and Dr Debra Elton at the Animal 
Health Trust for use in PVNAs. Neutralisation assays were performed as described in 
(Chapter 2 Methods section 2.3.3). Briefly, serum samples were serially diluted and 
mixed with PVs for 1hr at 37°C. HEK293T/17 cells were then added and the reagents 
incubated for 48hrs. Luciferase expression was quantified using BrightGlo reagent 
(Promega). 
 
5.2.4 Statistical analysis 
See Chapter 2 Methods section 2.3.4 for details of statistical analysis. Briefly, IC50 values 






5.3.1 Production of wild type and mutant equine HA PVs 
All Nm79 PCR products were successfully cloned into pI.18 (WT shown in results section 





Figure 38. A) PCR screening of A/equine/Sussex/1/1989 (Sx89) WT, 159 and 189 colony lysates. 
Lanes 1-6, 8, 9, 12 and 13 were positive for Sx89 WT. Lanes 15, 16 and 19-23 were positive for 
Sx89 159 (17 and 18 were negative). Lanes 24, 25, 27, 31, 32 and 34-37 were positive for Sx89 
189 (28 was negative). Lanes 10 and 29 were positive controls using pI.18-Nm79 WT. Lanes 11 
and 30 were negative controls using pI.18 cut with BamHI/XhoI. B) Plasmid digest screen of Sx89 
227 mutant; lanes 1 and 4 indicate positive clones. Lanes 7 and 8 were negative and positive 
controls (pI.18 cut with BamHI/XhoI and pI.18-Nm79 WT respectively). Orange arrows indicate 





Using site directed mutagenesis, all Nm/5/03 and SA/4/03 mutant HA-pI.18 plasmids 
were successful generated and verified by sequence analysis before use in transfections 
to produce PVs (Figure 39). 
 
                           10         20         30         40         
50              
Nm/5/03 (WT)      SQNPISGNNT ATLCLGHHAV ANGTLVKTIS DDQIEVTNAT ELVQSISMGK 
Nm/5/03 (V78A)    SQNPISGNNT ATLCLGHHAV ANGTLVKTIS DDQIEVTNAT ELVQSISMGK 
 
                           60        70        78  80         90       
Nm/5/03 (WT)      ICNNSYRILD GRNCTLIDAM LGDPHCDVFQ YENWDLFIER SSAFSNCYPY 
Nm/5/03 (V78A)    ICNNSYRILD GRNCTLIDAM LGDPHCDAFQ YENWDLFIER SSAFSNCYPY 
 
                          110        120        130        140        
Nm/5/03 (WT)      DIPDYASLRS IVASSGTLEF TAEGFTWTGV TQNGRSGACK RGSADSFFSR 
Nm/5/03 (V78A)    DIPDYASLRS IVASSGTLEF TAEGFTWTGV TQNGRSGACK RGSADSFFSR 
 
                          160        170        180        190        
Nm/5/03 (WT)      LNWLTKSGNS YPTLNVTMPN NKNFDKLYIW GIHHPSSNQE QTKLYIQESG 
Nm/5/03 (V78A)    LNWLTKSGNS YPTLNVTMPN NKNFDKLYIW GIHHPSSNQE QTKLYIQESG 
 
                          210        220        230        240        
Nm/5/03 (WT)      RVTVSTKRSQ QTIIPNIGSR PWVRGQSGRI SIYWTIVKPG DILMINSNGN 
Nm/5/03 (V78A)    RVTVSTKRSQ QTIIPNIGSR PWVRGQSGRI SIYWTIVKPG DILMINSNGN 
 
                          260        270        280        290        
Nm/5/03 (WT)      LVAPRGYFKL KTGKSSVMRS DVPIDICVSE CITPNGSISN DKPFQNVNKV 
Nm/5/03 (V78A)    LVAPRGYFKL KTGKSSVMRS DVPIDICVSE CITPNGSISN DKPFQNVNKV 
 
                          310        320       330   
Nm/5/03 (WT)      TYGKCPKYIR QNTLKLATGM RNVPEKQIR 
Nm/5/03 (V78A)    TYGKCPKYIR QNTLKLATGM RNVPEKQIR 
 
Figure 39. Alignment of A/equine/Newmarket/5/2003 (Nm/5/03 WT) (GenBank Accession 
number: ACI48804.1) and Nm/5/03 V78A mutant HA sequences. Incorporation of amino acid 
change V78A (highlighted in red) was confirmed.  
 
Titration assay results revealed successful production of WT and mutant Nm79, along 
with Sx89, Nm/1/93, Nm/5/03 and SA/4/03 PVs (Figure 40A, B and C). All PVs were 
compared to their respective delta envelope controls and all had significantly higher 















































Figure 40. PV titres of A) A/equine/Newmarket/1979 (red) and A/equine/Sussex/1/1989 (blue). 
B) A/equine/Newmarket/1/1993 (green) and A/equine/Newmarket/5/2003 (purple). 
C) A/equine/Newmarket/5/2003 (brown) and A/equine/South Africa/4/2003 (orange). 
Wild type (WT) and HA mutant mean titres are expressed in relative luminescence units (RLU/ml) 
based on eight replicates +SEM. All PVs were significantly higher in titre than delta env (p < 0.05). 














C)            Nm/1/93                             Nm/5/03 
[86] 
 
Interestingly the titres of Nm/1/93 193K and Nm/5/03 190Q, although functional, were 
significantly lower than the mean titres of the respective WT PVs (p<0.05). To 
understand if this was due to the mutation at specific residues, double mutants were 
produced. Initially, primers were designed to incorporate the 190E mutation into 
Nm/1/93 193K and for the introduction of 193E mutation into Nm/5/03 190Q. The 
primers designed to incorporate 190E into Nm/1/93 193K (Table 10) did not amplify the 
template DNA. Nm/5/03 was successfully amplified with primers designed to introduce 
193E (Table 10), however sequence analysis confirmed that the mutagenesis was 
unsuccessful. New primers were designed to incorporate both 190Q and 193E into 
Nm/5/03, in the same PCR cycle (Table 10): Sequence analysis confirmed successful 
SDM. Furthermore, with both 190Q and 193E mutations present, the PV titre was 















Figure 41. PV titres of A/equine/Newmarket/5/2003 (Nm/5/03) 190Q and Nm/5/03 190Q, 193E 
mutants. Mean titres are expressed in relative luminescence units (RLU/ml) based on eight 
replicates +SEM. * indicates a significant difference to Nm/5/03 190Q using an unpaired T-test 





5.3.2 Nm79 and Sx89 PVNAs 
5.3.2.1 Ferret anti-sera 
Nm79 and Sx89 PVs were initially used in PVNAs against their homologous serum 
pairings, which were raised in ferrets (F) and known to be positive for equine influenza 
H3 subtype-specific antibodies. Following this, fold-differences in IC50 values were 
calculated between each WT PV against its respective homologous and heterologous 
serum (Table 11). The IC50 for Nm79 WT PV with Sx89 serum was 60-fold less than the 
homologous pairing. Similarly, the IC50 for Sx89 WT PV with Nm79 serum was 50-fold 
less than its respective homologous pairing. Based on these findings it is evident that 
the PVNA can detect antigenic differences between viruses. 
 
 
Table 11. IC50 results obtained from PVNAs using Nm79 and Sx89 WT PVs against respective 
homologous and heterologous ferret anti-sera. Fold-differences were calculated between the 
IC50 of the homologous and heterologous PV, for each serum sample. A negative fold-difference 
indicates a decrease in the efficacy of the serum to neutralise the PV. Mean IC50 values reported 
for each assay (n= minimum of 4). Anti-sera were raised in ferrets (F). 
 
 Nm79 (F) serum Sx89 (F) serum 
PV IC50 Fold-difference IC50 Fold-difference 
Nm79 WT 98793 
 
1.00 1238 -51.99 




Single mutant PVs were then compared by fold-difference to the WT PVs, when assayed 
against the same homologous serum sample. The homologous WT pairings yielded the 
highest IC50 values compared to the mutant viruses, with the exception of the 227 
mutant, which was marginally higher (but less than 2-fold) than the WT for both Nm79 
and Sx89 (Table 12). Interestingly, the Sx89/189N mutant reduced the IC50 by 16-fold. 
None of the other mutant viruses had greater than a 2-fold effect on the IC50. 
 
 
Table 12. IC50 results obtained from PVNAs with Nm79 and Sx89 mutant PVs and homologous 
serum (ferret, F). Fold-differences provide comparison of the WT PV to mutant viruses when 
assayed against the same serum. Mean IC50 values reported for each assay (n= minimum of 4). 
 
 Nm79 (F) serum 
PV IC50 Fold-difference 
Nm79 WT 98793 
 
1.00 
Nm79/159 N 73707 -1.34 
Nm79/189 K 89603 -1.10 
Nm79/227 S 116592 1.18 
 Sx89 (F) serum 
Sx89 WT 64360 1.00 
Sx89/159 D 33320 -1.93 
Sx89/189 N 4021 -16.01 






Furthermore, PVNAs were conducted with mutant PVs and heterologous sera. There 
was a decrease in IC50 with all Nm79 PVs assayed against Sx89 serum, compared to the 
IC50s against homologous Nm79 serum. However, IC50 values obtained with both 159 and 
189 mutants were more than 5-fold greater than with the WT, indicating that the 
introduction of these mutations (from the Sx89 strain) increased the PV neutralisation 
efficacy of the Sx89 serum (Table 13B).  
The Sx89 WT PV tested with Nm79 serum mimics the serological scenario for a 
vaccinated horse at the time of the Sx89 outbreak: A 50-fold decrease in IC50 compared 
to the homologous serum pairing reflects the drop in immunogenicity. Interestingly the 
Nm79 serum displayed a 9-fold increase in ability to neutralise the Sx89/159D mutant 
(in direction of Nm79) compared to the Sx89 WT PV (Table 13A). The Sx89/189N and 
227P mutants (again towards Nm79) showed less than a 2-fold change in IC50 with the 
Nm79 serum compared to the Sx89 WT PV. 
 
Table 13. IC50 results obtained from PVNAs using ferret sera A) Nm79 PVs against heterologous 
Sx89 serum. B) Sx89 PVs against heterologous Nm79 serum. Sx89 WT + Nm79 serum mimics the 
outbreak scenario in nature (indicated in blue bold). Fold-differences provide comparison of the 
WT PV to mutant viruses when assayed against the same serum. Homologous serum and PV 
pairings are included in both tables for reference (highlighted in grey). Mean IC50 values reported 
for each assay (n= minimum of 4). 
 





Sx89 WT 64360 1.00 Nm79 WT 98793 1.00 
Sx89/159 D 33320 -1.93 Nm79/159 N 73707 -1.34 
Sx89/189 N 4021 -16.01 Nm79/189 K 89603 -1.10 
Sx89/227 P 68938 1.07 Nm79/227 S 116592 1.18 
 Nm79 (F) serum  Sx89 (F) serum 
Sx89 WT 1610 1.00 Nm79 WT 1238 1.00 
Sx89/159 D 14716 9.14 Nm79/159 N 6253 5.05 
Sx89/189 N 1804 1.12 Nm79/189 K 9148 7.39 





5.3.2.2 Equine anti-sera 
Following the PVNAs using ferret sera, sera raised against Nm79 and Sx89 viruses in 
horses were also trialled (E  ? equine). The IC50 for Nm79 WT PV against homologous 
Nm79 serum was almost 70-fold greater than the Sx89 WT PV against the Nm79 serum 
(Table 14), which highlighted the antigenic difference between the viruses. Contrary to 
expectations, the IC50 for Sx89 WT PV was 3-fold lower against the homologous Sx89 
serum, compared to Nm79 WT PV (Table 14). 
 
Table 14. IC50 results obtained from PVNAs using Nm79 and Sx89 WT PVs against respective 
homologous and heterologous equine (E) serum samples. Fold-differences were calculated 
between the IC50 of the homologous and heterologous PV, for each serum sample. A negative 
fold-difference indicates a decrease in the efficacy of the serum to neutralise the PV. Mean IC50 
values reported for each assay (n= minimum of 3).  
 
 Nm79 (E) serum Sx89 (E) serum 
PV IC50 Fold-difference IC50 Fold-difference 
Nm79 WT 25482 1.00 10270 2.99 






When assayed against the homologous Nm79 serum, the Nm79 WT PV was most 
effectively neutralised and all Nm79 mutant PVs had lower IC50 values. The Nm79/189K 
mutant had the greatest impact on Nm79 serum, with a 6-fold decrease in IC50. The Sx89 
serum did not generate the highest IC50 against the Sx89 WT PV, although the 
differences to the mutants were marginal; mutants Sx89/159D and 227S increased the 
IC50 less than 2-fold and Sx89/189N decreased the ability of Sx89 serum to neutralise 
the virus, reducing the IC50 by 3-fold (Table 15). 
 
Table 15. IC50 results obtained from PVNAs with Nm79 and Sx89 mutant PVs and homologous 
equine (E) serum. Fold-differences provide comparison of the WT PV to mutant viruses when 
assayed against the same serum. Mean IC50 values reported for each assay (n= minimum of 3). 
 
 Nm79 (E) serum 
PV IC50 Fold-difference 
Nm79 WT 25482 1.00 
Nm79/159 N 16447 -1.55 
Nm79/189 K 3978 -6.41 
Nm79/227 S 16561 -1.54 
 Sx89 (E) serum 
Sx89 WT 3437 1.00 
Sx89/159 D 4485 1.30 
Sx89/189 N 1271 -2.70 





The equine serum samples were also tested against heterologous PVs. All of the Nm79 
mutant PV IC50 values increased compared to Nm79 WT when tested against the Sx89 
serum; Nm79/159N increased 1.5-fold, Nm79/189K 2-fold and Nm79/227S 3.5-fold 
(Table 16A). The Sx89 WT PV against Nm79 serum gave the lowest recorded IC50 at <400: 
A low IC50 was expected with this combination of PV and serum as it represents the 
outbreak scenario that occurred in nature in 1989. Results from Nm79 serum against 
Sx89/159D and Sx89/227P were incomplete. Interestingly, the Sx89/189N mutant 
increased the ability of Nm79 serum to neutralise the virus by 18-fold (Table 16B). 
 
Table 16. IC50 results obtained from PVNAs with equine (E) serum A) Nm79 PVs against 
heterologous Sx89 serum. B) Sx89 PVs against heterologous Nm79 serum. Sx89 WT + Nm79 
serum mimics the outbreak scenario in nature (indicated in blue bold). Fold-differences provide 
comparison of the WT PV to mutant viruses when assayed against the same serum. Homologous 
serum and PV pairings are included in both tables for reference (highlighted in grey). Mean IC50 
values reported for each assay (n= minimum of 3). 
 
 Nm79 (E) serum 
PV IC50 Fold-difference 
Nm79 WT 25482 1.00 
Nm79/159 N 16447 -1.55 
Nm79/189 K 3978 -6.41 
Nm79/227 S 16561 -1.54 
 Sx89 (E) serum 
Nm79 WT 10270 1.00 
Nm79/159 N 14895 1.45 
Nm79/189 K 22965 2.24 
Nm79/227 S 35584 3.46 
 
 
 Sx89 (E) serum 
PV IC50 Fold-difference 
Sx89 WT 3437 1.00 
Sx89/159 D 4485 1.30 
Sx89/189 N 1271 -2.70 
Sx89/227 P 4511 1.31 
 Nm79 (E) serum 
Sx89 WT 366 1.00 
Sx89/159 D Data set incomplete 
Sx89/189 N 6643 18.15 






5.3.3 Nm/1/93 and Nm/5/03 PVNAs 
Nm/1/93 and Nm/5/03 PVs were assayed against homologous and heterologous serum 
samples, raised in ferrets, in order to establish if the PVNA could identify the antigenic 
differences between them.  Both homologous pairings of PV and serum gave the highest 
IC50 values. Heterologous pairings were both between 1 and 2-fold lower in IC50. The 
difference between Nm/5/03 PV against Nm/1/93 serum and its homologous pairing 
was minimal at 1.16-fold decrease (Table 17).  
 
Table 17. IC50 results obtained from PVNAs using Nm/1/93 and Nm/5/03 WT PVs against 
respective homologous and heterologous serum samples. Fold-differences were calculated 
between the IC50 of the homologous and heterologous PV, for each serum sample. A negative 
fold-difference indicates a decrease in the efficacy of the serum to neutralise the PV. Mean IC50 
values reported for each assay (n= minimum of 3). Anti-sera were raised in ferrets (F). 
 
 Nm/1/93 (F) serum Nm/5/03 (F) serum 
PV IC50 Fold-difference IC50 Fold-difference 
Nm/1/93 WT 121942 1.00 60597 -2.13 
Nm/5/03 WT 105311 -1.16 129222 1.00 
 
 
All mutant PVs tested against the respective homologous serum sample, had IC50 values 
within a 1.6-fold difference compared to the WT PV (Table 18). The result from Nm/5/03 
190Q PV against Nm/5/03 serum was inconclusive. 
 
Table 18. IC50 results obtained from PVNAs with Nm/1/93 and Nm/5/03 mutant PVs and 
homologous serum (ferret, F). Fold-differences provide comparison of the WT PV to mutant 
viruses when assayed against the same serum. Mean IC50 values reported for each assay (n= 
minimum of 2). 
 
 Nm/1/93 (F) serum 
PV IC50 Fold-difference 
Nm/1/93 WT 121942 1.00 
Nm/1/93 48M 130988 1.07 
Nm/1/93 190E 128578 1.05 
Nm/1/93 193K Data set incomplete 
 Nm/5/03 (F) serum 
Nm/5/03 WT 129222 1.00 
Nm/5/03 48I 82991 -1.56 
Nm/5/03 190Q Data set incomplete 
Nm/5/03 193E 153504 1.19 
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Fold-differences between Nm/1/93 mutant PVs and Nm/5/03 serum were very similar 
to Nm/1/93 WT with less than a 1.5-fold increase in IC50 (Table 19A). Results for the 
Nm/1/93 193K mutant PV against Nm/5/03 serum and Nm/5/03 190Q against Nm/1/93 
serum were not obtained due to the low titre PVs that could not be taken forward into 
the PVNA. The Nm/5/03 193E mutant increased the IC50 3-fold, compared to the WT, 
when tested against Nm/1/93 serum (Table 19B). 
 
Table 19. IC50 results obtained from PVNAs with A) Nm/1/93 PVs against heterologous Nm/5/03 
serum. B) Nm/5/03 PVs against heterologous Nm/1/93 serum. Anti-sera were raised in ferrets 
(F). Fold-differences provide comparison of the WT PV to mutant viruses when assayed against 
the same serum. Homologous serum and PV pairings are included in both tables for reference 
(highlighted in grey). Mean IC50 values reported for each assay (n= minimum of 2). 
 
 
 Nm/1/93 (F) serum 
PV IC50 Fold-difference 
Nm/1/93 WT 121942 1.00 
Nm/1/93 48M 130988 1.07 
Nm/1/93 190E 128578 1.05 
Nm/1/93 193K Data set incomplete 
 Nm/5/03 (F) serum 
Nm/1/93 WT 60597 1.00 
Nm/1/93 48M 46643 1.30 
Nm/1/93 190E 60992 1.01 




 Nm/5/03 (F) serum 
PV IC50 Fold-difference 
Nm/5/03 WT 129222 1.00 
Nm/5/03 48I 82991 -1.56 
Nm/5/03 190Q Data set incomplete 
Nm/5/03 193E 153504 1.19 
 Nm/1/93 (F) serum 
Nm/5/03 WT 105311 1.00 
Nm/5/03 48I 87375 -1.21 
Nm/5/03 190Q Data set incomplete 







5.3.4 Nm/5/03 and SA/4/03 PVNAs 
As with the previous outbreak scenarios, homologous and heterologous serum samples 
were tested against Nm/5/03 and SA/4/03 PVs. In this scenario, with anti-sera raised in 
ferrets, the PVNA highlighted the antigenic difference between Nm/5/03 and SA/4/03 
WT PVs when assayed against SA/4/03 serum with a 6-fold decrease (Table 20). 
However, there was a minimal difference between the two WT PVs when tested against 
Nm/5/03 serum (less than two fold). 
 
Table 20. IC50 results obtained from PVNAs using Nm/5/03 and SA/4/03 PVs against respective 
homologous and heterologous serum pairings. Fold-differences were calculated on the 
difference between the homologous and heterologous pairings for each PV. A negative fold-
difference indicates a decrease in the efficacy of the serum to neutralise the PV. Mean IC50 values 
reported for each assay (n= minimum of 2). Anti-sera were raised in ferrets (F). 
 
 Nm/5/03 (F) serum SA/4/03 (F) serum 
PV IC50 Fold-difference IC50 Fold-difference 
Nm/5/03 WT 75056 1.00 34448 -5.87 
SA/4/03 WT 102872 1.37 202239 1.00 
 
 
Nm/5/03 78A and 159S mutants had less than a 2-fold increase in IC50 when tested 
against Nm/5/03 serum, compared to Nm/5/03 WT. The difference in neutralisation of 
the Nm/5/03 159S mutant against SA/4/03 serum was also minimal, with a 1.14-fold 
decrease in IC50. The introduction of the 78A mutation (from SA/4/03) to Nm/5/03 
decreased the IC50 3-fold, which was the opposite of what might be expected. 
 
Table 21. IC50 results obtained from PVNAs with Nm/5/03 and SA/4/03 mutant PVs and 
homologous serum (ferret, F). Fold-differences provide comparison of the WT PV to mutant 
viruses when assayed against the same serum. Mean IC50 values reported for each assay  
(n= minimum of 2). 
 
 Nm/5/03 (F) serum 
PV IC50 Fold-difference 
Nm/5/03 WT 75056 1.00 
Nm/5/03 78 A 142476 1.90 
Nm/5/03 159 S 70186 1.07 
SA/4/03 WT 102872 1.37 
 SA/4/03 (F) serum 
SA/4/03 WT 202239 1.00 
Nm/5/03 78 A 74991 -2.70 
Nm/5/03 159 S 178107 -1.14 




The aim of this chapter was to generate PV mutants to look at the impact of single amino 
acid changes on equine H3 subtype specific neutralising antibody responses. Ferret and 
equine sera were used in PVNAs against the mutant PVs, to investigate the impact of 
the mutations that occurred during three different outbreak scenarios. 
The first outbreak scenario had three amino acid changes between the Nm79 
and Sx89 HA gene, which were highlighted by HI tests as potentially important antigenic 
differences (Woodward et al., 2015). To confirm the ability of PVNAs to distinguish 
antigenically different viruses, WT PVs were trialled first. Anti-serum raised in ferrets 
against both Nm79 and Sx89 WT viruses exhibited higher IC50 values for homologous 
pairings than for heterologous, as expected. 
The effect of each single mutant against the homologous serum pairing (raised 
in ferrets) was then investigated. Looking first at the Sx89 virus backbone with single 
Nm79 amino acid changes, the Sx89/189N mutant PV reduced the IC50 16-fold against 
the Sx89 serum indicating that this particular mutation decreased the efficacy of the 
serum to neutralise the virus. This was more than seen for either of the 159D and 227P 
mutants: Sx89/159D mutant decreased the IC50 2-fold and the IC50 against 227P did not 
change compared to WT Sx89. Mutating lysine to asparagine at position 189 in Sx89 
does not introduce a potential N-linked glycosylation site but it is possible that the 
change interferes with the neutralising antibody response. Position 189 resides within 
the 190 helix of the HA, which forms part of the receptor binding site as well as antigenic 
site B (Woodward et al., 2015). Interestingly, results using reverse genetics (RG) resulted 
in a similar finding, such that the highest decrease in HI titre was 100-fold with the 189N 
RG mutant and there was a 2.5-fold decrease with the 159D mutant. However, with the 
Sx89/227P RG mutant, despite no changes in neutralising antibody response being 
detected in the PVNA, a 22-fold titre decrease was observed using HI (Woodward et al., 
2015). 
Considering the Nm79 virus backbone with Sx89 single amino acid changes, the 
mutation of asparagine to lysine at position 189 (Nm79/189K) did not reduce the 
neutralisation efficacy of the Nm79 serum, as was seen with the reciprocal Sx89/189N 
mutation. Similarly, Sx89/159D and 227P mutants had minimal effects on the IC50 with 
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less than a 0.5-fold decrease and increase, respectively. These results are in agreement 
with those obtained using mutants generated via reverse genetics; all three mutants had 
less than a 0.5 fold change in HI titre (Woodward et al., 2015). It is possible that more 
than one single amino acid change is necessary to cause a decline in antibody 
recognition of epitopes (reflected in the IC50). A triple mutant was generated using RG, 
with the Nm79 virus backbone, to incorporate the following mutations; T187S, N189K, 
V196I. Compared to the single N189K mutant, the triple mutant virus further decreased 
the HI titre 2-fold (Woodward et al., 2015). In future work, it would be interesting to 
incorporate both 159 and 189 changes into Nm79 and Sx89 to observe the effect on the 
IC50. 
When testing the PV mutants against heterologous serum, an increase in IC50 
was considered logical because the mutation increases the similarity of the PV towards 
the virus strain, to that which is homologous to the anti-serum. Nm79/159N and 189K 
increased the IC50 by 5 and 7-fold, respectively, whereas no difference was observed 
between the IC50 of Nm79/227S and Nm79 WT when assayed against Sx89 serum. 
Compared to the Sx89 WT PV, assayed against Nm79 serum, the Sx89/159D mutant 
increased the IC50 by 9-fold but less than a 0.6-fold difference was observed with 
Sx89/189N and 227P. In the PVNA, the change at position 159 effects the reactivity of 
both Nm79 and Sx89 with the heterologous serum but this does not hold true for HI 
tests (Woodward et al., 2015). Amino acid changes at position 159 have been 
highlighted as a crucial change during the evolution of EI sublineages and a change of 
N159S currently distinguishes Florida clade 1 and clade 2 viruses (Bryant et al., 2009). 
The HI test measures inhibition of virus binding due to the presence of antibodies but 
these do not necessarily correlate with neutralising antibody responses that are 
measured by the PVNA, which may explain the difference in results (reviewed in Kinsley 
et al., 2016). The mutation at residue 227, in either virus backbone, did not appear to 
greatly affect the IC50. Neutralising antibodies are known to target the globular head of 
HA1 that encompasses amino acid positions 159 and 189 but not 227, therefore changes 
at position 227 may not have been detected by the PVNA (Figure 33). 
Results from PVNAs with anti-serum raised in horses did not generate a trend as 
clear as that with ferret anti-sera. Unexpectedly, the heterologous pairing of Nm79 WT 
against Sx89 serum gave a 3-fold increase in IC50 compared to Sx89 homologous pairing. 
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Employing polyclonal serum samples can enable cross-reactive antibodies to increase 
an IC50 but in this case the serum was monoclonal; obtained from a horse vaccinated 
against Sx89 only. Equine serum is typically less specific than ferret serum, as discussed 
previously, and the serum samples available for this study differed in generation (post-
vaccination and post-infection respectively). The homologous pairing of Nm79 WT PV 
and Nm79 serum gave a 70-fold increase in IC50 compared to Sx89 WT PV, as expected. 
It is interesting, however, that the Nm79 serum was polyclonal; the horse was 
vaccinated against Miami/63 followed by Nm79. A previous study showed minimal 
evidence of cross-reactivity between the Miami/63 virus and Sx89 serum with an HI titre 
of 4 (Daly et al., 1996), which is likely to explain why the heterologous pairing of Sx89 
and Nm79 serum was still considerably lower than the homologous pairing. 
Following the WT PV assays against homologous and heterologous equine sera, 
the single-mutant PVs were trialled. The Nm79/189K mutant PV reduced the IC50 by 6-
fold when assayed against Nm79 equine serum, which was not observed with the PV 
and ferret serum combination nor was it reported with mutant viruses in HI assays with 
anti-serum raised in ferrets (Woodward et al., 2015). Compared to Nm79 WT against 
Nm79 serum, the IC50s for Nm79/159N and Nm79/227S PV mutants differed by 0.5-fold, 
which agreed with the results obtained from ferret serum. A 3-fold decrease in IC50 was 
attributed to the Sx89/189N mutant against Sx89 serum, which although was not seen 
against ferret anti-serum with PVs, is in agreement with the RG mutant data (Woodward 
et al., 2015). Therefore the impact of mutation at position 189 was highlighted in PVNAs 
using equine sera. The amino acid change in the Nm79 backbone from asparagine, a 
polar molecule, to lysine that carries a positive charge, may interfere with receptor 
binding and or antibody interactions. The impact of introducing asparagine into the Sx89 
WT backbone was particularly prominent when assayed against the Nm79 equine serum 
with an 18-fold increase in IC50. Therefore, the substitution of the charged lysine 
molecule increases the efficacy of Nm79 specific antibodies to neutralise the Sx89 virus. 
The second outbreak scenario in the UK considered the antigenic differences 
between Nm/1/93 and Nm/5/03. Specifically, the only three amino acid changes that 
occurred within antigenic sites; sites A and B (Figure 34). Two of these changes were 
close together at positions 190 and 193, within antigenic site B and the 190 helix, which 
forms part of the receptor-binding site. Altering the amino acid combination at these 
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positions caused a decrease in PV titre for Nm/1/93 193K and Nm/5/03 190Q mutants. 
Due to the close proximity of the mutations it was possible that they were compensatory 
to one another. This theory was further supported by the increase in titre when 
Nm/5/03 190Q and 193E changes were introduced at the same time (Figure 41). Due to 
the low PV titres, PVNAs with Nm/1/93 193K and Nm/5/03 190Q mutant PVs were not 
completed. It would be beneficial to reduce the RLU input of these single mutants in 
future PVNAs and to trial the double mutant PV (Nm/5/03: 190Q, 193E). The only single 
mutation to affect IC50 by more than 2-fold was Nm/5/03 193E against Nm/1/93 serum. 
Interestingly, the change from lysine to glutamic acid does not alter the charged nature 
of the residues and therefore associated steric interactions were unlikely to be altered. 
At the time of the Nm/5/03 outbreak SRH antibody levels from vaccinated horses 
appeared adequate for protection and the differences in HA, to Nm/1/93, did not appear 
to constitute a cause for vaccine failure. These data are in agreement with the lack of 
fold-differences in IC50 values from the PVNAs. It was suggested that perhaps a 
combination of the antigenic changes and other pathogenicity factors resulted in the 
Nm/5/03 outbreak (Daly et al., 2006). For example, a truncated NS1 gene was 
demonstrated to increase virulence of an equine influenza strain (Janet Daly pers. 
comm). There is also evidence to suggest that immunoreactivity may be found outside 
of the five epitopes  ?<ǁĂƑŶŝŬet al., 2015). 
The final study investigated the difference between Nm/5/03 and SA/4/03. This 
outbreak scenario was attributed to a lack of biosafety measures in South Africa, not a 
case of vaccine breakdown (Guthrie et al., 1999). As few as two amino acid changes 
distinguished the strains as two separate clades: Florida clade 1 (SA/4/03) and clade 2 
(Nm/5/03), however, a vaccine update was deemed necessary. A study at the time 
showed that a Nm/1/93 vaccine boost would provide protection against SA/4/03 (Daly 
et al., 2007b). Due to the slow process of updating equine influenza vaccines available 
on the veterinary market, such studies are valuable for determining what current 
vaccine(s) will provide a level of protection. The PVNA was employed to investigate the 
difference in neutralising antibody response between the two clades. There was a 6-fold 
decrease in IC50 between SA/4/03 and Nm/5/03 WT PVs against SA/4/03 serum, 
indicating a difference between the clades. However, the fold-difference between the 
WT PVs and Nm/5/03 serum was minimal at 1.4-fold. The Nm/5/03 159S mutant PV also 
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had a minimal effect on reactivity with either homologous or heterologous serum 
sample (1.07 and 1.14 fold-differences respectively). However, there was a 3-fold 
decrease in IC50 with the 78A mutant against SA/4/03 serum, which was the opposite to 
expectation but as mentioned earlier, whether or not this fold-difference is significant 
needs to be established. 
Understanding the changes that cause equine influenza vaccine failure is 
complicated. Changes are continuously evaluated through improved serosurveillance 
programmes. Comparisons have been made to human H3 viruses, however, it is 
apparent that the same rules for cases of vaccine failure cannot be applied to equine 
influenza viruses. The rate of human H3 evolution is faster than equine H3: 0.87% amino 
acid changes over 14 years compared to 0.36% over 16 years (Skehel et al., 1983).  In 
human H3 strains, a minimum of four amino acid changes within two or more antigenic 
sites is attributed to drift variants with epidemiological implications (Wilson & Cox, 
1990). However, for equine H3, eight amino acid changes that include changes within 
antigenic site B plus another site have led to major outbreaks (Woodward et al., 2015). 
Following this work, mutant PVs may provide a tool to study the location of amino acids 
that affect neutralising antibody responses. 
The difficulty in interpreting the PVNA results is to understand how a fold-change 
in IC50 relates to protection levels within the equine host. For HI, seroconversion is 
defined by a 4-fold increase or decrease in titre, but, at present, there is no such 
measure for the PVNA. Another point to address is that PVs with a titre less than 2x107 
RLU/ml is not routinely used in a standard PVNA protocol, equating to an RLU input of 
1x106 in 50µl. Therefore, either PV optimisation is necessary to increase titre or the RLU 
input for all PVs that are to be used in a comparative assay have to be reduced. The most 
important factor is that the RLU input is consistent across all PVs, if comparisons are to 
be made. Evidently, there will always be variation in the RLU and thus further work 
needs to be done to establish acceptable levels of variation for RLU input. Here, the 
Sx89/159 mutant PV had the largest RLU output range from 9x103  ? 6x105 RLU. Whether 
this variation has led to inaccurate comparisons of neutralising antibody efficacy 





6 APPLICATION OF PSEUDOTYPED VIRUSES FOR SEROSURVEILLANCE 
AND POTENTIAL TO STUDY REASSORTMENT EVENTS 
6.1 Introduction 
Influenza is a classic zoonotic infection and the emergence of circulating subtypes in 
novel species is a long-ƐƚĂŶĚŝŶŐ ŐůŽďĂů ĐŽŶĐĞƌŶ ? dŚĞ ƌĞĐĞŶƚ  ? ? ? ?  ‘ƐǁŝŶĞ ? influenza 
pandemic serves as a potent reminder of the novel transmission events that can affect 
mankind (Isaacs, 2010; Smith et al., 2009). 
The H3N8 influenza virus subtype is one of the most abundant subtypes 
circulating in wild aquatic birds and it was also recently identified in domestic pigeons 
(Zou et al., 2016). The virus is non-pathogenic in the intestine of aquatic birds, causing 
few or no clinical signs. Transmission events between different species of birds, birds to 
mammals, and mammals to mammals often occur as short-lived infections but the H3N8 
virus, in particular, has become endemic in several mammalian hosts. The clinical signs 
associated with on-going outbreaks in horses, dogs and seals, tend to be worse than in 
avian hosts and in some cases are fatal (Anthony et al., 2012; Crawford, 2005; Yondon 
et al., 2013). Furthermore, the mammalian H3N8 host range extends to camels (Yondon 
et al., 2014), donkeys (Qi et al., 2010) and pigs (Tu et al., 2009). Due to such a broad host 
range, the potential transmission to other mammalian species including humans is often 
considered. The H3 subtype is responsible for seasonal influenza outbreaks in humans 
and the potential for genetic reassortment of an H3 virus, leading to another pandemic, 
is a cause for concern (Kreibich et al., 2013). For example, the Hong Kong pandemic of 
1968 was caused by an H3 virus (Viboud et al., 2005). Historically, reports indicated 
possible influenza transmission events from horses to humans over several centuries, 
ŝůůƵƐƚƌĂƚĞĚďǇƚŚĞůĂƌŐĞ ? ? ? ? ‘ĞƉŝǌŽŽƚǇ ?ŝŶƚŚĞh^ ?,ŽǁĞǀĞƌ ?ƚŚĞƐǇŵƉƚŽŵƐǁĞƌĞŐĞŶĞƌĂů
and could not be definitively attributed to influenza due to lack of available tests 
(Morens & Taubenberger, 2010). In 1965, five volunteers were infected with equine 
influenza; one individual suffered with febrile illness and the remaining four developed 
a high level of neutralising antibodies (Kasel et al., 1965). Interestingly, the neutralising 
antibodies against the EI virus also elicited a response against a human strain of 
influenza. Then in 1967, EI was administered to a cohort of 33 volunteers and out of the 
33, approximately two-thirds were infected but not all had symptoms or suffered with 
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illness (Alford et al., 1967). Overall there is little evidence supporting human H3N8 
infections after contact with infected horses (Burnell et al., 2014). Although, a recent 
study identified seropositive horse handlers with multiple tests (microneutralisation 
assay, neuraminidase inhibition, enzyme-linked lectin assay and HI) against the 
A/equine/Ohio/2003(H3N8) virus strain in Iowa, U.S. (Larson et al., 2015) and a review 
of papers dating back to 1959 also surmises that there is potential for human infection 
with equine influenza (Xie et al., 2016). 
A novel transmission event of the H3N8 virus from an equine to canine host was 
first reported in 2004 at a Greyhound racing facility in Florida, USA. Outbreaks across 
several states were then reported and it was subsequently declared endemic in the USA 
(Crawford, 2005). A separate transmission event of the H3N8 virus was also reported in 
foxhounds, in the United Kingdom (Daly et al., 2008). Housing foxhounds within close 
proximity to horses demonstrated that it was possible for direct transmission of the virus 
to occur (Yamanaka et al., 2009). However, prior to contracting the disease, the affected 
foxhounds had eaten an infected horse carcass including the lungs, which may provide 
an alternative explanation for transmission (Daly et al., 2008). During the equine 
influenza outbreak in Australia 2007 interspecies transmission of the H3N8 virus to dogs 
was also recognised (Kirkland et al., 2010). 
Host sialic acid receptors are a known factor in determining transmissibility 
[reviewed in (de Graaf & Fouchier, 2014)]. Equine influenza viruses preferentially bind 
ƚŽɲ-2,3 linked sialic acid host receptors, which are present in the upper respiratory tract 
of horses (Suzuki et al., 2000). A comparative study between horse and dog tracheal 
ĞǆƉůĂŶƚƐĨŽƵŶĚɲ-2,3 receptors in the respiratory tract epithelium of dogs, providing a 
possible explanation for a direct transmission event (Daly et al., 2008; Muranaka et al., 
2011). Phylogenetic analysis confirmed that the first reported outbreak strain 
(A/canine/Florida/43/04) was most closely related to isolates circulating in horses at the 
time and further comparisons, to other canine strains, identified two conserved amino 
acid changes at positions W222L and I328T in HA (Collins et al., 2014; Crawford, 2005). 
These amino acid changes are believed to be important in facilitating the transmission 
of the equine H3N8 virus to the canine host; position 222 resides within the receptor 
binding site of HA1 and position 328 is the C-terminus of HA1 (Collins et al., 2014). 
[103] 
 
Canine influenza has also independently appeared on another continent. The 
H3N2 virus was isolated in South Korea in 2007 (Song et al., 2008) but a retrospective 
study highlighted that the virus was in fact circulating in China in 2006, based on a case 
with a pet dog in Guangdong, China (Li et al., 2010). Within five years it was then isolated 
from roaming dogs in China (Su et al., 2013). An undesirable environment are the dog 
farms in China, such close proximity of the dogs and mixing of individuals facilitates fast 
transmission of the virus and as an example, one farm showed 100% seropositivity as a 
consequence of the outbreak (Lee et al., 2009). Similarly to the US H3N8 transmission 
event, direct transmission and the consumption of infected meat were thought to be 
the cause (Song et al., 2008). However, sequence analysis confirmed that this virus was 
of avian origin. Avian influenza viruses share the same preferred ďŝŶĚŝŶŐƐƉĞĐŝĨŝĐŝƚǇƚŽɲ-
2,3 linked sialic acid host receptors, which are found in the canine upper respiratory 
tract. Interestingly, the amino acid change at position 222 within the receptor binding 
site (tryptophan to leucine) found in the canine H3N8 virus was also present in the H3N2 
virus. 
China and South Korea are known for holding crowded animal markets, where 
birds and dogs are sold with the intention for consumption, which provides conditions 
for possible inter-species transmission. The transmission of canine influenza viruses, not 
only to other animals but to humans, provokes concern as dogs are widespread 
domestic companion animals. There have not been any reports of human infections with 
canine influenza virus thus far, but influenza isolates closely related to the human 1968 
Hong Kong pandemic were previously isolated from dogs; H1N1, H2N2 and H3N2 (Chang 
et al., 1976). Furthermore, H1N1 and H3N2 human isolates have recently been shown 
to replicate within canine tracheal explants (Gonzalez et al., 2014). 
 
Marine mammals are also known to be susceptible to type A influenza infections 
(Fereidouni et al., 2014). For example, seals have been recently affected by multiple 
influenza A outbreaks with high mortality rates. New England, US (Anthony et al., 2012) 
and Swedish coast lines (Zohari et al., 2014) were two of the affected regions where 
hundreds of harbour seals (Phoca vitulina) died as a result of respiratory infection. An 
H3N8 virus was responsible for the outbreak in New England and an H10N7 subtype in 
Sweden. Phylogenetic sequence analysis indicated that both subtypes were of avian 
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origin. Studies have since investigated the receptor binding specificity of the seal H3N8 
ǀŝƌƵƐ ĂŶĚ ĨŽƵŶĚ ƚŚĂƚ ŝƚŚĂƐ ĂŶ ŝŶĐƌĞĂƐĞĚ ĂĨĨŝŶŝƚǇ ĨŽƌ ɲ ? ? ?linked sialic acid receptors, 
which are associated with human influenza virus infections. The virus infected human 
lung cells and could undergo respiratory transmission in a ferret model (Karlsson et al., 
2014). Although seals are less likely to come into contact with humans, compared with 
dogs and horses, the virus still poses a potential threat to human health. Haemagglutinin 
Inhibition (HI) assays were performed with pre and post human H3 seasonal vaccine 
serum samples, against the A/harbor seal/Massachusetts/1/2011 (H3N8) virus, and 
there was no evidence of cross-reactivity suggesting that the human population could 
be susceptible to the virus (Karlsson et al., 2014). 
The production of novel PVs, such as canine and phocine (seal) influenza 
pseudotypes, would provide a new platform for sero-surveillance of these viruses 
particularly in the case of seals as it is problematic to take samples from wild animals 
during acute infection. Moreover, developing tools to understand the factors that 
enable successful transmission events is of primary interest to public health 
organisations. We have so far demonstrated that it is possible to produce an equine 
H3N8 pseudotyped virus. Further to this, the production of PVs with novel HA/NA strain 
combinations, may provide an insight into viable HA/NA pairings from a transmission 
prediction perspective. We have also demonstrated that it is possible to produce mutant 
HA PVs, which could be valuable tools to study the effect of mutations on receptor 
binding specificity and virus entry. An advantage of using non-replicative PVs for this 
work is the lowered risk of working with novel (potentially harmful) combinations of 
HA/NA. 
The objectives of the work described in this chapter were to; i) generate canine 
and phocine influenza virus pseudotypes; ii) employ the phocine PVs in PVNAs to detect 
neutralising antibodies in wild seal serum samples and/or vaccinated control samples, 
respectively; iii) introduce single canine influenza HA mutations into Nm/5/03 equine 
H3 PV for use in red blood cell binding assays and iv) investigate the generation of novel 
subtype combinations of HA/NA PVs. The overall aim was to generate pseudotype 




6.2 Materials and methods 
6.2.1 HA, NA and protease plasmids 
Canine HA genes; H3 A/canine/Colorado/30604/2006 (H3N8) (GenBank accession 
number: AB537183.1) and H3 A/canine/Guangdong/3/2011 (H3N2) (GenBank accession 
number: JX195358.1) were synthesised, incorporating BamHI/KpnI and EcoI/BglII 
restriction sites, respectively, and cloned into pUC57 by Genscript® (Central, Hong 
Kong). Genscript® also provided both canine HA genes cloned in mammalian expression 
vector pDREAM2.1. 
The seal H3 A/harbor seal/Massachusetts/1/2011 (H3N8) (GenBank accession 
number: JQ433879.1) gene was synthesised, incorporating KpnI/SalI restriction sites and 
cloned into pUC57 by Bio Basic Inc® (Ontario, Canada). Upon receipt, the cloned DNAs 
were resuspended, re-transformed and HA genes subcloned into pI.18 (Chapter 2 
Methods sections 2.1.2 and 2.1.3). The A/chicken/Germany/N49 H10 HA clone was 
kindly provided by Dr Davide Corti (Institute for Research in Biomedicine, Bellinzona, 
Switzerland). 
 Site directed mutagenesis of the A/equine/Newmarket/5/2003 (H3N8) HA gene 
was performed as described in (Chapter 2 Methods section 2.1.9). 
 
NA genes 1, 2, 4, 5 and 7 (Table 22) cloned in pI.18 were all kindly provided by Dr Nigel 
Temperton (Viral Pseudotype Unit, Kent) and re-transformed from original stocks. NA 
genes 3 & 6 (Table 22) were synthesised, incorporating EcoRI/XhoI and BamHI/XhoI 
restriction sites respectively and cloned into pUC57 by GenScript®. Upon receipt, the 
cloned DNA were resuspended, re-transformed and NA genes subcloned into pI.18 




Table 22. Influenza virus strains from which neuraminidase genes were isolated for pseudotype 
studies, including full subtype and associated GenBank accession numbers. 
 
 Neuraminidase GenBank 
accession number Isolate Subtype 
1 A/chicken/Italy/1067/1999 H7N1 CAC95055.1 
2 A/Udorn/307/1972 H3N2 DQ508931 
3 A/canine/Guangdong/3/2011 H3N2 JX195360.1 
4 A/chicken/Pakistan/34669/1995 H7N3 AAO62018.1 
5 A/turkey/Ontario/6118/1968 H8N4 EU429793.1 
6 A/equine/Richmond/1/2007 H3N8 KF559336.1 
7 A/avian/Shanghai/2/2013 H7N9 AGL44440.1 
 
 
Plasmids expressing the pCAGGS-TMPRSS2 and pCAGGS-HAT endoproteases were 
kindly provided by Dr Eva Böttcher-Friebertshäuser and Professor Hans Dieter Klenk 
(Institute of Virology, Philipps University Marburg, Germany). Other protease expression 
plasmids; pcDNA3.1-TMPRSS3, pCMV-Tag3-TMPRSS4 and pcDNA3.1-TMPRSS6 were a 
kind gift of Professor Stefan Pöhlmann (Infection Biology Unit, German Primate Center, 
Germany). The Kallikrein 5 (KLK5) encoding plasmid was originally purchased from 
Genscript® and kindly provided by Dr Nigel Temperton (Viral Pseudotype Unit, Kent). 
 
6.2.2 PV production and titration 
PVs displaying solely HA on their envelope were produced as described in (Chapter 2 
Methods section 2.3.1.1). Briefly, a four plasmid co-transfection of HEK293T/17 cells 
(using transfection reagent PEI) with plasmids expressing an influenza HA surface 
glycoprotein, HIV gag-pol, firefly luciferase reporter gene and endoprotease. For 
production of HA and NA PVs, a five plasmid co-transfection protocol was used with the 
addition of 125ng of NA plasmid (4:1 ratio of HA:NA, in an attempt to mimic ratio on 
wild type virus). All PV titrations were performed as described previously and titres 




6.2.3 Serum, ELISA and PVNA 
Wild seal sera for use in PVNAs were obtained from seals caught in the Baltic Sea (North-
western Europe; n=5) and Caspian Sea (Europe/Asia border; n=11), which were kindly 
provided by Sasan Fereidouni (University of Veterinary Medicine, Vienna). Sera from 
seals inhabiting the Pacific Ocean (n=30) were gifted from Frances Gulland (The Marine 
Mammal Center, California). All sera were tested by competitive ELISA for influenza 
nucleoprotein (not subtype specific), using a commercial kit developed at Friedrich-
Loeffler-Institut (ID Screen, ID.VET).   
Control serum; positive H3 serum was from a horse that had been vaccinated with 
several H3 equine influenza strains (Scott et al., 2012), positive H10 serum was from a 
vaccinated chicken obtained from the World Organisation for Animal Health (OIE) and 
positive influenza B serum (anti-B/Brisbane/60/2008) was from NIBSC (11/136 sheep). 
Fetal bovine serum (FBS) was used as a negative control. 
 
PVNAs were performed as described in (Chapter 2 Methods section 2.3.3). Briefly, serum 
samples were serially diluted and mixed with PV supernatent for 1hr at 37°C. 
HEK293T/17 cells were then added and the reagents incubated for 48hrs. Luciferase 
expression was quantified using BrightGlo reagent (Promega). 
 
6.2.4 Neuraminidase activity assays 
Influenza MUNANA neuraminidase activity assays were used to assess the 
neuraminidase activity associated with PVs displaying both HA and NA glycoproteins 
(Chapter 2 Methods section 2.4). 
 
6.2.5 Statistical analysis 
Comparison of two titration assay data sets was carried out using an unpaired T-test, 
except in cases where a normal distribution could not be assumed. In such cases, the 
Mann-Whitney test was applied (indicated when applied in results section). Values 
outside of the 95% confidence limits were deemed to be statistically significant. 




6.3.1 Production of canine influenza PVs 
Subcloning of the HA genes from the H3N8 A/canine/Colorado/30604/2006 (Colo06) 
and H3N2 A/canine/Guangdong/3/2011 (Guang11) into plasmid vector pI.18 was 
successful, using restriction enzymes BamHI/KpnI and EcoI/BglII, respectively. Positive 
clones were confirmed by colony PCR. Following this, the standard transfection protocol 
(Chapter 2 Methods section 2.3.1) was employed in an attempt to produce H3-only PVs. 
In addition to the pI.18 HA-encoding plasmids, two further transfections were carried-
out simultaneously, using an alternative mammalian expression vector, pDream, 
harbouring the Colo06 and Guang11 HA genes. By comparison to the delta env negative 
control, pI.18-Colo06 facilitated the production of a functional PV (p = 0.007) however, 
pDream-Colo06 did not (p = 0.182). Neither pI.18 nor pDream expression vectors 













Figure 42. Attempted generation of H3-only PVs derived from A/canine/Colorado/30604/2006 
H3N8 (Colo06) and A/canine/Guangdong/3/2011 H3N2 (Guang11) strains using different HA-
encoding plasmid vectors; pDream and pI.18. Mean PV titres are reported in relative 
luminescent units (RLU/ml) based on eight replicates with error bars indicating +SEM. 






Troubleshooting the lack of Guang11 H3 PV generation began with protease 
optimisation. Transfections with different quantities of TMPRSS2 and HAT proteases, 
which have facilitated the generation of other H3 PVs previously, were trialled (125-
500ng) but all yielded titres not significantly different to that of the delta env control. 
Other available proteases were subsequently trialled; TMPRSS3, TMPRSS4, TMPRSS6 

























Figure 43. Testing A/canine/Guangdong/3/2011 H3-only PV generation with A) TMPRSS2 
(TMP2) and HAT. B) TMPRSS3 (TMP3), 4 (TMP4), 6 (TMP6) and Kallikrein 5 (KLK5) proteases. 
Number indicates the quantity of protease expressing plasmid used (ng), if not stated 125ng was 
used. Mean PV titres are reported in relative luminescent units (RLU/ml) based on eight 









The sequence at the HA cleavage site of Guang11 H3 was compared to that of other PVs 
that have been successfully generated. Whilst Guang11 is different to equine H3s, its 
cleavage site is the same as a strain of seal influenza H3, which was successfully 
pseudotyped using both TMPRSS2 and HAT (Figure 44). It is therefore likely to be 
another aspect of PV production that is preventing generation of this particular strain, 




Figure 44. Alignment of H3 cleavage sites from different species; equine, canine, human and seal 
H3. Blue box indicates protease cleavage region with the arginine (R) cleavage site highlighted 





Our standard laboratory protocol includes 500ng of HA-encoding plasmid for H3 PV 
production. In order to ensure that the quantity of HA was not a limiting factor in the 
production of Guang11, 1µg of pI.18-Guang11 H3 plasmid was added to the 
transfection, alongside 250ng of TMPRSS2 or HAT protease plasmid. The increased 
quantity of HA (with TMPRSS2) did improve the PV titre compared to delta env control 
(p = 0.037) (Figure 45). However, the titre did not reach the target of 2x107 RLU/ml for 













Figure 45. Testing A/canine/Guangdong/3/2011 H3-only PV production using different 
quantities of pI.18-HA encoding plasmid, in the presence of 250ng TMPRSS2 (green) or 250ng 
HAT (orange) protease plasmids. Mean PV titres are reported in relative luminescent units 
(RLU/ml) based on eight replicates with error bars indicating +SEM. ** Indicates a significant 





HEK293T/17 cells are readily amenable to transfection and are therefore a common 
choice for pseudotype virus production and titration. PV entry into a target cell depends 
on the surface glycoprotein present on the PV and the receptors expressed on the target 
cell membrane. Therefore, the titre of a PV is dependent on the target cell line used in 
the titration assay. Here, a canine cell line (A72 canine tumour of the thigh  ? Chapter 2 
Methods section 2.2.1) was trialled alongside the standard HEK293T/17 as a target cell 
line for both Colo06 and Guang11 canine influenza PVs. Colo06 was successfully titrated 
using both A72 and HEK293T/17 cell lines and there was no significant difference 
between the titres (p = 0.187). Whereas, Guang11 H3-only produced a lower titre when 
titrated on A72 cells compared with the standard HEK293T/17 cells (Figure 46). 
Therefore, in the case of canine PVs, infectivity was not increased by changing to a target 














Figure 46. Titration of A/canine/Colorado/30604/2006 H3 PV (Colo06) and 
A/canine/Guangdong/3/2011 H3 PV (Guang11) using two different target cell lines; HEK293T/17 
(HEK in blue) and A72 (red). Delta env negative control was also titrated on both cell lines. Mean 
PV titres are reported in relative luminescent units (RLU/ml) based on eight replicates with error 




6.3.2 Neutralisation of A/canine/Colorado/30604/2006 H3 PV  
Due to a lack of being able to source canine serum for testing against the 
A/canine/Colorado/30604/2006 H3 PV, a PVNA was set up using a known positive 
equine H3 polyclonal serum (Methods section 6.2.3): Figure 47 shows the neutralisation 
curve of the PVNA. There is strong evidence of cross-reactivity between the equine 















Figure 47. Percentage neutralisation from PVNA of A/canine/Colorado/30604/2006 H3 PV 
against a known positive equine H3 polyclonal serum. Each data point in the two-fold serial 





6.3.3 HA-mutant canine influenza PVs for use in HA binding assay 
Canine influenza PVs bearing HA proteins containing specific mutations were produced 
and used to investigate the impact on virus-host cell interactions. An equine Nm/5/03 
wild type (WT) HA gene was mutated to incorporate two conserved mutations, 
independently, that are thought to have contributed to the transmission of the H3N8 
virus to dogs (W222L and I328T) (Collins et al., 2014). The mutations were confirmed by 
sequence analysis. Following this, the two mutant HA-encoding plasmids were used to 
produce PVs. Mutant W222L did not form a functional PV, based on a comparison to 
Delta env control (p = 0.491). On the other hand, mutant I328T was successfully 















Figure 48. Titration of A/equine/Newmarket/5/2003 (Nm/5/03 WT), mutant W222L, mutant 
I328T and A/canine/Colorado/30604/2006 H3 (Colo06 WT) PVs. Mean PV titres are reported in 
relative luminescent units (RLU/ml) based on eight replicates with error bars indicating +SEM. 





Although mutant W222L PV was not functional, both mutant PVs were taken forward 
into a HA-binding assay alongside the Nm/5/03 WT and Colo06 WT PVs previously 
generated to ascertain any differences in binding of viral particles to sialic acid receptors 
on target cells. Three different types of red blood cells (RBCs) were used; derived from 
guinea pig, chicken and sheep species (Figure 49). PVs were serially diluted (two-fold) 
and the lowest virus titre that caused agglutination of the RBCs was recorded. A 
Nm/5/03 WT virus was used as a positive control for the assay and it was evident that 
the whole virus caused agglutination of RBCs at a much lower concentration than the 
equivalent Nm/5/03 WT PV. The Nm/5/03 WT PV caused agglutination of guinea pig and 
chicken red blood cells, indicating the presence of HA on the PV surface. The non-
functional W222L mutant served as a negative control and did not cause agglutination 
of RBCs from any species, as expected. The mutant I328T and Colo06 WT, also, did not 
cause any agglutination of RBCs even at the highest concentration of virus particles 
(Table 23). Therefore, it was not possible to analyse any difference in receptor binding 
that could be attributed to the incorporated mutations using this assay. 
 
 
Table 23. Virus titres (the lowest dilution at which the pseudotyped virus agglutinates RBCs) 
obtained in HA binding assays using three sources of red blood cell; guinea pig, chicken and 
sheep. A two-fold serial dilution of virus was carried-out. Nm/5/03 wild type (WT) virus was used 

















A) Guinea pig 128 16 < 2 < 2 < 2 
B) Chicken 128 16 < 2 < 2 < 2 






Figure 49. Illustration of haemagglutination (HA) binding assay results using three different 
sources of red blood cell; A) guinea pig, B) chicken and C) sheep. A two-fold serial dilution of 
each virus was carried-out beginning in well 1 (1/2 dilution). 
  
1       2        3        4       5       6       7       8       9     10     11    12        
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6.3.4 Production of a seal influenza PV 
Firstly, the A/harbor seal/Massachusetts/1/2011 H3 gene was successfully subcloned 
into the pI.18 expression plasmid (Figure 50) and used to produce the seal H3 influenza 
PV. TMPRSS2 and HAT proteases were used in the standard transfection protocol 
(Chapter 2 Methods section 2.3.1.1) and both were thus clearly successful in cleaving 










Figure 50. Plasmid digest of pI.18-HA A/harbor seal/Massachusetts/1/2011 H3 using restriction 
enzymes KpnI and SalI. Lanes 2 and 4 indicate positive clones. Negative control (lane 5) is pI.18 












Figure 51. Titration of A/harbor seal/Massachusetts/1/2011 PVs produced with TMPRSS2 and 
HAT proteases. ȴ protease and ȴ env negative controls are included. Mean PV titres are reported 




PVs were then used to assay serum samples taken from wild seals caught in the Baltic 
Sea (BS) and Caspian Sea (CS) for neutralising antibodies targeting H3 and H10 subtype 
influenza HAs (Table 24). None of the BS samples were positive for neutralising 
antibodies against either H3 or H10 PVs. Nine CS samples were positive by H3 PVNA and 
three via H10 PVNA. All H10 positives were also H3 positive, but three some samples 
only showed positivity with H3. Furthermore, known positive H3 (equine) and H10 
(chicken) sera were assayed against H10 and H3 PVs, respectively, to confirm that the 
results were subtype specific, not due to cross reactivity (Table 24). The two PVNA 
experiments showed consistency, with all positives seen in the first assay also positive 
in the second. ELISA results showed a similar pattern to the positive and negative PVNA 
results, with the exception of two H3 PVNA positives (CS16 & 22) that were negative by 
ELISA (Table 24). 
 
Table 24. PVNA results of seal serum samples assayed against A/harbor 
seal/Massachusetts/1/2011 H3 and A/chicken/Germany/N49 H10 PVs (blue and purple 
respectively). ELISA results reported as percentage inhibition and highlighted in green. Colour 
gradient indicates strength of response, whereby the darkest shade represents the strongest 
ƉŽƐŝƚŝǀĞƌĞƐƉŽŶƐĞ ? ‘AM ?indicates IC50 <400 (IC50 reported as the reciprocal serum dilution range 
that leads to 50% neutralisation.) BS  ? Baltic Sea, CS  ? Caspian Sea. 
 
 





H3 (expt 1) H3 (expt 2) H10 (expt 1) H10 (expt 2) 
BS1 0 < < < < 
BS2 0 < < < < 
BS3 0 < < < < 
BS4 0 < < < < 
BS5 0 < < < < 
CS2 19.9 < < < < 
CS9 9.0 < < < < 
CS14 33.9 800 - 1600 400 - 800 < < 
CS15 89.4 < < < < 
CS16 11.5 ~ 800 400 - 800 < 400 - 800 
CS17 36.8 < < < < 
CS20 75.9 1600 - 3200 1600 - 3200 800 - 1600 800 - 1600 
CS21 18.8 < < < < 
CS22 17.5 400 - 800 < < < 
CS23 75.5 400 - 800 < < < 
CS25 4.9 < < < < 
H3 Positive N/A 3200 - 6400 < 
H10 Positive N/A < >6400 




Using the A/harbor seal/Massachusetts/1/2011 H3 PV, further PVNAs were set up to 
analyse the neutralising antibody response in serum samples collected in the Pacific 
Ocean. Only one sample, number eight, out of the 30 samples was negative in both 
PVNAs against the seal H3 PV (Table 25). Samples 21, 25, 27, 28 and 30 had low IC50 
titres in the first PVNA but tested negative in the second. Overall, there was a range of 
IC50 values across the set of serum samples but majority gave strong positive results 
against the H3. Surprisingly, all samples tested negative (triplicate repeats) in the same 







Table 25. IC50 results obtained from a PVNA using Pacific Ocean seal serum samples against A/harbor seal/Massachusetts/1/2011 H3 PV. H3 (equine) 
positive and fetal bovine negative control sera were included. ELISA results illustrated in green (all samples negative). Colour gradient indicates strength 











IC50  SERUM 
SAMPLE 
IC50  SERUM 
SAMPLE 
IC50 
Assay 1 Assay 2  Assay 1 Assay 2  Assay 1 Assay 2 
1 1600 - 3200 1600 - 3200  11 800 - 1600 400  ? 800  21 400 - 800 * 
2 100  ? 200 100  ? 200  12 800  ? 1600 800  ? 1600  22 1600  ? 3200 400  ? 800 
3 400  ? 800 800  ? 1600  13 800  ? 1600 200 - 400  23 400  ? 800 400  ? 800 
4 200  ? 400 100  ? 200  14 1600  ? 3200 200 - 400  24 400  ? 800 800 - 1600 
5 200  ? 400 400  ? 800  15 800  ? 1600 800  ? 1600  25 400 - 800 * 
6 400  ? 800 800  ? 1600  16 400  ? 800 200 - 400  26 200  ? 400 100  ? 200 
7 800 - 1600 1600 - 3200  17 400  ? 800 200 - 400  27 200  ? 400 * 
8 * *  18 200 - 400 200 - 400  28 100 - 200 * 
9 800  ? 1600 800  ? 1600  19 400  ? 800 800  ? 1600  29 800  ? 1600 3200  ? 6400 
10 400  ? 800 800  ? 1600  20 400  ? 800 800  ? 1600  30 100  ? 200 * 
H3 Positive 3200 - 6400 >6400  H3 Positive 3200 - 6400 >6400  H3 Positive >6400 >6400 
FBS Negative * *  FBS Negative * *  FBS Negative * * 
[121] 
 
6.3.5 Production of different HA/NA combination PVs 
Attempts were made to produce PVs bearing different combinations of HA and NA to 
investigate the effect of multiple surface glycoproteins on PV titre and the potential to use 
the PVs as reassortment prediction tools. All combinations of HA and NA trialled currently 
circulate in nature, predominantly in avian hosts. However, in this study the compatibility 
of HA and NA from different species was investigated. Initially, all available NA-encoding 
plasmids were co-transfected with A/equine/Richmond/1/2007 H3 or A/Viet 
Nam/1194/2004 H5 (Table 26). All NA plasmids facilitated the production of high titre 
H5NA PVs, which confirmed that all NA plasmids were functional, expressing NA. 
Furthermore, with the exception of N2, all NA plasmids produced higher titres than the 
standard addition of exogenous NA (ExNA) for H5 PVs (Figure 52). It is noteworthy that the 
N2 of human origin produced viable PVs that were significantly higher in titre than the H5 
delta NA control (p = <0.001). Whereas this was not the case for H3; the human N2 plasmid 
did not facilitate the production of an H3N2 PV above the level of H3 delta NA (p = 0.462 
and p = 0.798 respectively). Only the H3N1 combination produced a titre that was 
statistically comparable to ExNA (p = 0.505). The N3, N4 and N9 plasmids produced PVs 
with significantly increased titres, compared to H3 delta NA, but none were comparable to 
the highest titre using ExNA. Interestingly, the matching strain HA and NA (H3N8) was 




Table 26. Combinations of HA and NA (4:1) PVs generated. The matched equine subtype that is 
currently circulating is highlighted in purple. Functional PVs were defined by a significantly higher 
titre than a delta NA control (Mann-Whitney test, p A? 0.01) are highlighted green. Non-functional 
PVs are highlighted red. 
 
HA Origin NA Origin Combination 
A/equine/Richmond/1/2007 (H3N8)  A/chicken/Italy/1067/1999 (H7N1) H3 N1 
A/equine/Richmond/1/2007 (H3N8)  A/Udorn/307/1972 (H3N2) H3 N2 
A/equine/Richmond/1/2007 (H3N8)  A/chicken/Pakistan/34669/1995 (H7N3) H3 N3 
A/equine/Richmond/1/2007 (H3N8)  A/turkey/Ontario/6118/1968 (H8N4)  H3 N4 
A/equine/Richmond/1/2007 (H3N8)  A/equine/Richmond/1/2007 (H3N8)  H3 N8 
A/equine/Richmond/1/2007 (H3N8)  A/avian/Shanghai/2/2013 (H7N9)  H3 N9 
A/Viet Nam/1194/2004 (H5N1) A/chicken/Italy/1067/1999 (H7N1) H5 N1 
A/Viet Nam/1194/2004 (H5N1) A/Udorn/307/1972 (H3N2)  H5 N2 
A/Viet Nam/1194/2004 (H5N1) A/chicken/Pakistan/34669/1995 (H7N3) H5 N3 
A/Viet Nam/1194/2004 (H5N1) A/turkey/Ontario/6118/1968 (H8N4)  H5 N4 
A/Viet Nam/1194/2004 (H5N1) A/equine/Richmond/1/2007 (H3N8)  H5 N8 




Figure 52. A/equine/Richmond/1/2007 H3 (orange) and A/Vietnam/1194/2004 H5 (blue) mean PV 
titres generated by co-transfection with different NA plasmids (Table 22 contains NA strains). 
Species origin of NA denoted by; A  ? avian, C  ? canine, E  ? equine, and H  ? human. An exogenous 
source of NA (ExNA) was added 24hours post transfection as a positive control and Delta (without) 
NA was generated as a negative control. PV titres reported in relative luminescent units (RLU/ml), 
+/- SEM of eight replicates. Statistically significant differences (Mann-Whitney test) between mean 





Further combinations of equine, canine, phocine and human HA and NAs were trialled with 
a view for reassortment potential (Table 27), based on the concept of HA/NA evolution 
whereby not all combinations are compatible to generate infectious virus particles. 
Surprisingly, the matching human H3N2 strain did not generate a functional PV (p = 0.07). 
Novel combinations of seal H3 with human N2 and human H3 with equine N8 also did not 
generate functional PVs. Interestingly however, one out of the two H1 human and N8 
equine PV combinations was successfully generated (South Carolina; p = 0.005). The H3 
canine and N8 equine combination was also successful (Figure 53).  
 
Table 27. Combinations of HA and NA (4:1) PVs generated. The matched human subtypes that is 
currently circulating is highlighted in purple. Functional PVs were defined by a significantly higher 
titre than the delta env control (Mann-Whitney test, p A? 0.01) are highlighted green. Non-
functional PVs are highlighted red. 
 
PV HA Origin NA Origin Combination 








3 A/Udorn/307/1972 (H3N2) A/Udorn/307/1972 (H3N2) H3 N2 
4 A/harbor seal/Massachusetts/1/2011 (H3N8) A/Udorn/307/1972 (H3N2) H3 N2 






















Figure 53. H1N8, H3N2 and H3N8 combination PVs. Mean PV titres generated by co-transfection 
with different HA and NA plasmids (Table 27 contains HA and NA strains for PVs 1-6). Delta 
envelope (env) was generated as a negative control. PV titres reported in relative luminescent units 
(RLU/ml), +/- SEM of eight replicates. Statistically significant differences (Mann-Whitney test) 
between mean RLU/ml of each HA/NA combination PV and the Delta env control are indicated by 
** = p<0.01; *** = p<0.001.  
[124] 
 
The three highest titre H3NA PVs were taken forward into a preliminary PVNA to establish 
whether PVs incorporating both HA and NA proteins on their surface can be neutralised. 
An H3 positive serum from a horse that had been serially vaccinated with several H3 
equine influenza strains was used (Scott et al., 2012). All PVs were neutralised and those 
with both HA and NA resulted in higher IC50 values compared with the H3-only PV 
produced with exogenous NA; H3N1 showed a 2-fold increase, H3N3 was the greatest 
increase by 11-fold and H3N4 increased by 3-fold. Hence the presence of NA on the surface 




Table 28. PVNA IC50 values obtained from an H3 positive equine polyclonal serum against HA/NA 
combination PVs. Fold-difference to the equine H3 only PV (produced with exogenous 
neuraminidase) are stated for all HA/NA combinations. PV titres greater than 2 x 107 RLU/ml were 
used in the assay. 
 
 
PV  IC50  Fold-difference 
Equine H3 + Avian N1  92,463 1.93 
Equine H3 + Avian N3 541,169 11.32 
Equine H3 + Avian N4  156,340 3.27 





6.3.5.1 Neuraminidase activity assays 
In order to provide a potential explanation for differences in PV titre with different 
combinations of HA and NA, NA activity assays were carried-out. Initially, PVs were diluted 
to an equal titre (based on the lowest titre PV) and NA activity was measured in relative 
fluorescent units (RFUs) (Table 29). Using diluted PVs, only supernatant samples of the H3 
and H5 PVs produced with exogenous NA gave a high level of activity and the H3N9 PV 
showed a low level of activity. All other PVs showed minimal or no NA activity, at the same 
level as the negative control. The NA activities using neat PVs were higher for all 
combinations apart from the N2 PV. However, the titres differed when using neat PVs, and 
therefore the activity of the NA can only be compared in cases where PV titre could be 
normalised i.e. the same titre: this is true for H3N3 & H3N9 and H5N3 & H5N8. The levels 
of NA activity are similar in these cases, indicating that the titre of a PV could be affected 
by the level of NA activity. This is also supported by the low titre H3N2 PVs (Table 29) 
exhibiting low NA activity.  
 
 
Table 29. Neuraminidase activity levels of H3NA and H5NA combination PVs produced with 
plasmid-encoding NAs or an exogenous NA (ExNA) control. PV titres are reported in relative 
luminescent units/ml (RLU/ml). Activity was measured in relative fluorescent units (RFUs). 
 
          
  H3 PVs H5 PVs 
NA Titre (RLU/ml) 
NA Activity (RFU) 
Titre (RLU/ml) 
NA Activity (RFU) 
Neat Diluted Neat Diluted 
N1 2.5 x 108 216 9 8.4 x 1010 393 5 
N2 < 105 7 - 1.4 x 108 6 5 
N3 2.5 x 107 10 8 1.0 x 1011 149 5 
N4 7.1 x 107 11 6 7.6 x 1010 24 - 
N8 9.8 x 106 9 8 1.1 x 1011 598 6 
N9 2.9 x 107 28 17 9.0 x 1010 110 - 
ExNA 2.8 x 108 871 560 2.6 x 1010 1073 15 
Negative N/A 5 5 N/A 5 6 
    







Canine influenza H3 PVs 
Novel expression vectors for use in mammalian cells are continuously being developed and 
can be purchased from numerous companies. Genscript® provided an opportunity to test 
an alternative expression vector, pDREAM2.1, to our standard pI.18 plasmid in our 
lentiviral-based pseudotype virus system. pDREAM2.1 was engineered with several 
promoters in order to function within bacteria, insect cells and mammalian cells. Our 
standard protocol plasmid, pI.18, contains a human cytomegalovirus promoter (CMV) that 
drives expression of the HA gene in HEK293T/17 cells. The CMV promoter is also present 
in pDREAM2.1, however, the plasmid did not facilitate expression of either canine HA 
genes (Colo06 or Guang11) to a level that generated functional pseudotyped viruses and 
the plasmid was therefore disregarded from further use. 
The Colo06 pI.18-H3 encoding plasmid, alongside the core gag-pol plasmid (p8.91) 
and luciferase reporter (pCSFLW), facilitated the generation of Colo06 H3-only PV but 
Guang11 pI.18-H3 did not. Cleavage of HA is essential for infection by an influenza virion 
and therefore optimising the protease is a strategy employed to rescue pseudotype virus 
production. TMPRSS2 and HAT are commonly used to cleave H3 subtypes but did not 
facilitate the production of functional Guang11 PV. Furthermore, the cleavage site in 
Guang11 is identical to the seal H3 (A/harbor seal/Massachusetts/1/2011) cleavage site, 
which was successfully cleaved by TMPRSS2 and HAT. Alternative proteases were 
therefore trialled in an attempt to produce functional Guang11 H3-only PV. TMPRSS4 has 
been shown to successfully cleave H3 subtypes (Bertram et al., 2010a) however, for 
Guang11 H3, cleavage was not successful. Data published on TMPRSS3 and TMPRSS6 
proteases reported no HA cleavage (Kühn et al., 2016) and our results were in agreement; 
neither TMPRSS3 or 6 increased PV titres above that of the delta envelope control. KLK5, 
a protease found in the blood, has been shown to cleave HA (Hamilton & Whittaker, 2013) 
but was also not successful for cleaving Guang11 H3. It is possible that amino acid 321I, 
which is different to 321V contained within other H3s that have been successfully 
pseudotyped, impacts the HA protein folding and furthermore affects cleavage. 
Alternatively, cleavage of few PVs could be occurring, yet a combination of low-expression 
of the H3 gene and lack of binding to target cells could be causing a low titre PV to be 
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generated. Functional H3-only equine, canine and phocine PVs were produced with a 
standard 500ng of HA-encoding plasmid DNA, however this was not successful with 
Guang11 H3. Increasing the quantity of HA could increase the abundance of HA protein on 
the surface of the PV, which would increase the likelihood of PV virus binding to target 
cells, assuming that cleavage of the HA has been successful. Doubling the quantity of the 
HA-encoding plasmid did increase the titre of the Guang11 PV, however, the titre did not 
reach 2x107 RLU/ml, which is the desired input for a PVNA. Future work should include 
increasing the quantity of HA-encoding plasmid and carrying-out western blot analysis to 
confirm a) expression of the HA protein b) presence of cleaved HA and c) optimised vs non-
codon optimised genes. 
A study based on VSV-pseudotyped influenza viruses illustrated that matching HA 
and NA proteins enhance HA-fusion and furthermore entry of PVs compared to HA-only 
pseudotypes (Hsu et al., 2015). Independently, we also demonstrated that it is possible to 
generate HA and NA lentiviral pseudotypes (Scott et al., 2016) and decided to investigate 
if the presence of the native A/canine/Guangdong/3/2011 N2 protein would increase PV 
titre. Sequence analysis of the subcloned N2 gene in pI.18 uncovered two issues; firstly, 
the orientation of the gene was reversed as a result of incorrect cloning and secondly, a 
stop codon was present mid-way through the gene. These issues have since been rectified 
ďƵƚ ƚŚĞ ƌĞƐƵůƚŝŶŐ 'ƵĂŶŐ ? ? , ? ĂŶĚ E  ‘ŵĂƚĐŚŝŶŐ ? Ws ǁĂƐƐƚŝůů ŶŽŶ-functional (Martin 
Mayora-Neto pers. comm.). 
Another approach to trouble-shooting the non-functional canine Guang11 PV was 
to change the target cell line from human to canine origin. HEK293T/17 cells are permissive 
to influenza pseudotyped viruses, although not thus far for Guang11. Therefore, a change 
in receptor composition on the target cell surface may be required for GuangH3-mediated 
entry. A canine cell line A72 was trialled without success. MDCK (Madin-Darby Canine 
Kidney) cells are commonly used in influenza virus studies and would be a good candidate 
cell line for future studies (Hsu et al., 2015; Lin et al., 2016). 
Agglutination of RBCs in binding assays has been demonstrated with highly 
pathogenic H5N1 lentiviral pseudotypes and furthermore, single amino acid changes have 
been shown to alter the binding specificity of PVs (Tang et al., 2016). Here, we adopted 
the same approach, with A/equine/Newmarket/5/03 wild-type H3 PV and introduced two 
separate canine influenza-associated mutations. All three PVs were added to RBCs to 
[128] 
 
ascertain any differences in binding. However, it was not possible to analyse differences in 
receptor binding because the mutants did not cause the RBCs to agglutinate. The W222L 
mutant did not form a functional PV and therefore a lack of HA on the PV surface would 
explain a lack of binding. On the other hand, the I328T mutant generated a higher titre PV 
than the A/equine/Newmarket/5/03 and A/canine/Colorado/30604/2006 H3 wild-type 
PVs, yet did not cause agglutination of RBCs. It is possible that the canine influenza does 
not cause agglutination of guinea pig, chicken or horse RBCs. Haemagglutination inhibition 
assays have successfully been conducted using turkey RBCs, therefore this assay should be 
repeated with turkey RBCs (Anderson et al., 2012b; Crawford, 2005). 
 
Seal influenza H3 PV 
Following successful generation of the A/harbor seal/Massachusetts/1/2011 H3 PV, 
serosurveillance of wild seal sera was conducted using the PVNA. Sera were collected from 
seals in the Baltic and Caspian Seas and were originally tested in a competitive ELISA (Sasan 
Fereidouni and Elke Starick unpublished data), which detects antibodies against the 
nucleocapsid protein of the influenza virus. The ELISA results were overall in agreement 
with the PVNA results, whereby positive ELISA results were also positive in the PVNA. 
However, there were two exceptions with samples CS15 and CS23, which tested as strong 
ƉŽƐŝƚŝǀĞƐŝŶƚŚĞ>/^ďƵƚǁĞƌĞĐŽŶƐŝĚĞƌĞĚĂƐŶĞŐĂƚŝǀĞĂŶĚ ‘ǁĞĂŬůǇƉŽƐŝƚŝǀĞ ?ŝŶƚŚĞWsE ?
respectively. This was the first serosurveillance study of seal sera conducted with the PVNA 
and therefore the negative threshold of samples needs to be considered. A threshold for 
equine serum negative for specific influenza antibodies was originally established on a 
limited set of samples (Scott et al., 2012) but whether this threshold is applicable for seal 
sera needs to be addressed. Negative ELISA results equated to an IC50 between 400 and 
800, which is higher than the threshold of 80 for equine samples. It is possible that non-
specific binding of proteins in the seal sera elevated the IC50 result. 
 Another serosurveillance study was conducted on a set of wild seal sera, collected 
from pups in the Pacific Ocean. Interestingly, ELISA results were negative but IC50 results 
from the PVNA were considered to be positive, based on the original equine threshold of 
IC50 below 80. It would be interesting to PVNA test this set of sera from the Pacific Ocean 
against another influenza subtype to establish if the higher, than expected, level of 
neutralisation is seen against other subtypes. The PVNA has been reported with higher 
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levels of sensitivity compared to other serological assays, such as single radial haemolysis 
(Scott et al., 2012). One of the advantages of the PVNA is that small quantities of sera are 
required, however, this means that sera tested in PVNAs are typically at lower 
concentrations than in other ĂƐƐĂǇƐ ƐƵĐŚ ĂƐ ƚŚĞ >/^ ? dŚĞƌĞĨŽƌĞ ƚŚĞ  ‘ƉŽƐŝƚŝǀĞ ? ƌĞƐƵůƚ 
cannot be attributed to a higher concentration of serum. It would be beneficial to carryout 
ELISA and PVNAs with the same dilution of sera in order to understand equivalent read-
outs for the different assays. Unfortunately, with the limited serum sample volumes in this 
study, it was not possible to carry-out the PVNA at the same concentration as the ELISA. 
Another point to consider is that the ELISA employed here detects antibodies against the 
nucleocapsid protein whereas the PVNA detects neutralising antibodies against HA, 
therefore a direct comparison between the assays would not be possible. An ELISA that 
detects antibodies against H3 HA would be beneficial to aid correlation enquires.  
 
HA and NA PVs 
A proof of principle study in chapter 3 demonstrated that it is possible to generate an 
equine H3N8 influenza pseudotype, bearing both HA and NA surface glycoproteins. In this 
chapter, the concept was extended to generate different combinations of HA and NA PVs, 
how this affects PV titre and if mismatched HA&NA combinations are functional. One PV 
study has already shown that matching HA and NA proteins enhanced HA-fusion and 
furthermore entry of PVs compared to HA-only pseudotypes, which is due to the positive 
effect on HA-trafficking through the producer cell to the cell surface and thus increasing 
the amount of HA on the PV surface (Hsu et al., 2015). However, there is also evidence to 
suggest that adding either exogenous or endogenous NA yields similar PV titres (Su et al., 
2009). Here, the production of H5 PVs was enhanced by the presence of endogenous NA 
compared to the bacterial source of exogenous NA, which is in agreement with Tsai and 
colleagues (2009), whereas for H3 PV production exogenous NA generated the highest PV 
titre. Interestingly, the matching combination of A/Udorn/307/1972 H3 and N2 was not 
functional and neither were other combinations that incorporated the N2; 
A/equine/Richmond/1/2007 H3 and A/harbor seal/Massachusetts/1/2011 H3. The N2-
encoding plasmid was transfected alongside a H5-encoding plasmid and formed a 
functional PV, therefore the plasmid was functional. However, the resulting H5N2 PV was 
2 logs lower in titre than other H5 and NA PVs. A neuraminidase activity assay was carried-
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out and found that the N2 activity was lower that all other NAs, which provides an 
explanation for the resulting low titre and non-functional N2 PVs. A reassortment study 
with the H9 subtype also found that N2 activity was lower than N1 and N3 (Yan et al., 
2016). 
 Although the transfection ratio of HA:NA is representative of the 4:1 ratio on an 
influenza virion, we have not established the distribution pattern of the proteins on the PV 
surface. The expression of both proteins may not be equal and therefore different 
quantities of each embedded in the membrane could be impacting PV titre and 
furthermore neutralisation assays. Neutralisation assays with H3NA PVs (H3N1, H3N3 and 
H3N4) were trialled and the neutralising antibody responses against the PVs with NA 
expressed were greater than against the HA-only PV produced with exogenous NA, which 
initially suggested the H3 polyclonal serum (serially vaccinated equine) had antibodies 
against NA. However, NA antibodies are well-known to facilitate the release of progeny 
virions and therefore this should not impact the neutralisation of PVs because they do not 
replicate and egress from the target cells. Therefore, it is more likely that the HA & NA PVs 
have less HA on the surface and thus the anti-HA antibody activity is more efficacious in 
neutralising the PV. For future work, western blots need to be carried out to determine 






7. CONCLUSIONS AND FUTURE WORK 
 
The pseudotype platform has been employed for different purposes in this PhD study 
(thesis chapters 4 ?6); for use in a vaccine efficacy trial, dissecting antigenic drift using 
mutant PVs, serosurveillance studies and to assess its potential use in studying 
reassortment events, respectively. Much has been written and debated concerning the 
advantages and disadvantages of different serological assays, but the most important 
point is to choose the appropriate assay for the application. 
 Employing the PVNA in an equine influenza vaccine efficacy trial is the first known 
study of its kind and the results demonstrated potential for application in future 
commercial studies the field (Romain Paillot pers. comm.). The results of the PVNA 
correlated well with SRH data, which is used by the OIE as a standard assay for equine 
influenza vaccine testing (OIE, 2008). There is a strong correlation between post-
vaccination protective immunity and antibody detection in the SRH assay, which is why it 
is a favoured choice for testing vaccine efficacy. The quantification of the two assays differs 
however; the SRH assay generates a continuous read-out measurement e.g. 123 mm2, 
whereas the PVNA is based on a two-fold serial dilution series. GraphPad Prism software 
enables a neutralisation curve to be plotted on a continuous scale (serum concentration) 
such that the IC50 ĐĂůĐƵůĂƚĞĚŝƐŶŽƚƌĞƐƚƌŝĐƚĞĚƚŽĂŶĞǆĂĐƚ ‘ƚŝƚƌĞ ? ?ďƵƚǁŝůůĨĂůůƐŽŵĞǁŚĞƌĞŝŶ
the range of two serial dilution points. The results of a PVNA could therefore be presented 
in three ways i.e. the IC50 value, a titre range (in which the IC50 falls) or the titre value at 
which at least 50% neutralisation is reached. For the purpose of vaccine efficacy testing 
using SRH, minimal values for protection have been defined (Mumford & Wood, 1991). 
Further work needs to be conducted to try and determine a protective level of antibody 
measured by PVNA, as for the SRH, and how these values will be reported. In future 
studies, data on virus shedding and clinical signs post challenge would be necessary to 
differentiate between clinical protection and prevention of viral shedding when assessing 
correlates of protection. 
 The PVNA was also applied to another investigation. For historical cases where 
vaccines have failed to protect against emerging equine influenza strains, mutant HA PVs 
were generated to dissect the changes in immune response and investigate how specific 
mutations can impact vaccine efficacy. Reactivity of sera (both ferret and equine) against 
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single mutant PVs were compared with the respective wildtype PV and changes in 
recognition by antibodies were evident, but how these changes would be reflected in 
clinical signs is unknown. Future work could investigate the impact of multiple mutations 
within the HA on the immune response and whether significant changes are observed. A 
caveat to generating mutant PVs is how the changes can affect production. Due to 
different PV titres obtained with mutant and wildtype PVs it was essential to have an 
equivalent RLU input, in order to draw comparisons between mutant and wildtype PVs. In 
some cases, a mutant PV was not included in an assay due to low titre; future work could 
implement a lower RLU input threshold. A study has shown that it is possible to reduce the 
RLU input of PVs to as low as 2.5x103 RLU (Logan et al., 2016), which would allow lower 
titre mutants to be used in assays. In addition to lowering RLU input, it would be beneficial 
to implement a TCID50 titration assay to ascertain a level of infectious units that are added 
to an assay (Wright et al., 2009) aiding quantification of PV input. It is also important to 
consider that, although the HA protein is well documented as the primary target for 
antibodies, other studies are looking into the effect of other proteins on virus evolution 
and subsequent immune escape (Murcia et al., 2011). A recent study suggests that NA 
contributes considerably to protective immunity (Memoli et al., 2016). Future work could 
involve investigating influenza NA pseudotypes and mutations within this surface 
glycoprotein. 
  Novel PVs, such as those derived from canine and phocine (seal) influenza 
strains have been produced and provide a new platform for serosurveillance and 
seroepidemiology of these viruses, particularly in the case of wild or feral animals, due to 
issues with obtaining samples from wild animals during acute infection. It is also possible 
that canine PVs could be used in future canine vaccine efficacy testing. 
 In conclusion, pseudotypes have demonstrated to be flexible tools and the PVNA 
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